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Abstract 
Scientific background. Infection remains a major cause of morbidity and technique failure 
in PD patients. The mechanisms that underpin the clinical severity of peritonitis episodes 
and their link to outcomes remain poorly defined. γδ T cells together with MAIT cells play 
a crucial role in orchestrating acute immune responses by the recognition of metabolites 
(HMB-PP and vitamin B2 derivatives) present in many pathogenic bacteria. My work aimed 
to understand the molecular and cellular mechanisms underlying the local recognition of 
bacterial pathogens by peritoneal unconventional T cells, which could be exploited for 
targeted therapies and novel point of care diagnostic test.  
Approach. The local and systemic frequency of unconventional T was analysed before and 
during acute microbial infections, in a well-defined cohort of individuals with end-stage 
kidney disease receiving peritoneal dialysis (PD). In addition, the responsiveness of 
peritoneal unconventional T cells to HMB-PP and/or vitamin B2 producing bacteria was 
assessed ex vivo.  
Results. This study demonstrated that: (i) peritoneal Vγ9/Vδ2 T cells and MAIT cells are 
elevated in patients with infections caused by HMB-PP and/or vitamin B2 positive bacteria 
(e.g. E. coli) but not in infections caused by HMB-PP and vitamin B2 negative species (e.g. 
Streptococcus ); (ii) peritoneal Vγ9/Vδ2 T cells and MAIT cells are dominant producers of 
the pro-inflammatory cytokines TNF-α and IFN-γ in response to HMB-PP and/or vitamin 
B2 positive bacteria; and (iii) in turn, TNF-α and IFN-γ are potent stimulators of peritoneal 
mesothelial cells and fibroblasts. Outcome analyses showed that infections caused by 
bacteria that are able to activate Vγ9/Vδ2 T-cells and/or MAIT cells were associated with 
higher risks of technique failure such as mortality and catheter removal. 
Conclusions. My studies provide a molecular basis for the existence of pathogen-specific 
immune fingerprints that have diagnostic and prognostic value, identify key pathways by 
which unconventional T-cells can amplify early inflammatory responses, and highlight 
potential therapeutic targets that may be exploited to improve outcomes. 
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Chapter 1. Introduction 
1.1 Overview of the immune response 
The immune system defines the sets of cells and molecules that protect the body against 
foreign agents, known collectively as antigens. This system is made up of two components 
that complement each other: the innate and the adaptive immune responses (Mackay et al., 
2000a).  
The innate immune response is a non-specific line of defence, which is invoked at equal 
magnitude every time that a pathogen is encountered. This response includes phagocytic 
cells such as neutrophils and monocytes and inflammatory cells such as basophils and mast 
cells. Together, these cells protect the body from microbes present at the site of infections. 
This process is mediated by the release of complement proteins and cytokines (e.g. 
interferons and tumour necrosis factor (TNF)-α). Indeed, innate immune cells are able to 
recognise pathogen-associated molecular patterns (PAMPs). In this way innate immune 
cells can distinguish foreign microbes from self-components (Medzhitov, 2007). Cell 
recruitment to the site of infection and subsequent activation is the major cause of the 
phenomenon called “inflammation”. Overall, this process is beneficial, eliminating 
pathogens and promoting tissue healing. However, dysregulation of the innate immune and 
inflammatory responses may lead to tissue damage and death (Medzhitov, 2007, 2008) 
The adaptive immune response is triggered when a pathogen overcomes the first line of 
defence of the innate immune response. It occurs throughout the lifetime of an individual 
allowing adaptation to infections and preparing the immune system for a potential future 
challenge by the same pathogen. This response is mediated mainly by antigen-specific B 
cells and T cells, which are activated by antigen-presenting cells (APC) such as dendritic 
cells (DC) and macrophages. Once activated, B cells mainly secrete antigen specific 
immunoglobulins (antibodies) that help eliminate extracellular microorganisms. Activated 
T cells are able to kill infected cells directly or through the activation of macrophages 
(Mackay et al., 2000a).  
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1.1.1 T cell development 
Committed T cells are generated in the bone marrow and migrate to the thymus to complete 
their development. Pre-mature thymocytes lack expression of the T cell receptor (TCR) and 
of the co-receptors CD4 and CD8. They are referred to as double negative (DN) thymocytes. 
The TCR consists of two chains, which are formed by a process of gene rearrangement. 
During this process there is first the generation of the TCR β, γ and δ chains and then the 
TCRα. In this way thymocytes with a successful pre-TCR proliferate and switch from DN 
to a CD4 and CD8 double positive (DP) phenotype. DP TCR αβ thymocytes interact with 
cortical epithelial cells that express major histocompatibility complex (MHC) class I or II 
associated with self-peptides. The DP thymocytes, which recognise self-peptides resulting 
in an intermediate level of TCR signalling, develop into single positive thymocytes. TCRs 
that binds MHC-class I complexes become CD8+ T cells, whereas TCRs that bind MHC-
class II complexes become CD4+ T cells. T cells are then ready to be exported to the 
peripheral circulation as naïve T cells (Attaf et al., 2015; Mackay et al., 2000b; Yates, 2014) 
1.1.2 Unconventional T cells 
The rearrangement of the genes encoding for TCRα and TCRβ can generate a vast TCR 
diversity to recognise an extensive range of antigens. Usually peptides derived from 
extracellular antigens are processed and presented in association with a highly polymorphic 
MHC complex. αβ T cells that are activated by this type of antigen presentation are referred 
to as “conventional” and are different from “unconventional” T cell. Indeed, this last 
population of cells i) does not recognise classical peptide antigens, ii) becomes activated by 
presenting molecules encoded by non-polymorphic genes localised outside the MHC locus 
such as CD1a, CD1b, CD1c, CD1d and MR1 (Van Rhijn and Moody, 2015), iii) tends to 
localize in non-lymphoid tissues, and iv) is abundant in peripheral blood for a rapid antigen 
response and proliferation (Godfrey et al., 2015).  
αβ T cells belonging to the unconventional T cells group include mucosal associated 
invariant T (MAIT) cells, invariant natural killer T (iNKT) cells and germline-encoded 
mycolyl-reactive (GEM) T cells. Another group of unconventional T cells are γδ T cells. 
This last group together with αβ T cells and B cells represent the third lymphocytes lineage 
discovered in jawed vertebrates (Liuzzi et al., 2015; Vantourout and Hayday, 2013). 
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The importance of unconventional T cells lies in their ability to bridge the innate and the 
adaptive immune responses through the activation of inflammatory cells and the generation 
of antigen presenting cells (Tyler et al., 2015; Ussher et al., 2014a). In particular, Vγ9/Vδ2 
T cells and MAIT cells are able to discriminate among a wide range of pathogens by the 
recognition of metabolic molecules (Liuzzi et al., 2015), which are essential for certain 
microorganisms and are absent in human cells. These antimicrobial responses are acquired 
at the foetal development stage, when these unconventional T cells already manifest effector 
function prior to the encounter with foreign pathogens (Dimova et al., 2015; Leeansyah et 
al., 2014). 
 
1.1.3 Human γδ T cells  
γδ T cells develop in the thymus before αβ T cells and acquire antimicrobial responses 
during foetal development (Pablo Pereira and Susumu Tonegawa, 1993). In humans, they 
typically constitute 1-5% of all lymphocytes in blood. However, they are able to localize in 
tissue (skin, intestine and reproductive tract) and make up to 50 % of T cells during 
microbial infections (Vantourout and Hayday, 2013). γδ T cells in the blood express a Vδ2 
chain mostly paired to a Vγ9 chain, whereas the majority of γδ T cells in epithelial tissue 
carry a Vδ1 chain (LeFranc et al., 1986; Morita et al., 2007).  
γδ T cells do not respond to peptide antigens presented by MHC class I and II that normally 
stimulate the majority of conventional αβ T cells. Extensive studies have been performed 
on the activation of Vδ2+ T cells in the presence of so-called phosphoantigens (pAg). 
Distinctly, it has been suggested that Vδ1+ T cells are enriched in tissue mucosa and 
recognise self and foreign lipids presented by CD1, and the stress related MHC-like 
molecule MICA and MICB (Godfrey et al., 2015; Groh et al., 1998; Uldrich et al., 2013). 
In addition, Willcox et al. showed that Vδ2neg T cells can bind the endothelial protein C 
receptor (EPCR), a ligand present in cytomegalovirus (CMV) infected cells with homology 
to CD1d. Moreover, the study showed that this binding was independent of the presence of 
lipids (Willcox et al., 2012). 
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1.1.3.1 Vγ9/Vδ2 T cells and pyrophosphate antigens 
Vγ9/Vδ2 T cells represent the major γδ T cell subset present in peripheral blood, constituting 
up to 5% of the lymphocytes, but able to reach up to 50% and more of all peripheral T cells 
in infected patients (Morita et al., 2007). They respond to a class of low molecular weight 
molecules called “phosphoantigens” such as isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP). These molecules are generated in eukaryotes and 
some microbes via the mevalonate pathway through the action of the upstream enzyme 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase and downstream enzymes such as 
isopentenyl-PP (IPP) isomerase and farnesyl pyrophosphate synthase (Tanaka et al., 1995). 
Normally the levels of IPP present in microbes are not sufficient to induce an effective γδ 
T cell activation. Instead, it was found that metabolites derived from the non-mevalonate 
(MEP) pathway (Figure 1.1, Table 1.3) were able to induce a full activation of γδ T cells. 
Bacteria producing IPP via the classic mevalonate pathway failed to do so (Jomaa et al., 
1999). These findings suggested that other compounds in addition to IPP were responsible 
for this activation. The discovery of the compound that was able to induce such a strong 
activation of γδ T cells came from studies where enzymes in the MEP pathway of the E. 
coli strains were disrupted or deleted from the genome. This study led to the discovery of a 
novel metabolite, (E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate (HMB-PP), which is 
the direct precursor of IPP and 10,000 times more potent in stimulating Vγ9/Vδ2 T cells 
than IPP itself (Eberl et al., 2003; Hintz et al., 2001). 
It has been shown that dysregulation of the mevalonate pathway in tumour cells leads to an 
accumulation of IPP followed by activation of Vγ9/Vδ2 T cells. This mechanism is caused 
by alteration of the mevalonate pathway with increased expression of the enzyme HMG-
CoA reductase (Gober et al., 2003; Harwood et al., 1991). Manipulation of the mevalonate 
pathway by aminobisphosphonates such as zoledronate and related drugs can be used 
experimentally to sensitise target cells to γδ T cell-mediated killing for novel cancer 
immunotherapies (Dieli et al., 2007; Meraviglia et al., 2010; Wilhelm et al., 2003) 
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Figure 1.1 Mevalonate and MEP pathway for isoprenoid biosynthesis.  
The MEP pathway is found in most Eubacteria (with the exception of Gram+ cocci) as well as apicomplexan 
protozoa and chloroplasts of algae and higher plants. The mevalonate pathway is found in Archaebacteria, 
Eubacteria such as Gram+ cocci, eukaryotes and the cytoplasm of plants. Adapted from Morita et al. 2007. 
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1.1.3.2 Vγ9/Vδ2 T cell activation: HMB-PP and microbial infection 
HMB-PP is an intermediate of the MEP pathway, which is found in Eubacteria such as 
mycobacteria and Gram negative bacteria such as Pseudomonas, Salmonella, Vibrio, E. coli, 
Neisseria and Brucella. These bacteria are responsible for diseases such as tuberculosis, 
diphtheria, typhoid, plague and cholera (Gill et al. 2006; Eberl et al. 2003), (Table 1.1). 
Listeria monocytogenes is unique in being the only pathogenic species known to possess 
both the mevalonate and MEP pathways (Begley et al. 2004b). Staphylococci and 
streptococci do not use the MEP pathway (Morita et al. 2007). 
The MEP pathway is also present in plant chloroplasts, which share common ancestry with 
an organelle present in parasitic protozoa responsible for the spread of malaria (Morita et 
al., 2007). Indeed, Vγ9/Vδ2 T cells are able to proliferate and exert effector functions during 
infections caused by Plasmodium falciparum (Costa et al., 2011). This parasite is able to 
invade red blood cells and expand in the microcirculation. The control of this parasite is 
fundamental to avoid the progression of the disease. Once activated γδ T cells contribute to 
the parasite growth inhibition. This mechanism is mediated mainly by cytotoxic molecule 
like granulsyn but not perforin (Costa et al., 2011; Farouk et al., 2004). γδ T cells activation 
is triggered either during the intraerythrocytic parasitic stage or by the extracellular 
merozoite stage. Indeed, γδ T cells once activates are able to expand to up to 40% of all T 
cells and inhibit the replication of Plasmodium by a TCR-dependent mechanism 
(Bordessoule, Gaulard, and Mason 1990; Elloso et al. 1994).  
One of the most detrimental pathogens possessing the MEP pathway is Mycobacterium 
tuberculosis (Table 1.1). In a macaque model of M. tuberculosis infections, Vγ9/Vδ2 T cells 
were found distributed in lungs, bronchial lymph nodes and spleens (Huang et al., 2008a). 
It may be that peripheral Vγ9/Vδ2 T cells reach the site of infection through trans-
endothelial migration conferring protection against this bacterium (Huang et al., 2008a). 
Moreover, it has been shown that Vγ9/Vδ2 T cells were able to arise a memory-type immune 
response when Mycobacterium bovis BCG-vaccinated monkeys were infected with M. 
tuberculosis by aerosol (Chen et al., 2013; Shen et al., 2002). At the same time the lack of 
Vγ9/Vδ2 T cells can be associated with low protection against the infections. Indeed, the 
deficiency of Vγ9/Vδ2 T cells may explain why HIV patients show a poor protection against 
M. tuberculosis infections (Chen et al., 2013; Martini et al., 2002). 
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It has been shown that γδ T cells respond to neutrophils after bacterial phagocytosis. This 
activation is dependent on the ability of bacteria to produce HMB-PP and independent of 
the presence of other pathogen associated molecular patterns such as LPS (Davey et al., 
2011a). The addition of alkaline phosphatase to these co-cultures can abrogate this response, 
confirming that HMB-PP is the main soluble activator released by neutrophils upon 
phagocytosis of bacteria that is able to stimulate Vγ9/Vδ2 T cells (Davey et al., 2011a). The 
mechanism by which HMB-PP is recognized by Vγ9/Vδ2 T cells is still unclear. However, 
a functional Vγ9/Vδ2 TCR and cell-cell contact are mandatory for full γδ T cell activation 
(Eberl et al., 2009; GREEN et al., 2004).  
Of note, excessive γδ T cell stimulation can have detrimental consequences. In bacterial 
sepsis γδ T cell are activated in less than 24 hours and their frequency correlates with 
severity of the inflammatory response and clinical outcome (Davey et al., 2014; Matsushima 
et al., 2004). Moreover, a dysregulation of the crosstalk between monocytes and Vγ9/Vδ2 
T cells at the site of infection can be the cause of excessive production of inflammatory 
mediators and increase of morbidity and mortality in HMB-PP+ infection (Eberl et al., 2009; 
Lin et al., 2013). 
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Table 1.1. Microbial pathogen HMB-PP production. 
HMB-PP+   
Gram− bacteria  Gram+ bacteria  Other bacteria 
Acinetobacter baumannii Bacillus anthracis Ehrlichia chaffeensis 
Enterobacter aerogenes Clostridium difficile Mycoplasma penetrans b 
Escherichia coli Corynebacterium diphtheriae Treponema pallidum 
Francisella tularensis Listeria monocytogenes a  
Haemophilus influenzae Mycobacterium tuberculosis  
Helicobacter pylori Propionibacterium acnes  
Klebsiella pneumoniae    
Neisseria meningitidis   
Pseudomonas aeruginosa  Protozoan parasites 
Salmonella enterica  Plasmodium falciparum  
Shigella dysenteriae  Toxoplasma gondii 
Vibrio cholerae    
Yersinia pestis   
   
HMB-PP−   
Gram− bacteria  Gram+ bacteria  Other bacteria 
Legionella pneumophila Enterococcus faecalis Borrelia burgdorferi 
 Staphylococcus aureus Mycoplasma genitalium b 
 Streptococcus pneumoniae Rickettsia prowazekii 
 (Listeria innocua) a  
a The HMB-PP species L. innocua is non-pathogenic but listed here because of its close phylogenetic 
relation to the HMB-PP+ pathogen L. monocytognes (Begley et al., 2004). 
b Most mycoplasma species have no isoprenoid biosynthesis of their own. M. penetrans is the only human 
pathogenic mycoplasma known so far to produce HMB-PP (Eberl et al., 2004). Taken from Eberl and 
Moser 2009. 
 
 
1.1.3.3 Presentation of phosphoantigens to Vγ9/Vδ2 T cells by BTN3 
Although the discovery of γδ T cells dates back three decades and the discovery of 
phosphoantigens two decades, it remains unclear how γδ T cells are able to sense pAg. 
However, it is clear that cell-cell contact is necessary for full activation of Vγ9/Vδ2 T cells 
and that a cell surface receptor is implicated in this process. It is known that B7 related 
receptors are implicated in the induction of TCR-activated proliferation and differentiation 
of naïve T cells. This family includes members such as the Skint and butyrophilin (BTN) 
subfamilies. Skint1 is implicated in thymic selection, maturation, and skin-tissue homing of 
murine Vγ5/Vδ1 dendritic epidermal T cells (DETCs) (Barbee et al., 2011; Harly et al., 
2014; Rhodes et al., 2016) This molecule is composed of two butyrophilin-related Ig domain 
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and three transmembrane regions. The human proteins which are most similar to it are the 
BTNs. These are type I membrane proteins with two immunoglobulins domain, IgV and 
IgC2 and a cytosolic domain B30.2 (PRYSPRY) (Karunakaran et al., 2014). This domain 
is shared with the one present in TRIM molecules, where it acts as PRR binding associated 
with infections. Although a crucial role of BTN3 for human Vγ9/Vδ2 T cells response has 
been confirmed, there are contradictory studies about this interaction (Rhodes et al., 2016; 
Vavassori et al., 2013). 
Independent studies described an interaction of pAg molecules with the BTN3A1 B30.2 
domain, confirming the presence of a binding pocket where mutation of charged residues 
can render T cells unresponsive to BTN3A1 (Hsiao et al., 2014; Sandstrom et al., 2014). 
The intracellular HMB-PP sensing might be favoured by an interaction between the 
cytoskeletal adaptor protein periplakin and the leucine motif located next to the cytoplasmic 
B30.2. This interaction is followed by conformational changes in the B30.2 domain and 
transmission of conformational changes to the cell surface (Rhodes et al., 2015) (Figure 
1.2). A second model supports pAg binding to the external IgV domain of BTN3A1 
mimicking a MHC like presenting molecule. A third model suggests that BTN3A simply 
acts as adhesion factor promoting cell-cell interation without taking part in TCR ligand 
recognition (Rhodes et al., 2016; Vavassori et al., 2013) (Figure 1.2). 
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Figure 1.2. Currently proposed models for the presentation of phosphoantigens to Vγ9Vδ2 TCR by 
BTN3A molecules.  
(A) Direct interaction model: BTN3A1 is the ligand for the Vγ9/Vδ2 TCR. (B) The coreceptor model: the γδ 
TCR interacts with a MHC-like molecule and BTN3A with a structure related to CTLA4 and CD28. (C) The 
cell adhesion model: BTN3A structure mediates homotypic interactions to promote cell contact among T cells 
and APCs. Taken from Rhodes, Reith, and Trowsdale 2016.  
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1.1.3.4 Vγ9/Vδ2 T cell effector functions  
Once activated Vγ9/Vδ2 T cells are able to perform different effector functions such as  DC 
maturation, priming of CD4+ and CD8+ T cells and supporting survival and maturation of 
monocytes and neutrophils (Davey et al., 2011a; Eberl et al., 2009; Moser and Eberl, 2007). 
During the adaptive immune response DC, upon recognition of danger signal via PRR, are 
able to upregulate co-stimulatory molecules and migrate to the lymph node to present the 
up taken antigen to the αβ T cells. However, activated Vγ9/Vδ2 T cells, thanks to the release 
of IFN-γ and TNF-α, are able to induce upregulation of HLA-DR, CD86 and CD83 on 
immature DC (Tyler et al., 2015). In addition, the co-culture of these two types of cells lead 
to the upregulation of CCR7, a receptor essential for DC migration to the secondary 
lymphoid tissue for antigen presentation. In this regard, it has been shown that Vγ9/Vδ2 T 
cells-matured DC were able to prime CD4+ T cells towards a Th1 phenotype. This response 
was due to an increase IFN-γ release by activated Vδ2+ T cells (Shrestha et al., 2005). CCR7 
can also be upregulated on activated γδ T cells, triggering their recruitment to the lymph 
nodes. Once in the lymph nodes, it is believed that γδ T cells can act as APCs by the 
upregulation of co-stimulatory molecule such as CD80, CD86 and CD40 and the adhesion 
receptors CD11a, CD18 and CD54. Moreover, γδ T cells are able to polarize CD4+ T cells 
toward Th1 phenotype, through the production of IFN-γ and TNF-α (Brandes, 2005; Moser 
and Brandes, 2006). 
Vγ9/Vδ2 T cell effector features are not possible without cell-cell contact, explaining why 
the presence of accessory monocytes is beneficial for Vγ9/Vδ2 T cell activation by HMB-
PP. This was demonstrated by an in vitro study in our laboratory, where HMB-PP induced 
monocyte activation within 6-18 hours, at a physiologically relevant concentration of 0.1 
nM HMB-PP in the presence of a ratio of Vγ9/Vδ2 T cells and monocytes as low as 1-50-
1:500. (Eberl and Moser, 2009). Indeed, activated Vγ9/Vδ2 T cells can induce monocyte 
differentiation into APC. This can occur by downregulation of the marker CD14 and 
upregulation of CD40, CD86 and HLA-DR and DC related markers CD83 and CD209. This 
effect is also induced on monocytes present in the peritoneal cavity in the presence of HMB-
PP. This scenario mimics what happens at early stages on inflammation when low number 
of bacteria produce HMB-PP and monocytes outnumber local γδ T cells (Eberl et al., 2009).  
The expression of inflammatory chemokines receptors on Vγ9/Vδ2 T cells (e.g. CCR2, 
CCR5,CCR6 and CXCR3) confirm the capacity of these innate immune cells to migrate to 
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the site of infection (Brandes, 2003; Cipriani et al., 2000; Glatzel et al., 2002) (Figure 1.3). 
Once at the site of infection, Vγ9/Vδ2 T cells are also able to shape the neutrophil phenotype 
during cell activation. This action involves: i) activation of Vγ9/Vδ2 T cells by HMB-PP+ 
microbes phagocytosed by neutrophils, ii) release of pro-inflammatory cytokines IFN-γ and 
TNF-α, iii) expression of APC-related markers such as CD40, CD54, CD64 and CD83 as 
well as MHC molecules on neutrophils, and iv) subsequent activation of αβ T cells (Davey 
et al., 2011a, 2014) (Figure 1.3).  
Another important function played by Vγ9/Vδ2+ T cells is the release of cytotoxic molecules 
or the induction of apoptosis in the presence of infected or tumour cells. Indeed, γδ T cells 
can kill infected molecule through the engagement of death-inducing receptors (FAS/FAS 
ligand) and the release of cytolytic granules containing perforins and graenzym and/or 
granulysin (Bonneville et al., 2010). Once released perforin formed pores on the target cells 
membrane facilitating the entry of graenzym A and B leading to the target cell lysis. 
Granulysin released by Vγ9/Vδ2+ T cells has been associated with the protection against 
detrimental pathogens such as M. tuberculosis (Dieli et al., 2001) and the inhibition of the 
growth of the parasite responsible for malaria (P. falciparum) (Farouk et al., 2004). 
Granulysin acts increasing the influx of calcium from extracellular and intracellular stores 
contributing in this way to the cell mitochondrial damage (Krensky and Clayberger, 2009). 
There are others Vγ9/Vδ2 T cells functions that will not be discussed here such as the 
importance of these cells in providing B cells help in the production of immunoglobulins 
(Caccamo et al., 2006; Tyler et al., 2015) 
Altogether, these findings highlight the role of Vγ9/Vδ2+ T cells in bridging the innate and 
adaptive immune response in the presence of HMB-PP+ microbes by the immediate release 
of pro-inflammatory cytokines and expression of APC-related markers implicated in CD4+ 
and CD8+ T cells expansion. 
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Figure 1.3. HMB-PP dependent interaction between γδ T cells, neutrophils and monocytes and 
migration to the lymph node in acute microbial infection.  
The presence of inflammatory chemokines such as CXCL8 leads to recruitment of γδ T cells, monocytes and 
neutrophil to the site of infection. Neutrophils engulf invading microbes and release microbial metabolites 
such as HMB-PP into the microenvironment, which become visible to γδ T cells in the context of BTN3A1 
and contact-dependent signals provided by monocytes or other accessory cells. Activated γδ T cells release 
pro-inflammatory cytokines such as TNF-α, which supports local γδ T cell expansion and acts as a monocyte 
and neutrophil survival signal. Crosstalk between monocytes and γδ T cells induces differentiation of γδ T 
cells into APCs and migration to the lymph node, where they initiate a microbe specific CD4+ and CD8+ T 
cell activation and expansion. Adapted from Moser and Eberl 2011 and Davey et al. 2011.  
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1.1.3.5 Human γδ T cells in metabolic disorders and inflammatory diseases 
Apart from the beneficial role of Vγ9/Vδ2 T cells in antimicrobial defence, uncontrolled 
activation of these cells at the site of infection may result in a dysregulated inflammation 
process, with implications for inflammatory and metabolic diseases.  
It has been shown that Vγ9/Vδ2 T cells tend to increase in the skin of patients with psoriasis 
and decrease in the peripheral blood (Laggner et al., 2011). This cell recruitment was 
associated with the expression of the chemokine receptor CCR6 on peripheral Vγ9/Vδ2 T 
cells. Vγ9/Vδ2 T cells in the psoriatic lesions where able to release an array of cytokines 
implicated in tissue inflammation such as IL-17A and TNF-α, and to induce activation of 
keratinocytes (Laggner et al., 2011). Similarly, another study highlighted the presence of 
Vγ9/Vδ2 T cells in the intestinal mucosa, which after activation were able to promote 
activation of αβ T cells via production of IFN-γ (McCarthy et al., 2013). Moreover, gut-
homing Vγ9/Vδ2 T cells tend to increase in patients with Crohn’s disease when compared 
with healthy controls. This may be caused by an increased gut permeability, changes in 
microbiota composition and translocation and activation of Vγ9/Vδ2 T cells by bacterial 
products (McCarthy et al. 2015). 
Together with other unconventional T cells, γδ T cells are reduced in blood and duodenum 
of patients with coeliac disease. Among all γδ T cell subpopulations, these patients 
presented a predominant Vδ1+ profile, highlighting the possible contribution of these cells 
to the gut repair via TGF-β production (Dunne et al., 2013). 
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1.1.4 Human MAIT cells 
Another type of cells that bridge the innate and the adaptive immune system are MAIT cells. 
They represent up to 5% of peripheral T cells and mucosal tissue but reach up to 50% of T 
cell in the liver (Lopez-Sagaseta et al., 2013). Their TCR is characterized by the expression 
of a Vα7.2-Jα33/12/20 chain paired with a limited number of Vβ2 segments, and has the 
capacity to recognize ligands restricted to the MHC related-1 (MR1) molecule (Lopez-
Sagaseta et al., 2013).  
MAIT cells exit the thymus as “naïve” T cells and the intra thymic selection is restricted to 
the presence of hematopoietic MR1 positive cells excluding B cells. On the contrary, B cells 
and commensal flora are necessary for the selection of MAIT cells and expansion either in 
the peripheral blood or in the mucosal tissue (Gapin, 2009). This last study has been 
confirmed in patients with mutated Bruton tyrosine kinase, who have reduced levels of 
MAIT cells (Treiner et al., 2003) 
1.1.4.1 The MR1 protein and its ligands 
By conducting refolding assays followed by mass spectrometry, Kjer-Nielsen et al. 
discovered in 2012 that cell culture medium induced refolding of human MR1 in vitro, 
suggesting the presence of MR1 ligand(s) in the medium. The same results were found when 
MR1 was cultured with supernatant from Salmonella typhimurium. These findings led to 
the identification of two vitamin B compounds: vitamin B9 (folic acid) derivatives and 
vitamin B2 (riboflavin) intermediates (Kjer-Nielsen et al., 2012). 
Products of folic acid such as 6-formylpterin (6-FP) were able to cause a rapid upregulation 
of MR1 but did not stimulate MAIT cells. On the contrary, MAIT cells were only activated 
in the presence of intermediates of the riboflavin pathway. This pathway includes ligands 
known as ribityllumazines including 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-
OH), 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe) and, as the most potent activator, 
reduced 6-hydroxymethyl-8-D-ribityllumazine (rRL-6-CH2OH). McWilliam et al. 
described that MAIT cell activation was caused by the presence of a ribityl tail in the 
ribityllumazine structures, which was absent in the formylpterins (McWilliam et al., 2015) 
(Figure 1.4 and Table 1.3). 
Recently it was discovered that the most potent MAIT cell activators are in fact the 
pyrimidines 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-
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oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU). These molecules are formed upon 
reaction of the precursor 5-amino-6-D-ribitylaminouracil (5-A-RU) with methylglyxal or 
glyoxal present in host cells and bacteria; once formed they perfectly accommodate in the 
MR1 binding cleft (Corbett et al., 2014; McWilliam et al., 2015) (Figure 1.5 and Table 1.3).  
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Figure 1.4 Schematic representation of the riboflavin biosynthesis pathway.  
Gene names follows the nomenclature of the Saccharomyces Genome Database (SGD). RIB1: GTP 
cyclohydrolase II, RIB7: 2,5-Diamino-6- ribosylamino-4-(3H)-pyrimidinone-5'-phosphate reductase, RIB2: 
2,5-Diamino-6-ribitylamino-4-(3H)-pyrimidinone-5'-phosphate deaminase, RIB3: 3,4-dihydroxy-2-
butanone-4-phosphate synthase, RIB4: 6,7-dimethyl-8-ribityllumazine synthase, RIB5: riboflavin synthetase. 
Adapted from Marx et al. (Marx et al., 2008). 
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Figure 1.5. MR1 restricted antigens. 
 Reaction scheme for the condensation of 5-amino-ribityl uracil (5-A-RU) with small reactive aldehydes or 
ketones such as glyoxal or methylglyoxal to form pyrimidines and lumazines. Adapted from McWilliam et al. 
(McWilliam et al., 2015). 
 
The MHC class I-related protein MR1 is able to process antigens by an endocytic pathway, 
which do not include the typical proteasome degradation and transporter associated with 
antigen processing (TAP). On the contrary, it requires the MHC class II chaperone invariant 
chain (Ii) and HLA-DM for endocytic trafficking (Huang et al., 2008b).  
Recent analyses have shown that MAIT cells were able to recognise pathogens in ex-vivo 
experiments using distinct TCR repertoires both between and within individuals (Gold et 
al., 2014). This results suggested that MAIT cells may discriminate between pathogen 
derived-ligands in a clonotype-dependent manner (Gold et al., 2014). 
 
1.1.4.2 MAIT cells: microbial reactivity 
In 2010 Le Bourhis et al. observed that both human and mice MAIT cells were able to 
respond in a MR1 dependent manner to APC co-cultured in the presence of live bacteria 
such as Enterobacteriacae, Staphylococcus and Mycobacterium but not in the presence of 
Enterococcus and Streptococcus (Le Bourhis et al. 2010). In addition, this responsiveness 
was always directed against bacteria but not viruses (Gold et al. 2010). It was demonstrated 
that mice lacking of MR1 were more susceptible to K. pneumoniae infection, whereas wild-
type mice were able to clear the infection in two days (Georgel et al. 2011). This activity 
was abrogated in the presence of anti-MR1 neutralising antibodies, and the activation was 
translated in release of IFN-γ. It was later confirmed that the activation of MAIT cells was 
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caused by the vitamin B2 pathway, which was present in the most detrimental pathogenic 
and commensal Gram negative (E. coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa) and Gram positive (Mycobacterium tuberculosis, Staphylococcus aureus and 
Clostridium difficile) bacteria but not in Streptococcus and Enterococcus species (Table 
1.2). This study emphasized the role of MAIT cells in pathogen defence (Cowley, 2014; 
Kjer-Nielsen et al., 2012). 
 
       Table 1.2. MAIT cell activating and non-activating microbial pathogens 
Bacteria riboflavin+ Bacteria riboflavin− 
Escherichia coli Streptococcus spp. 
Pseudomonas aeruginosa Enterococcus faecalis 
Klebsiella pneumoniae Listeria monocytogenes 
Staphylococcus aureus  
Staphylococcus epidermidis  
Mycobacterium abscessus  
Mycobacterium tuberculosis  
Salmonella typhimurium  
Yeast riboflavin+  
Candida albicans  
Candida glabrata  
Saccharomyces cerevisiae  
Adapted from Kjer- Nielsen et al. 2012.  
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1.1.4.3 MAIT cells: antimicrobial functions 
Recent research showed that Vα7.2+ T cells from neonate-derived thymuses had the capacity 
to react against Mycobacterium tuberculosis and release TNF-α in vitro, in the absence of 
prior antigenic exposure (Gold et al., 2013). Furthermore, cells derived from peripheral 
blood had already a memory phenotype, highlighting the capacity of MAIT cells to adapt 
in response to the microenvironmental signal shaping intrinsic effector functions. 
MAIT cells typically express a naïve phenotype in cord blood (CD45RA+ CCR7+ CD62L+) 
and an effector memory phenotype in adult (CD45RO+ CCR7− CD62L− CD27+ CD28+). 
They are usually identified as Vα7.2+ and CD161++ T cells and are also positive for IL-18Rα 
and IL-12R receptors (Figure 1.6) (Dusseaux et al. 2011). CD161 is a C-type lectin-like 
membrane receptor which binds the ligand lectin-like transcript 1 (LLT1), with yet unclear 
function. A mRNA microarray study on CD161++ T cells described the association between 
the presence of this receptor and the expression of IL-12 and IL-18 receptors, highlighting 
the production of IFN-γ as one of the main feature of these cells (Fergusson et al., 2014). 
MAIT cells are able to produce various cytokines including IL-2, IFN-γ, TNF-α and IL-17 
(Figure 1.6). The latter is associated with expression of the Th17 transcriptional factor 
RORγt. However, the production of IL-17 is restricted to CD161++ MAIT cells, and 
stimulation of the TCR is necessary for a complete activation (Dusseaux et al., 2011). In 
addition, MAIT cells are also able to upregulate granzyme B, especially enhancing perforin 
expression, after interaction with infected epithelial cells (Le Bourhis et al., 2013; Jeffery et 
al., 2016; Kurioka et al., 2015).  
Similar to Vγ9/Vδ2 T cells, MAIT cells express chemokine receptors implicated in tissue 
tropism such as CCR5, CCR6, CCR9 and CXCR6 confirming the capacity of these cells to 
migrate to the tissue during episodes of infections (Figure 1.6) (Dusseaux et al., 2011; 
Treiner et al., 2003). Indeed, neutrophils which engulf vitamin B2+ bacteria at the site of 
infection are able to induce MAIT cell activation (Davey et al., 2014). Once activated, 
MAIT cells, similarly to Vγ9/Vδ2 T cells, trigger survival and differentiation of neutrophil 
in APC highlighting the role of these cells in orchestrating inflammatory events at the site 
of infection.  
The contribution of MAIT cells to inflammation is also due to the capacity of these cells to 
become activated in the presence of IL-12 and IL-8 in a MR1 independent fashion (Ussher 
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et al., 2014b). IL-12 and IL-18 are pro-inflammatory cytokines released by APC after 
microbial stimulation. Indeed, APCs infected with E. faecalis, a bacterial species lacking 
vitamin B2, are able to produce sufficient IL-12 and IL-18 to activate MAIT cells. The same 
type of responses is induced in the presence of TLR4 and TLR8 agonists (Ussher et al., 
2014b). This means that MAIT cells can be activated in the presence of different PAMPs 
and can amplify inflammatory response even in the absence of antigen recognition.  
 
 
Figure 1.6. Overview of MAIT cell activation by riboflavin synthesizing bacteria.  
Bacteria utilizing the riboflavin pathway enter in the APC cells. Riboflavin intermediates are loaded onto MR1 
in the endoplasmic reticulum and transported to the cell surface by the Golgi apparatus. At the cell surface, 
MR1 and the bound ligand are presented to MAIT cells, which become activated and lyse infected cells by 
the release of perforin and granzyme B and pro-inflammatory cytokines such as TNF-α, IFN-γ and IL-17. 
Adapted from Hinks 2016 (Hinks, 2016). 
 
1.1.4.4 MAIT cells in infectious disease 
Studies performed in the last few years have focused on the variation in frequencies of 
MAIT cells in the peripheral blood between healthy and infected patients. In particular 
during HIV infection, CD8+CD161++ MAIT cells were found to be dramatically reduced in 
blood of early and chronic HIV patients compared to healthy controls, and were not rescued 
after 2 years of antiretroviral therapy (Cosgrove et al., 2013). It was suggested that the 
decrease of this population was partially due to a downregulation of CD161. However, in 
2014 Fernandez et al., using a MR1 tetramer, showed that MAIT cells were absent from the 
Vα7.2+ CD161− population (Fernandez et al., 2014). One of the major implications of HIV 
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infection is the depletion of intestinal CD4+ T cells and the destruction of the intestinal 
immune system. It is possible that the loss of the gut integrity and translocation of microbial 
products into the blood stream may induce migration of MAIT cells to the gut followed by 
depletion associated with apoptosis caused by persistent cell activation. All these 
mechanisms may explain the progressive loss of MAIT cells in the periphery and the high 
susceptibility to M. tuberculosis in patients with HIV infection (Cosgrove et al., 2013; Gold 
et al., 2015; Sonnenberg et al., 2005). 
Alterations in MAIT cells subsets have also been described in patients with severe sepsis. 
In this regard, Grimaldi et al. observed that peripheral MAIT cells were decreased in early 
septic patients with severe chronic infection and in critically ill patients (Grimaldi et al., 
2014). Of note, MAIT frequencies were less decreased in patients with infections caused by 
streptococci, suggesting a ligand-specific recruitment to the site of infection in response to 
pathogens utilizing the riboflavin pathway (Szabo et al., 2015). 
 
1.1.4.5 MAIT cells in metabolic disorder and inflammatory disease  
MAIT cells appear numerically and functionally impaired in in metabolic disorder and 
inflammatory disease. Type 2 diabetes (T2D) and obesity are associated with low grade 
inflammation and alterations in the gut microbiota. Indeed, it was observed that patients 
with these disorders had lower levels of MAIT cells in the periphery compared to the healthy 
control (Apostolopoulos et al., 2016; Magalhaes et al., 2015). In obese patients, MAIT cell 
numbers were higher in the adipose tissue than in blood. Moreover, in both patients group 
MAIT displayed a Th17-like inflammatory profile. This suggests that different metabolic 
and inflammatory mediators released in obesity and T2D patients may affect MAIT cell 
activation. Similarly to this study Harms et al. showed the presence of terminally 
differentiated CD27− MAIT cells in a young cohort of type 1 diabetic patients (T1D). It was 
suggested that this phenotype is induced by an increase level of IL-18 in the same cohort of 
patients (Harms et al., 2015). 
In an inflammatory disorder such as asthma MAIT cell levels were found to be reduced in 
blood and bronchial biopsies. Indeed, the deficiency of these cells was associated with an 
increased risk of infection with riboflavin-synthesizing pathogen such as Mycobacterium 
tuberculosis (Hinks, 2016). Another study described the changes in frequency of MAIT 
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cells in inflammatory bowel disease. In this study MAIT cells were found to be decreased 
in blood and increased in the inflamed tissue and were associated with a Th17 profile 
(Serriari et al., 2014). Similarly, MAIT cells were found in large proportions in patients with 
psoriatic skin (Johnston and Gudjonsson, 2014; Teunissen et al., 2014), in the synovial fluid 
of rheumatoid arthritis patients (Cho et al., 2014) and were reduced in peripheral blood of 
patient with cystic fibrosis (Smith et al., 2014) and systemic lupus (Cho et al., 2014). 
 
1.1.5 Other pathogen-specific unconventional T cells: NK T cells and GEM T cells. 
NKT cells are unconventional T αβ cells with a semi-invariant TCR restricted by CD1d. 
Two types of NKT cells have been described. Invariant iVα14+NKT cells, usually called 
type I NKT cells, express the Vα14-Jα18 chain in mice and Vα24-Jα18 in humans. Type II 
NKT cells express a diverse non-Vα14+ TCRs (Rossjohn et al., 2012). This second 
population was discovered observing that NK cells function was detectable in mice lacking 
type I NKT cells but not in mice lacking of CD1d molecule (Godfrey and Kronenberg, 
2004). NKT cells represent approximately 0.1% of T cells in human blood and are strongly 
activated in the presence of the marine sponge-derived glycolipid α-galactosylceramide (α-
GalCer), which is generally used for immunotherapeutic applications. Type II NKT cells do 
not recognize α-GalCer but recognize the myelin-derived glycolipid sulfatide (Godfrey et 
al., 2015) (Table 1.3). 
NKT cells respond promptly upon TCR engagement, releasing Th1 and Th2 type cytokines. 
During the late phase of activation, they tend to produce more IFN-γ and TNF-α (Gumperz 
et al., 2002). Like MAIT cells, NKT cell numbers are reduced in inflamed tissues in diseases 
such as rheumatoid arthritis, lupus and inflammatory bowel disease (Balato et al., 2009). 
They are also implicated in microbial defence and inhibition of autoimmune disease 
(Gumperz and Brenner, 2001; Taniguchi et al., 2003). 
A third population of unconventional T cells that expresses a highly restricted TCR α-chain 
are germline-encoded, mycolyl-reactive (GEM) T cells. They are CD4+ and express the 
same Vα7.2 segment as MAIT cells but rearranged to the α chain joining region 9 (TRAJ9), 
which differs from the MAIT Jα. Notably, GEM T cells react against lipids presented by 
CD1b molecules. This interaction leads to the release of antimicrobial cytokines such as 
TNF-α and IFN-γ (Kronenberg and Zajonc, 2013; Van Rhijn and Moody, 2015) (Table 1.3). 
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Mycolic acid (MA) is the main component of the M. tuberculosis cell wall used by this 
pathogen to resist to the immune cells attack. A study done on MA reactive T cells 
demonstrated that TB patients, but not healthy donors, were more responsive to this antigen. 
The response was measured as release of IFN-γ (Montamat-Sicotte et al., 2011) and was 
inhibited after blocking of CD1b with monoclonal antibody. The authors also observed that 
IFN-γ–secreting MA-specific T cells were undetectable in the blood of some patients but 
were present in the lung of TB patient. This observation suggests a preferential recruitment 
of these cells to the site of infection.  
To study lipid-reactive T cells in the context of TB, Van Rhijn et al. generated a CD1b 
tetramer loaded with glucose monomycolate (GMM), which is produced in vivo during TB 
infection and activates CD1b reactive T cells. The clone sorted from the CD1b tetramer 
positive cells comprised 0.01% of all circulating T cells. This clone was able to produce a 
large amounts of IFN-γ and IL-2 after treatment with GMM but less so after MA treatment. 
This result suggested that GMM is the prevalent antigen triggering activation of GEM T 
cells (Van Rhijn et al. 2013). Although at low frequency, compared with others 
unconventional T cells, CD1b tetramers also identified GEM T cells in blood of healthy 
donors. These cells had low CD69 expression and lacked of the transcriptional factor PLZF 
responsible for the effector phenotype, suggesting that GEM T cells are more dependent on 
infection to drive expansion. A second population of GMM-specific T cells with lower 
avidity for CD1b tetramer has been identified recently. This population expresses a TCR 
with a preference of the TRAV17 and TRAV4-1 genes (Van Rhijn et al., 2014).  
Altogether, these findings emphasize the importance of GEM T cells in the diagnosis of 
tuberculosis and, given the non-polymorphic nature of CD1 protein, GEM T cells could be 
an important target for vaccine development (Godfrey et al., 2015; Kronenberg and Zajonc, 
2013; Liuzzi et al., 2015). 
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Table 1.3 Non polymorphic targets of human T cells 
Target TCR Type Natural antigens Synthetic agonists 
CD1a αβ Many lipids Fatty acid, squalene, wax esters, 
dideoxymycobactin 
CD1b αβ Many lipids Mycolic acid, sulfoglycolipid, 
phosphatidylinositol mannoside, 
glycerol monomycolate 
GEM T cells Glucose monomycolate Glucose monomycolate 
LDN5-like Glucose monomycolate Glucose monomycolate 
CD1c αβ Many lipids Phosphomycoketide, mannosyl-
phosphomycoketide, methyl-
lysophosphatidic acid 
CD1c γδ Unknown None  
CD1d αβ   
Type I NKT α-GalCer and other α-
linked glycolipids 
 Many a-GalCer analogues  
Type II NKT Many lipids Lysophosphatidylcholine, PPBF 
CD1d γδ   
TRDV1+   
 TRDV3+   
MR1 αβ Riboflavin derivatives 5-OP-RU  
MAIT cells 5-OE-RU  
RL-6-Me7-OH  
RL-6,7-diMe 
Butyrophilin γδ   
 TRDV2+ 
TRGV9+ 
HMB-PP, IPP Synthetic phosphoantigens  
References: (Chien et al., 2014; Van Rhijn et al., 2015; Rossjohn et al., 2012; Sullivan et al., 2008; Vantourout and 
Hayday, 2013) 
Adapted from Godfrey et al.  
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1.2 Peritoneal dialysis  
1.2.1 General overview  
Renal replacement therapies are employed in patients with end-stage renal disease (ESRD) 
to replace the normal filtration functions of the kidneys. The severity of kidney failure is 
divided into different stages (1 to 5) based on the glomerular filtration rate (GFR). Kidney 
failure is defined as GFR lower than 30 ml/min per 1.73 m2 (stage 4). The most common 
reason for renal failure in the UK is diabetic renal disease followed by glomerulonephritis, 
pyelonephritis, hypertension and renal vascular disease (UK Renal Registry 17th Annual 
Report, 2015) (Table 1.4). 
 
Table 1.4 Primary renal diagnosis RRT incidence rate (2013) per million population 
Diagnosis England N Ireland Scotland Wales UK 
Diabetes 25.2 20.2 22.7 31.8 25.1 
Glomerulonephritis 14.1 10.4 15.6 17.8 14.3 
Pyelonephritis 6.6 13.1 8.4 5.5 6.9 
Hypertension 8.3 5.5 3.0 3.6 7.5 
Polycystic kidney 7.4 9.8 7.7 7.8 7.5 
Renal vascular disease 4.9 7.1 6.2 10.7 5.3 
Other 18.7 15.8 16.5 13.6 18.1 
Uncertain aetiology 13.9 14.8 13.9 22.1 14.4 
Data not available 12.3 1.6 0.2 1.9 10.4 
All 111 98 94 115 110 
 
Patients with kidney failure will receive a renal replacement treatment (RRT) such as renal 
transplantation, peritoneal dialysis (PD) and haemodialysis (HD). However, most of the 
time, the lack of available organ donors in addition to comorbidity conditions in the patient 
means that PD and HD are the only available treatments.  
The 2013 UK renal registry contains records of patients who have been at least 90 days on 
RRT. Among them 66.9% were on HD, 19.0% on PD and only 8.3% on transplant (UK 
Renal Registry 17th Annual Report, 2015). Within the UK, Wales shows the highest 
incidence of RRT (Figure 1.7). 
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The patient choice between PD and HD depends on the patient lifestyle, geographic location 
(near or far from the dialysis centre), and patient and family employment. Patients on PD 
are in fact more likely to rate their medical care highly than patients on HD (Rubin et al., 
2004). The reason is because PD offers a better quality of life, with higher freedom for the 
patients than HD, and the possibility of home therapy with close medical care. Indeed, PD 
is more cost effective and is characterised by better survival rates in the first two years of 
dialysis treatment compared to HD (Chaudhary et al., 2011). Furthermore, complications 
related to infection appear to be higher in HD than in PD (Chaudhary et al., 2011; 
Sinnakirouchenan and Holley, 2011). 
 
 
Figure 1.7. RRT incidence in the UK 1990-2013.  
Taken from UK Renal Registry 17th annual report (UK Renal Registry 17th Annual Report, 2015). 
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1.2.2 Peritoneal dialysis techniques 
The preservation of three main components of PD therapy are fundamental for optimal PD 
treatment. These are: 1) PD catheter, 2) PD solutions and 3) the peritoneal membrane with 
blood vessels associated to it. During PD a dialysis solution (dialysate) is introduced into 
the patient’s peritoneal cavity by a catheter inserted into the abdominal cavity. The 
peritoneal membrane is used as dialyser to remove waste products and fluids by a diffusion 
and ultrafiltration process. The dialysis solutions contains: i) electrolytes such as sodium, 
potassium, magnesium and calcium; ii) a buffer (e.g. lactate and /or bicarbonate) and iii) an 
osmotic agent that makes the solution hyperosmolar. Typically the latest can be a substance 
with high molecular weight such as icodextrin or with low molecular weight such as glucose 
and amino acids. 
During the dwell time, the transport of solute across the peritoneum can be described by 
three processes, namely diffusion, ultrafiltration and convection processes. Diffusion allows 
the transport of solute as a consequence of the concentration gradient from the more 
concentrated area (capillary blood) to a less concentrated area (PD solution). This brings 
solutes such as creatinine and urea to flow from the blood to the PD fluid and osmotic agents 
such as glucose to flow in the opposite direction. This process depends on the peritoneal 
surface area and on the concentration gradient, which will affect the dwell time. 
Different models have been proposed to describe the transport of solute from the capillary 
to the peritoneal cavity. The most recent model is the “three pore model” (Rippe et al., 
2004), which assumes that the transport across the membrane is due to the presence of pores 
of different dimensions. Large pores (100-200 Å), clefts between endothelial cells, allow 
the passage of macromolecules, whereas small pores (40-60 Å), that may be present in the 
endothelium, allow the transport of small solute and water. The latter can also pass through 
ultra-small pores (aquaporins, 2.3-15 Å) (Rippe et al., 2004). 
Ultrafiltration is accomplished by an osmotic pressure gradient between the capillary and 
the PD solutions. This is achieved making the dialysate hypertonic adding high 
concentration of glucose or icodextrin depending on the dwell time. During this process 
small solutes are also transported by bulk flow of water (convective motion) (Teitelbaum 
and Burkart, 2003). 
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1.2.3 Peritoneal dialysis modality  
Depending on the peritoneal membrane transport status and performance, patients can be 
treated with two types of PD: continuous ambulatory peritoneal dialysis (CAPD) and 
automated peritoneal dialysis (APD). In CAPD, patients perform three manual short 
exchanges of dialysate during the day and two exchanges during the night, each with 2 to 
2.5 litres of dialysate solution. In APD, the patients program a dialysis cycler to perform 
multiple automated exchanges overnight, whereas the last “fill” of fluid is kept in the 
abdomen during the day (Teitelbaum and Burkart, 2003). 
 
1.2.4 Technique failure in PD 
There are different reasons that force PD patients to discontinue the therapy and these are 
grouped into infection and non-infection related reasons. 
1.2.4.1 Infectious complications 
Although PD patients have a better survival prospective than patient on HD in the first 2 
years of therapy (Chaudhary et al., 2011), technique failure caused by episodes of peritonitis 
is still high throughout the course of the therapy. Peritonitis is a common cause for catheter 
removal, transfer to HD, ultrafiltration failure and death in PD patients. Furthermore, there 
is a wide variation in peritonitis rates among treatment centres: from a very low rate of 
episodes per year in Taiwan (n=0.06) to a very high rate of episodes in Israel (n=1.66 per 
year) (Piraino et al., 2011). UK centres are somewhat in the middle (n=0.14 episodes to 1.0 
episodes per year) (Davenport, 2009) but still far from the rate that should be achieved 
according to the guidelines by the International Society for Peritoneal Dialysis (ISPD) (< 
0.24 per year). The differences among centres depend to a large extent on patient training 
and different protocols to prevent infections (Piraino et al., 2011). 
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1.2.4.1.1 Diagnosis 
In most cases, the first signs of peritonitis reported by a patient are cloudy effluents and 
abdominal pain. If the count of white blood cells (WBC) present in the effluent is greater 
than 100/µl, with more than half of the cells being polymorphonuclear cells, an episode of 
peritonitis is clinically confirmed (Teitelbaum and Burkart, 2003). Afterwards, a standard 
culture technique is used to identify the responsible organism for an appropriate antibiotic 
selection. 
Normally the culture results take up to 3 days, however if there are no results after 72 hours 
the culture is defined as negative (Fahim et al., 2010a). This can be caused by different 
reasons, such as i) inappropriate culture methods (e.g. suboptimal sample collection and 
processing); ii) recent antibiotic exposure; iii) presence of fastidious organisms such as 
mycobacteria; iv) chemical agents used during the treatment; or v) by effluent eosinophilia. 
ISPD recommends that culture-negative episodes should not exceed more than 20% of all 
episodes, but a rate higher than this percentage has been reported among 12% of the units 
in Australia (Fahim et al., 2010a). 
1.2.4.1.2 Microbiology 
Single Gram+ bacteria are responsible for almost 50% of PD associated infections. These 
are followed by single Gram− infection (up to 25% of all cases), fungal and polymicrobial 
infections. Among Gram+ bacteria, infections caused by the skin colonizer coagulase 
negative Staphylococcus (CoNS, 30% of all peritonitis episodes) are the most frequent ones, 
mainly caused by touch contamination at the time of catheter insertion. This is a clear 
indication of a problem with the training methods adopted by the PD nurses and 
consequently by the patients (Ghali et al., 2011). Touch contamination together with 
catheter infection can also lead to Staphylococcus aureus infection, whereas Streptococcus 
and Enterococcus infections are typically associated with contamination from the 
gastrointestinal tract and tunnel infection. A less common Gram+ infection is the one caused 
by Corynebacterium, which like CoNS, is difficult to identify as pathogen given its 
contribution to the normal skin microbiota (Li et al., 2010; Piraino et al., 2011). 
The most frequent Gram− bacterium in PD associated peritonitis is Pseudomonas 
aeruginosa, which like S. aureus is linked to high rates of catheter removal, high probability 
of hospitalizations and transfer to HD (Siva et al., 2009). This is followed by infections 
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caused by non-Pseudomonas Gram−  bacteria such as E. coli, Klebsiella and Proteus. Gram− 
bacteria may arise from bowel sources such as constipation, colitis or transmural migration, 
and are able to form biofilms around the catheter. The same biofilm composition can allow 
bacteria to acquire resistance to antibiotics (Dasgupta and Larabie, 2001; Jarvis et al., 2010; 
Szeto et al., 2006). The organisms found in polymicrobial infections are mainly Gram+ 
CoNS and S. aureus and Gram− E. coli and Pseudomonas (Ghali et al., 2011). 
1.2.4.1.3 Treatment of peritonitis 
When symptoms of peritonitis are confirmed, empiric antimicrobial therapies to cover both 
Gram+ and Gram− infections are adopted. Gram+ bacteria are targeted with vancomycin and 
cephalosporins, whereas Gram− bacteria are targeted with aminoglycosides or third 
generation cephalosporins. The choice of the right antibiotic depends on the patient and unit 
history for the organisms considered. Usually antibiotics are administered intraperitoneally 
to the dwell bag for at least 6 hours and the treatment should be continued for 2 weeks (Li 
et al., 2010). This can be revaluated as soon as the culture results are obtained. Three weeks 
of antibiotics treatment are suggested for infections caused by S. aureus, Gram− and 
enterococcal infections (Li et al., 2010). The London UK audit registered a high cure rate 
for CoNS (77%) and culture negative results (77%) followed by S. aureus infections (47%). 
On the contrary, cure rates for Gram− infections are as low as 20-60% (Davenport, 2009). 
This means that patients presenting with peritonitis caused by Gram bacteria are more likely 
to discontinue PD (Cho and Johnson, 2014; Jarvis et al., 2010). 
Indeed, in many cases the traditional diagnostic methods are not specific or rapid enough to 
target the cause of infection. As a result, patients are exposed to improper and unnecessary 
antibiotic treatment contributing for example to the spread of multidrug resistance (Arias 
and Murray, 2009). Moreover, if the effluent fails to clear within 5 days from the 
commencement of antibiotic treatment the catheter should be removed to avoid peritoneal 
membrane failure; this type of peritonitis is called refractory. Catheter removal is also 
considered in case of relapsing peritonitis, which refers to a new episodes of peritonitis that 
occurs within 4 weeks of completion of therapy with a recent episode with the same 
organism. Repeating peritonitis is instead defined as an infection that occurs with the same 
organism but after more than 4 weeks from the completion of the therapy; while recurrent 
peritonitis is an episode that occurs within 4 weeks but with a different organism (Burke et 
al., 2011; Piraino et al., 2011).  
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Collectively, this means that there is an urgent need of novel methods for early diagnosis of 
peritonitis to prevent technique failure. It is crucial to treat episodes of peritonitis on time 
to avoid worse outcomes. In a recent study, Szeto et al. reported how to predict relapsing or 
repeat peritonitis by measuring DNA fragments in PD effluent of patients with peritonitis 
(Szeto et al., 2013). In addition, in our laboratory, Lin et al. described how to use local 
cellular and humoral responses (immune fingerprints) evoked by the specific interaction of 
the immune system with microbial pathogens to discriminate between Gram−, Gram+ and 
culture negative episodes of peritonitis (Lin et al., 2013).  
 
1.2.4.2 Non-infectious complications 
Besides microbial infections, there are different non-infectious complications that may lead 
to cessation of PD, all of which have in common functional changes in the peritoneum. 
 Peritoneal membranes changes: long-term therapy exposition to a non-
physiological PD fluid can be harmful to the peritoneal membrane. Glucose, used as 
osmotic agent, together with low pH and presence of lactate can lead to 
modifications of the peritoneal membrane with vascular proliferation and fibrosis. 
 
 Ultrafiltration failure: it increases with time on PD; this is caused by an increased 
transport of small solutes followed by gradient dissipation during the dwell time. If 
an osmotic agent at slow absorption fails to solve this problem, patients are forced 
to move to HD. 
 
 Encapsulating peritoneal sclerosis (EPS): this is a complication followed by 
chronic abdominal inflammation resulting in bowel encapsulation. Long time on PD 
seems to be the main risk of factor for this complication (Lai and Leung, 2010) 
 
 Other reasons: PD can be also be discontinued for mechanical (e.g. catheter 
obstruction) or metabolic abnormalities (e.g. hypoalbuminaemia, hyperglycaemia 
and weight gain) (Teitelbaum and Burkart, 2003). 
 
1.2.5 Chronic inflammation in PD 
1.2.5.1 Anatomy of the peritoneal cavity 
The peritoneum is a large serous complex membrane consisting of parietal and visceral 
layers. The parietal peritoneum covers the inner surface of the abdominal and pelvic walls 
including the diaphragm, whereas the visceral peritoneum covers the gastrointestinal tract, 
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liver and spleen and forms the omentum and visceral mesentery (Blackburn and Stanton, 
2014). The visceral peritoneum is a reflection of the parietal peritoneum on the viscera. This 
reflection allows the peritoneum to form potential spaces. The space between the parietal 
peritoneum and the visceral peritoneum forms the peritoneal cavity, where the PD fluid is 
introduced. However, during PD it is the parietal peritoneum that performs most of 
peritoneal transport, whereas only 30% of the visceral peritoneum is in contact with the fluid 
(Flessner, 1996). 
The peritoneal membrane is a single layer of flat squamous epithelial cells called 
mesothelial cells, which are located on a thin basement membrane. Underneath this 
membrane there is a thick layer of connective tissue composed of fibres of collagen, 
scattered fibroblasts and blood vessels (Figure 1.8).  
Between the parietal and visceral layer there is typically 50-100 ml of fluid, necessary for 
the lubrication of the peritoneal surfaces. This fluid contains water, electrolytes, solutes, 
proteins and cells. These last are mainly mesothelial cells followed by macrophages, mast 
cells and fibroblasts. Under normal conditions there is a small net filtration from the 
capillary blood to the peritoneal cavity. The mesothelium cells layer is interrupted by 
intercellular gaps called stomas, which are connected with mediastinal lymph nodes where 
foreign antigens can be ingested by macrophages and presented to T and B lymphocytes in 
the lymphatic nodes. The integrity of these components is fundamental for successful PD 
therapy (Teitelbaum and Burkart, 2003). 
1.2.5.2 The role of leukocytes during PD associated inflammation 
In a healthy adult, the peritoneal fluid contains up to 90% monocytes/macrophages, 5% 
lymphocytes, and 5% of neutrophils. This scenario changes extensively during episodes of 
peritonitis and differs between culture negative and culture positive episodes of peritonitis 
(Glik and Douvdevani, 2006; Lin et al., 2013).  
In the first phase of the inflammation, bacterial products are recognized by resident 
peritoneal cells such as mesothelial cells, macrophages and DCs. After activation these cells 
release different vasoactive substances such as prostaglandins and histamines and 
chemokines such as CXCL8. This results in vasodilation and blood vessels permeability 
eliciting the infiltration of neutrophil (polymorphonuclear cells) at the site of infection 
(Figure 1.8). Indeed, at day 1 of the infection neutrophils can reach up to 95% of all 
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peritoneal cells (Glik and Douvdevani, 2006; Lai and Leung, 2010). Inflammatory 
mediators such as TNF-α, TGF-β, IL-1β, IL-6, IL-10, IL-22 and CXCL8 increase during 
episodes of acute peritonitis (Lin et al., 2013). Activated neutrophils in turn release granules 
with toxic content such as reactive oxygen and nitrogen species. They are also able to release 
soluble IL-6 receptor (sIL6-R), which together with IL-6 is responsible for the switch 
between polymorphonuclear and mononuclear cell recruitment to the site of infection. 
Indeed, IL-6 induce the release of CC chemokines such as CCL5, CCL2 and CXCL10 at 
the site of infection (Hurst et al., 2001; Jones, 2005) (Figure 1.8). 
At the site of infection, DCs, capture the antigen and migrate to the lymph nodes. Once at 
the lymph nodes, DCs are able to induce a CD4+ and CD8+ specific T cells response, which 
then differentiate, proliferate and migrate to the site of infection (Figure 1.8). CD4+ T cells 
are able to differentiate in different subsets (e.g. Th1, Th2, Th17, Treg and Th22 lineage) 
characterized by the release of different inflammatory mediators. A study on stable CAPD 
patients showed that these patients had high frequency of Th2 cells compared with control 
donors (Enríquez et al., 2002; Yokoyama et al., 2001). However, this pattern changes during 
episodes of peritonitis where there is an increase of Th1 cells and also Th17 cells (Wang 
and Lin, 2005). Moreover, it has been shown that the balance of the axis Th17-Treg is 
fundamental to avoid peritoneal damage. In effect, the presence of only TGF-β pushes the 
balance toward Treg activation by the induction of Foxp3 (Liappas et al., 2015). Instead, 
the simultaneous presence of inflammatory mediator such as IL-6 can tilt the balance toward 
activation of Th17 cells, which are the main cell type secreting IL-17 and contribute to the 
membrane damage (Liappas et al., 2015; Rodrigues-Díez et al., 2014). Moreover, in a mouse 
model with repeated episodes of infection, it has been demonstrated that IL-6 was 
responsible for the induction of peritoneal fibrosis enhancing IFN-γ secreting Th1 cells. 
This resulted in an increased production of matrix metalloproteinases in mesothelial cells, 
and the effect was reversed when STAT1 and IFN-γ signals were impaired (Fielding et al., 
2014). On the contrary, other studies have shown that Tregs cells have a protective effect 
on the peritoneal membrane, when mice were treated with agonists able to activate the 
peroxisome proliferator-activated receptor-γ (PPAR-γ) (Sandoval et al., 2010). 
Lin et al. showed that the peritoneal cell composition was markedly different between 
Gram− and Gram+ infections. Peritoneal leukocytes in patients infected with Gram− bacteria 
were dominated by a large proportion of neutrophils and high levels of IL-β, IL-10 and 
TNF-α. While these patients had only a relatively low proportion of T cells, they showed an 
35 
 
enrichment of peritoneal γδ T cells (Lin et al., 2013). On the contrary, Gram+ infections 
were dominated by elevated numbers of CD4+ and CD8+ T cells and peritoneal levels of 
CXCL10, IFN-γ and IL-22. This suggests that the specific immune response is shaped by 
the type of pathogen present at the site of the infection.  
 
Figure 1.8. Leukocyte activation in the peritoneum.  
The initial reaction against pathogens is induced by immune cells already present at the site of infection like 
peritoneal monocytes/macrophages (M) and recruited cells such as polymorphonucelar cells (PMNs) and γδ 
T cells. Activated PMNs release the soluble form of interleukin-6 receptor (sIL-6R), which together with IFN-
γ secreted by activated γδ T cells and IL-6 released by macrophages, induce peritoneal mesothelial cell 
stimulation and activation. Once activated they release chemokines responsible of mononuclear cells 
migration to the site of infection. IFN-γ is also important for the expression of MHC class II on both 
macrophages and mesothelial cells. Dendritic cells (DCs) take up antigens and migrate to the lymph node for 
antigen presentation to T cells. Antigen-specific T helper (Th) cells and cytotoxic T lymphocytes (CTLs) 
proliferate and migrate from lymph nodes to the peritoneum. Th cells may also become activated locally by 
antigen presented MHC class II molecules expressed on mesothelial cells. Adapted from Glik and Douvdevani 
2006 (Glik and Douvdevani, 2006). 
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1.2.5.3 Human peritoneal mesothelial cells 
Human peritoneal mesothelial cells (HPMC) are the first cells to encounter the pathogen 
during episodes of infection. Normally, they play an essential role in fluid and solute 
transport through the peritoneal membrane. However, many studies in the last few years 
have focused on the role of these cells in peritoneal inflammation and tissue repair. Given 
the acquisition of tight cell-cell contact including tight junctions, gap junctions, adherent 
junctions and desmosomes, HPMC have a clearly defined apical basal polarity. The integrity 
of these adherent cell proteins is fundamental for the formation/integrity of a continuous 
mesothelial monolayer.  
HPMC are endowed with microvilli and cilia essential for the movement of solutes across 
the peritoneal cavity and protect the peritoneal membrane from damage (Mutsaers, 2002). 
Given the location of these cells between the blood vessels and the peritoneal cavity, they 
are the first cells to be implicated in the peritoneal immune defence. During the first phase 
of the innate response, Gram+ and Gram− bacteria can directly activate HPMCs via TLR2 
and TLR5 receptors present on their cell surface (Colmont et al., 2011; Visser et al., 1996). 
The interaction with these receptors triggers the release of pro-inflammatory cytokines, such 
as IL-6, IL-1α and IL-1β as well as chemokines such as CXCL8, CXCL10, CCL2 and 
CCL5. Resident macrophages can also contribute to the HPMC activation by releasing 
TNF-α and IL-1β, which together with IFN-γ elicits a positive feedback on HPMC 
chemokines production (Betjes et al., 1993; Park et al., 2003; Topley et al., 1993a; Visser 
et al., 1998). 
HPMC participate in the inflammation also by the expression of adhesion molecules such 
as ICAM-1, which are necessary for leukocyte migration across the mesothelium. 
Hausmann et al. showed that HPMC were not only able to upregulate the expression of 
MHC class II molecule in the presence of IFN-γ but were also able to present S. aureus α-
toxins to CD4+ T cells releasing the T cell growth factor IL-15 (Hausmann et al., 2000). The 
ligation and the presence of a functional CD40 receptor on mesothelial cells is fundamental 
for T cell activation (Basok et al., 2001). This results in a full activation of CD4+ T cells not 
only by interaction with the TCR but also binding the leukocytes associated molecule LFA-
1 and the adhesion molecule ICAM-1 on HPMC. 
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1.2.5.4 Human peritoneal fibroblasts  
Human peritoneal fibroblasts (HPFB) are another component of the peritoneal cell 
compositions implicated in PD associated inflammation. They are scattered in the 
connective tissue and are mainly responsible for extracellular matrix and collagen 
production. HPFB are characterized by a spindle-shape conformation and by the expression 
of the fibroblast-specific protein-1 (FSP-1). In the presence of inflammatory mediators 
HPFB can adopt an activated phenotype characterized by the expression of α-SMA, 
acquiring an increased proliferation and motility. In this case they are called 
“myofibroblasts”. In addition, Kawka et al. observed that HPFB can be divided into two 
subsets according to the expression of CD90 (Thy-1), which is associated with a 
myofibroblastic phenotype (Witowski et al., 2015). In non-PD patients HPFB express the 
marker CD34, normally associated with bone marrow stem cells. The function of these 
markers is still unknown but is reduced in patients on long term PD and during peritoneal 
fibrosis (Jiménez-Heffernan et al., 2004). 
Like mesothelial cells, peritoneal fibroblasts actively participate in the peritoneal 
inflammation. It has been shown that they react to the presence of activated macrophages 
by releasing the chemokines CCL2 and CXCL8. This effect was found to be mainly induced 
by the presence of IL-1β (Witowski Janusz and Jörres Achim, 2006; Witowski et al., 2001). 
IL-1β is also able to induce the secretion of colony-stimulating factor (G-CSF) by HPFB, 
which permits neutrophil mobilization and survival (Witowski et al., 2009). Moreover, after 
treatment with IL-1β and TNF-α, peritoneal fibroblasts release CCL5. Similar to mesothelial 
cells, this chemokine is synergistically upregulated in the presence of IFN-γ followed by the 
expression of CD40 receptor (Brouty-Boyé et al., 2000; Kawka et al., 2014). This means 
that HPFB, together with HPMC, have a role in antigen presentation and amplification of 
inflammation in PD. 
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1.2.5.5 Epithelial to mesenchymal transition  
Long term PD exposure of peritoneal membrane to PDE and recurrent episodes of peritonitis 
can cause chronic peritoneal inflammation leading to peritoneal fibrosis, angiogenesis and 
vasculopathy. Myofibroblasts together with activated leukocytes recruited or present at the 
site of the infection are the main cell type responsible for this structural alteration. However, 
new myofibroblasts can be generated by differentiation of mesothelial cells through a 
process called epithelial to mesenchymal transition (EMT). During this process, mesothelial 
cells lose their intercellular junctions, mainly by downregulation of the adhesion molecules 
E-cadherin, claudins, occludins and zona occludens-1 (ZO-1). Consequently, they lose the 
apical-basal polarity and connection with the cytoskeleton, which causes changes in 
signalling programmes specific for cells conformation and gene expression (e.g. Snail). 
EMT process involves: i) cell motility, ii) denudation of the mesothelium and iii) invasion 
of the fibrotic stroma with parallel increase of mesenchymal markers (e.g. α-SMA, collagen-
I and fibronectin) (Figure 1.9). 
TGF-β is the main pro fibrotic cytokine associated with EMT. It has been associated with 
fibrosis in different organs and its presence has been correlated with worse PD outcomes 
(Lai et al., 2000). The effect of this pro-fibrotic cytokine has been confirmed in vivo 
experiments where TGF-β was able to convert mesothelial cells into myofibroblast in the 
rat peritoneum (Loureiro et al., 2011; Margetts et al., 2001). Together with TGF-β, vascular 
endothelial growth factor (VEGF) has been associated with increased peritoneal capillary 
numbers and vessel permeability. It was confirmed that mesothelial cells undergoing EMT 
were the main source of this proangiogenic factor (Aroeira et al., 2005; Mandl-Weber et al., 
2002). Other pro-inflammatory mediators such as TNF-α and IL-1β have also a role in the 
stimulation of resident cells and increase of extracellular matrix deposition (Aroeira et al., 
2007). Moreover, advanced glycation end products (AGE) presents in the PDE can 
indirectly induce EMT inducing PD cells to release TGF-β and VEGF (García-López et al., 
2012; Margetts Peter J. and Bonniaud Philippe, 2003). 
EMT can be blocked at different stages. For instance, treatment of mesothelial cells with 
the anti-fibrotic protein bone morphogenic protein 7 (BMP-7) blocks EMT induced by AGE 
or TGF-β in a Smad-dependent manner (Loureiro et al., 2010). EMT can also be reversed 
by using molecules such as inhibitors of Rho-activated kinase or AngII (Liu, 2004; Strippoli 
et al., 2016; Wang et al., 2016). In addition, recently was found that vitamin D is able to 
39 
 
protect the peritoneal membrane against EMT reversing the effect of TGF-β inducing EMT 
(Lee et al., 2015).  
 
 
 
 
Figure 1.9 Key events during EMT.  
Adapted from L. Aroeira et al. 
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1.3 Hypothesis and aims  
Hypothesis 
Vγ9/Vδ2 T cells and MAIT cells contribute to the amplification of local inflammation 
during acute infection by secretion of pro-inflammatory cytokines and stimulation of 
peritoneal epithelial and stromal cells.  
Aims 
The main aim of this study was to define the diagnostic, prognostic and therapeutic value 
of local immune responses triggered by unconventional T cells in PD patients during acute 
infection. 
To achieve this aim the following objectives were defined: 
 To study the responses of unconventional T cells from peripheral blood and 
peritoneal dialysis effluent in the presence of bacterial extracts ex-vivo; 
 To analyse the frequencies of Vγ9+ T cells and MAIT cells during acute PD 
associated infections in vivo; 
 To define clinical outcomes in the context of Vγ9/Vδ2 T cells and MAIT cells ligand 
production by the causative organism;  
 To analyse the capability of activated unconventional T cells to induce peritoneal 
mesothelial cells and fibroblast activation in ex-vivo assays.  
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Chapter 2. Materials and Methods 
2.1 Reagents 
2.1.1 Complete RPMI 1640 medium 
Complete RPMI 1640 medium used in cell culture was made by adding 10% foetal calf 
serum (FCS, Invitrogen), 50 mg/ml penicillin/streptomycin, 2 mM L-glutamine, 1% sodium 
pyruvate and 100 µM non-essential amino (NEAA) into RPMI-1640; all from Invitrogen. 
2.1.2 Complete M-199 medium 
Medium 199 (Life Technologies) was supplemented with penicillin (100 U/ml), 
streptomycin (100 µg/ml), L-glutammine (2 mM) and 10% foetal calf serum (FCS) from 
Invitrogen; and bovine pancreas insulin (5 µg/ml), hydrocortisone (0.4 µg/ml) and apo-
transferrin (5 µg/ml) from Sigma-Aldrich. 
2.1.3 Complete Ham’s F12 medium 
Ham’s F12 nutrient mixture medium (Life Technologies) was mixed at a 1:1 ratio with 
DMEM medium and supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), 
L-glutamine (2 mM), 20% foetal calf serum (FCS) and 100 µM NEAA from Invitrogen; 
and bovine pancreas insulin (5 µg/ml), hydrocortisone (0.4 µg/ml) and apo-transferrin (5 
µg/ml) from Sigma-Aldrich. 
2.1.4 MACS buffer 
To prepare magnetic-activated cell sorting (MACS) buffer, 2% FCS (Invitrogen) and 5 mM 
EDTA were added to sterile PBS and passed through 0.22 µm filter before use. 
2.1.5 FACS buffer 
To prepare fluorescent activated cell sorting (FACS) buffer, 2% FCS (Invitrogen) were 
added into sterile PBS and passed through 0.22 µm filter before use. 
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2.1.6 Freezing medium 
To store leukocytes at -70°C in Cryo Tubes after cell isolation, cells were quickly re-
suspended in complete medium supplemented with 40% FCS (Invitrogen) and 10% DMSO. 
 
2.2 Cell isolation 
2.2.1 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMCs were isolated from venous blood, collected from consented heathy volunteers. At 
the time of the collection, blood was mixed with anti-coagulant buffer made of 20 U/ml 
heparin and 15 mM EDTA (Fisher Scientific UK Ltd). Diluted blood was subsequently 
layered on top of Ficoll-Paque (Axis-Shield, Oslo, Norway) and centrifuged for 20 minutes 
at 1680 rpm at 18 °C with minimal acceleration and deceleration at lowest level. Afterwards, 
the white mononuclear cell layer (buffy coat) between the plasma and red blood cells 
(RBCs) was collected and washed three times with plain RPMI. The speed of centrifugation 
was gradually decreased from 1300 rpm, 1100 rpm to 900 rpm for three washes to reduce 
the number of platelets within the buffy coat. The cell pellet was then re-suspended in 
medium ready for the appropriate in vitro assays.  
2.2.2 Isolation of monocytes from PBMCs 
Monocytes were isolated by magnetic activated cell sorting (MACS) (Miltenyi) from 
PBMCs. In order to block non-specific binding of monoclonal antibodies to Fc receptors, 
PBMCs were firstly incubated with intravenous immunoglobulin (IvIg) (Kiovig; Baxter) at 
1:1000 dilution in MACS buffer. Cells were subsequently washed with 20 ml MACS buffer 
and incubated with anti-CD14 microbeads (Miltenyi) at 4°C for 20 min. At this point cells 
were positively selected by passing through one LS columns (Miltenyi) to obtain purities of 
>95% CD14+ monocytes, as determined by flow cytometry. 
2.2.3 Isolation of MAIT cells from PBMCs 
MAIT cells were isolated by MACS from monocyte-depleted PBMCs. Monocyte-depleted 
PBMCs were incubated with APC-conjugated anti-Vα7.2 mouse antibody (Biolegend) at 
4°C for 20 minutes. Subsequently, cells were washed with 20 ml MACS buffer and 
incubated with anti-APC microbeads (Miltenyi) at 4°C for 20 min.  Cells were then passed 
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through one LS columns to obtain purities of >95% Vα7.2+ T cells, as determined by flow 
cytometry. The percentage average of MAIT cells Vα7.2+ CD161+ among CD3+ Vα7.2+ T 
cells was 79.8% ± 6.49 (average ± SD). 
2.2.4 Isolation of γδ T cells from PBMCs 
γδ T cells were purified by MACS from PBMCs, depleted of both monocytes and Vα7.2+ T 
cells. The negative fraction of PBMCs following monocyte and MAIT cell purification was 
incubated with PE-Cy5-conjugated anti-Vγ9 mouse antibody (Immu360; Beckman Coulter) 
at 4°C for 20 minutes. Cells were then washed with 20 ml MACS buffer and incubated with 
anti-PE microbeads (Miltenyi) at 4°C for 20 min. Labelled cells were selected by LS 
columns (Miltenyi) to purities of >95%, as assessed by flow cytometry. 
 
2.3 Bacteria extract preparation 
Clinical bacterial isolates were kindly provided by Dr Mark Toleman, Division of Infection 
and Immunity, Cardiff University. These isolates were chosen based on their different 
capacity to utilise the non-mevalonate (HMB-PP) and vitamin B2 (DMRL) pathways (Table 
2.1). The utilisation of each pathway was determined based on the absence or presence of 
HMB-PP synthase (EC 1.17.7.1) and/or DMRL synthase (EC 2.5.1.78) in the genomes of 
corresponding bacterial strains, according to the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG; http://www.genome.jp/kegg). Bacteria stored at -70°C in cryotubes with 
cryogenic medium (sterile PBS supplemented with sucrose, glycerol and peptone) were 
inoculated onto Colorex urinary tract infections (UTI) agar plate (E&O Laboratories Ltd) 
and incubated aerobically for 24h at 37°C (Figure 2.1). The following day, the growth of 
single species was confirmed by the presence of uniform colonies with the same colour 
(corresponding to the single organism and not to contamination with others, Figure 2.1). 
Then, bacteria were transferred from agar plates to 20 ml Luria Broth (LB, tryptone, yeast 
extract and NaCl) in an universal tube (Thermo Fisher Scientific) and incubated for 2.5h at 
37°C with shaking to facilitate the bacterial division. Bacteria were harvested when the 
culture reached an optical density of 0.5-0.8 at a wavelength of 600 nm (OD600). Each tube 
was subsequently centrifuged at 3,600 rpm for 1h and the bacterial pellet re-suspended in 1 
ml of sterile PBS before sonication. Each bacterial suspension was kept on ice for sonication 
during the entire procedure using a Soniprep 150 sonicator for 10 min with 10 sec on and 
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20 sec off cycles. Bacterial extracts were then transferred to Eppendorf tubes (Fisher brand) 
and centrifuged at 20,000 g using an Eppendorf 5417R centrifuge, to pellet all cell debris. 
Next, collected supernatant was passed through Ultrafree-MC centrifugal filters (Durapore 
PVDF 0.1 µm, Millipore) and centrifuged for 10 min at 10,000 g, at 4°C, to remove larger 
aggregates. At this point a small aliquot was obtained to measure the protein concentration 
with BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific). To obtain fractions with 
lower molecular weight (<3kDa), the supernatant was then loaded on Ultracel YM-3 
centrifugal cellulose filters (3 kDa NMWCO, Millipore) and centrifuged for 60-90 min at 
10,000 g, 4°C. Bacterial extracts were then stored at -20°C and used for cell culture at 
dilutions corresponding to final protein concentrations of 60-100 µg/ml.  
Table 2.1. Bacterial strains used in the study for Vγ9/Vδ2 and MAIT cells activation assay  
  
Strain Antibiotic resistance Gram 
Non-
mevalonate 
pathway 
(Vγ9/Vδ2 T 
cell activation) 
Vitamin B2 
synthesis 
(MAIT cell 
activation) 
Klebsiella 
pneumoniae 
156 
NDM-1 and 16S 
rRNAmethylases  
positive 
resistance to 
 β-lactamases 
antibiotics (e.g. 
cephalosporins) and 
amynoglycosides 
− + + 
Escherichia coli 28 
NDM-1 and 16S 
rRNAmethylases  
positive 
resistance to 
 β-lactamases 
antibiotics (e.g. 
cephalosporins) and 
amynoglycosides 
− + + 
Escherichia coli 17 
NDM-1 and 16S 
rRNAmethylases  
positive 
resistance to  
β-lactamases 
antibiotic (e.g. 
cephalosporins) and 
amynoglycosides 
− + + 
Pseudomonas 
aeruginosa 
101-
5178 
SPM-1 positive 
resistance to  
β-lactamases 
antibiotics (e.g. 
cephalosporins) 
− + + 
Enterococcus 
faecalis 
12697 − − + − − 
Corynebacterium 
striatum 
 − − + − − 
Streptococcus 
pneumoniae 
12-799 − − + − − 
Staphylococcus 
aureus 
12981 − − + − + 
Listeria 
monocytogenes 
 − − + + − 
*The listed details include relevant features introduced into bacteria such as strain identification numbers, Gram 
staining (Positive, + or Negative, −), HMB-PP and Vitamin B2 synthesis status (Positive,+ or Negative, −), and 
enzyme that confer bacteria antibiotic resistance such as New Delhi MBL (NDM-1) and Sao Paulo β-lactamase 
(SPM-1).  
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Figure 2.1. Bacteria identification on urinary tract infection (UTI) agar plate.  
Bacteria were grown for single colony identification on UTI agar plates. This agar contains chromogens such 
as X-Gluc which is targeted towards β-glucosidase and allows the specific detection of E .faecalis through the 
formation of blue colonies. The other chromogen, Red-Gal, is cleaved by the enzyme β-galactosidase which 
is produced by E. coli and gives pink colonies, whereas S. aureus is characterized by a normal pigmentation. 
 
2.4 Ethic statement 
Recruitment of PD patients and healthy volunteers for this study was approved by the South 
East Wales Local Ethics Committee under reference numbers 04WSE04/27 and 
08/WSE04/17, respectively. It was conducted according to the principles expressed in the 
Declaration of Helsinki. All individuals provided written informed consent. The PD study 
was registered on the UK Clinical Research Network Study Portfolio under reference 
numbers #11838 "Patient immune responses to infection in Peritoneal Dialysis" (PERIT-
PD) and #11839 "Leukocyte phenotype and function in Peritoneal Dialysis" (LEUK-PD). 
Fresh omentum samples from consented patients were obtained from the Wales Kidney 
Research Tissue Bank. 
 
2.5 Patient information and data collection 
The local study cohort comprised 101 adults PD patients admitted to the University Hospital 
of Wales, Cardiff, on day 1 of acute peritonitis between September 2008 and October 2015. 
45 stable individuals receiving PD for at least 3 months and with no previous infection 
served as non-infected controls or stable PD samples (Table 2.2). Subjects known to be 
positive for HIV or hepatitis C virus were excluded. Clinical diagnosis of acute peritonitis 
46 
 
was based on the presence of abdominal pain and cloudy peritoneal effluent with >100 white 
blood cells/mm3. According to the microbiological analysis of the effluent by the routine 
Microbiology Laboratory, Public Health Wales, episodes of peritonitis were defined as 
culture-negative (with unclear aetiology) or as confirmed bacterial infections caused by 
specific subgroups of Gram-positive and Gram-negative organisms. The distribution of the 
non-mevalonate (HMB-PP) and vitamin B2 (DMRL) pathways across microbial species 
was determined based on the absence or presence of the enzymes HMB-PP synthase (EC 
1.17.7.1) and DMRL synthase (EC 2.5.1.78) in the corresponding genomes, according to 
the Kyoto Encyclopaedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg). 
Cases of fungal infection and mixed or unclear culture results were excluded from this 
analysis. 
 
Table 2.2. Characteristics of the PD patients recruited in this study. 
PD patients characteristics, Cardiff UK 
Total number 146 
Number of stable patients 45 
Number of infected patients 101 
Age (means ± SD) 68.4 ±13.6 
Women among positively identified patients (%) 32.6 
Culture positive episodes (%) 72.3 
HMB-PP+, Vitamin B2+ organisms among positively identified species (%) 34.2 
HMB-PP−, Vitamin B2+ organisms among positively identified species (%) 42.5 
HMB-PP−, VitaminB2− organisms among positively identified species (%) 23.2 
Culture negative infection (%) 22.7 
Fungal and mixed infections 4.9 
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2.6 T-cell culture 
2.6.1 PBMC cultured with bacterial extract or with the ligands HMB-PP and 
DMRL 
2.5 x 105 PBMCs per well were stimulated with bacterial extracts (Table 2.1) at a final 
protein concentration of 60 µg/ml in round-bottom, 96 well plates (Nunc plates; Thermo 
Scientific) and incubated overnight at 37°C. Similarly, PBMCs were stimulated with 0.1-
100 nM HMB-PP or 0.1-100 µM DMRL (Table 2.4) in the presence or absence of 10 µg/ml 
anti-CD277 antibodies and/or 20 µg/ml anti-MR1 antibodies. Following overnight 
incubation, plates were centrifuged at 1300 rpm for 3 min, and the supernatant was collected 
for measurement of cytokines by ELISA, whereas the cells were re-suspended in PBS for 
measurements of cell activation by flow cytometry. 
2.6.2 Co-culture of Vγ9+ T cells or MAIT cells with monocytes 
5 x 104 Vγ9+ T cells or Vα7.2+ T cells were co-cultured with autologous monocytes at 1:1 
ratios, in the presence of bacterial extracts (Table 2.1) at a final protein concentration of 60 
µg/ml in 96 well, round bottom plates (Nunc plates; Thermo Scientific) and incubated 
overnight at 37°C. For blocking experiments, anti-CD277 or anti-MR1 antibodies were 
added 30 min prior to stimulation of cultures. After overnight incubation, the plate was 
centrifuged at 1300 rpm for 3 min and the supernatant was collected for measurement of 
cytokines by ELISA, whereas cells were re-suspended in PBS for measurement of cell 
activation by flow cytometry. 
2.6.3 Conditioned Medium generation 
2.6.3.1 Preparation of Vγ9+ T cell-Conditioned Medium 
5 x 105 pure Vγ9+ T cells were re-suspended in 1 ml of complete RPMI medium and cultured 
in a 24-well flat bottom culture plates (Nunc plates; Thermo Scientific). Conditioned 
Medium (CoM) was generated by adding 100 nM HMB-PP (Table 2.4) to the cultured cells 
for 24h in a humidified incubator at 37°C with 5% CO2. Afterwards, the plate was 
centrifuged at 1400 rpm for 3 min and the supernatant (CoM) was collected carefully and 
stored at -70°C. Cell activation was confirmed by TNF-α and IFN-γ measurement in the 
CoM using ELISA. 
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2.6.3.2 Preparation of MAIT cell-Conditioned Medium 
5 x 105 pure Vα7.2+ MAIT cells were re-suspended in 1 ml of complete RPMI medium and 
cultured in a 24-well flat bottom culture plate (Nunc plates; Thermo Scientific). Conditioned 
Medium (CoM) was generated by adding Dynabeads® Human T-Activator CD3/CD28 
(Life Technologies) at 1:2 bead-to-cell ratio to the cell cultures for 24h, in a humidified 
incubator at 37°C with 5% CO2. The plate was then centrifuged at 1400 rpm for 3 min and 
the supernatant (CoM) was collected carefully and stored at -70°C. Cell activation was 
confirmed by TNF-α and IFN-γ measurement in the CoM using ELISA.  
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2.7 Isolation of peritoneal tissue cells and culture 
2.7.1 Mesothelial cell isolation and culture 
Human peritoneal mesothelial cells (HPMCs) were isolated from omental tissue of non-PD, 
consented patients undergoing abdominal surgery. Shortly after collection from surgery, 
tissue was stored in a sterile plastic container with PBS and incubated at 4°C until tissue 
dissection. In order to isolate HPMCs, omental tissue was subjected to 2 digestion cycles 
with 0.05% trypsin-EDTA solution (Invitrogen). Precisely, the tissue was placed in a petri 
dish and washed with PBS to remove blood and other material, and cut into small pieces 
depending on the tissue size. Each piece was then dissociated in a universal tube with 10 ml 
0.05% trypsin-EDTA solution (Invitrogen) and positioned on a rotated wheel at 37°C for 
15 minutes. Dissociated cells were pelleted by centrifugation at 1,300 rpm for 6 min at 15°C 
and supernatant was then carefully removed using a syringe. The cell pellet was re-
suspended and washed with 20 ml of complete M-199 medium by centrifuging at 1,300 rpm 
for 6 min at 15°C.Washed cells were re-suspended in 5 ml of fresh complete M199 medium 
and transferred into T25 flask (NUNC, Thermo Scientific) (passage  number 0) for further 
growth and expansion in culture. HPMCs were maintained at 37°C in a humidified incubator 
with 5% CO2. Cells were harvested and transferred to T75 flask when the cultures reached 
around confluency (≥80%) (passage 1). Prior to treatment, the growth of HPMCs was 
arrested by changing complete medium to serum-free M-199 for 48h. All the subsequent 
functional experiments were performed with the use of HPMCs expanded within 2 passages. 
2.7.2 Fibroblast cell isolation and culture 
Human peritoneal fibroblast cells (HPFBs) were isolated from omental tissue of consenting 
patients receiving abdominal surgery. Collected omental tissues were dissected into small 
pieces depending on the tissue size, and digested with 10 ml 0.05% trypsin-EDTA solution 
(Invitrogen) in tubes placed on rotated wheels at 37°C for 1h to facilitate the trypsinisation 
process. Digested cells were pelleted by centrifugation at 1,400 rpm for 6 min at 15°C and 
cell-free supernatant was then carefully removed. The cell pellet was re-suspended and 
rinsed with 20 ml of complete Ham’s F12 medium and centrifuged at 1,300 rpm for 6 min 
at 15°C.Washed cells were re-suspended in 5 ml of fresh complete Ham’s F12 medium and 
transferred into T25 flask (NUNC, Thermo Scientific) as passage 0 for further growth and 
expansion in culture. HPFBs were maintained at 37°C in a humidified incubator with 5% 
CO2. When the cultures reached confluency (≥80%), cells were harvested and transferred 
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to T75 flask (passage 1). Prior to treatment, the growth of HPFBs was arrested by reducing 
the proportion of FCS in complete medium to 0.2% for 48h. All the subsequent functional 
experiments were performed with the use of HPFBs expanded within 2 passages. 
2.7.3 Peritoneal mesothelial cells and fibroblast cell culture 
HPMCs and HPFBs were maintained in flat-bottom 96 well plate (NUNC, Thermo 
Scientific) around confluency, and then were arrested from proliferation by depleting or 
reducing FCS within the complete medium for 48h prior to subsequent treatments. 
Thereafter, cells were cultured under one of the following conditions: i) bacterial extract at 
indicated protein concentration, ii) CoM derived from Vγ9+ T cells or Vα7.2+ T cells at 
indicated dilution, iii) PD effluent derived from stable or infected PD patients at 1:1 dilution 
with cell medium, and iv) recombinant human TNF-α and IFN-γ, alone or in combination. 
For neutralisation of TNF-α and/or IFN-γ, CoM from unconventional T cells and PDE from 
infected patients were pre-treated with 10 µg/ml sTNFR p75-IgG1 fusion protein 
(Etanercept, Immunex) and anti-IFN-γ antibody together or alone for 30 mins before adding 
into cultures of HPMCs or HPFBs. 
All reagents were diluted in complete medium with reduced FCS concentration. For 
treatments, cells were incubated at 37°C in humidified incubator with 5% CO2 for 24h. 
Culture supernatant of HPMCs and HPFBs with various treatments was collected from plate 
centrifuged at 1,400 rpm for 5 min. Cytokines in collected supernatant were measured by 
ELISA according to manufacturers’ instruction. 
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2.8 Leukocyte isolation from PD fluid 
PD bags from stable patients (volume between 1 to 2.5 L from an overnight dwell) were 
collected as soon as possible in the morning after exchange and were placed on ice to reduce 
cell adhesion to the plastic bag. The date of collection, bag weight and patient details were 
recorded. Next, PD effluent was aliquoted in 500 ml centrifuge tube (Corning Inc., New 
York, USA) and centrifuged for 35 min at 2,000 rpm and 4 °C. 10 ml of cell-free supernatant 
was aliquoted into 2 ml labelled microcentrifuge tube (Fisher brand) and stored at -70 °C 
for cytokine analysis later. The remaining supernatant was decontaminated with chlorine 
tablets. The cells pellet was re-suspended in 50 ml centrifuge tube (Corning Inc., New York, 
USA) with cold phosphate buffered saline (PBS) (Invitrogen) and centrifuged for 8 min at 
1300 rpm at 4 °C. Cells were counted using a dual chamber haemocytometer (Assistant, 
Sondheim, Germany). While counting, the rest of the cells were re-suspended with 10 ml 
PBS and centrifuge for the second time for 8 min at 1,300 rpm and subsequently re-
suspended with appropriate volume of complete RPMI-1640 for further stimulation assays. 
Up to 14 x 106 cells were counted from one stable PD bag, among this 750,270 ± 1,3 x 106 
were CD3+ T cells. 
PD bags from infected patients were processed as described above. This procedure was 
performed predominantly by Dr. Ann Kift-Morgan and Dr. Chan-Yu Lin (Division of 
Infection & Immunity, Cardiff University) as previously described (Lin et al., 2013). 
2.8.1 Culture of peritoneal dialysis effluent cells 
To activate peritoneal unconventional T cells, 2.5 x 105cells were seeded per well in round-
bottom 96 well plate (Nunc; Thermo Scientific) and treated overnight with different 
bacterial extract positive and negative for HMB-PP and vitamin B2 (Table 2.1) and 
incubated overnight at 37°C in a humidified incubator with 5% CO2. In the indicated 
conditions, cells were pre-incubated with blocking antibodies against CD277 and MR1 at 
10 µg/ml for 30 min before addition of bacterial extracts. After overnight incubation, the 
plate was centrifuged at 1,300 rpm for 3 min and supernatant was collected for measurement 
of cytokines using ELISA, whereas the cells were re-suspended in PBS for measurement of 
cell activation by flow cytometry. 
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2.9 Flow cytometry 
Flow cytometry was used to assess the expression of activation markers by cells on their 
surface or secreted by various immune cells. Cells were firstly washed with PBS and then 
stained with Live/dead fixable Aqua dead cell stain kit (Life Technologies) for 15 min at 
RT to distinguish live cells from dead cells during analysis. Subsequently, cells were washed 
with FACS buffer, centrifuged at 1,400 rpm for 3 min and incubated with IvIg (Kiovig; 
Baxter) at 1:1000 dilution for 15 min in fridge to block non-specific binding of Fc receptors 
to antibodies. In order to stain for markers expressed on cell surface, cells were washed with 
FACS buffer and incubated with a cocktail of monoclonal antibodies conjugated with 
different fluorochromes (Table 2.3) in the fridge for 20 min. To process intracellular 
staining, cells were fixed for 15 min at RT with fixation buffer (eBioscience), washed with 
permeabilisation buffer (eBioscience), and then incubated for 20 minutes at RT with 
cocktails of fluorochrome-conjugated monoclonal antibodies (Table 2.3) diluted in 
permeabilisation buffer. Cells were finally washed with FACS buffer and results were 
acquired using FACS canto II (BD Biosciences). All analysis was performed using FlowJo 
(version 10.0.8; TreeStar Inc.) and the cells of interest were gated based on the appearance 
on side scatter and forward scatter area/high (SSC-A/FSC-A) for intact cells, forward scatter 
area/high (FSC-A/FSC-H) for single cells and live-dead/FSC-A for live cells. T cells were 
defined as CD3+ live cells. Among T cells, Vγ9+ T cells were defined as CD3+ Vγ9+ and 
MAIT cells as CD3+ Vα7.2+ CD161+ as previously described (Le Bourhis et al., 2010; 
Davey et al., 2011a).  
2.9.1 Flow cytometry analysis of intracellular IFN-γ and TNF-α 
Prior to staining, cells were simulated under different conditions in the presence of 5 µg/ml 
brefeldin A (Biolegend), which inhibits the intracellular protein transport, and incubated for 
5 hours at 37°C in humidified incubator with 5% CO2. Stimulated cells were then stained 
for surface markers and intracellularly for IFN-γ and TNF-α. 
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Table 2.3. Antibodies used in this study for surface and intracellular marker staining. 
 
Antigen Conjugate Clone Isotype Company 
Final 
concentration 
Surface 
marker 
staining 
CD3 APC-H7 SK7 Mouse IgG1,κ 
BD 
Bioscience 
1:60 
CD8 PE-Cy7 SK1 Mouse IgG1,κ 
BD 
Bioscience 
1:200 
CD14 PE-Cy7 61D3 Mouse IgG1,κ eBioscience 1:160 
CD15 APC HI98 Mouse IgM 
BD 
Bioscience 
1:5 
CD25 PE M-A251 Mouse IgG1, κ 
BD 
Pharmingen 
1:15 
CD69 FITC FB50 Mouse IgG1,κ 
BD 
Bioscience 
1:20 
CD161 BV421 HP-3G10 Mouse IgG1,κ Biolegend 1:50 
Vδ2 PE B6.1 Mouse IgG1,κ 
BD 
Bioscience 
1:100 
Vγ9 PE-Cy5 Immu360 Mouse IgG1,κ 
Beckman 
Coulter 
1:400 
Vα7.2 PE 3C10 Mouse IgG1,κ Biolegend 1:50 
Vα7.2 APC 3C10 Mouse IgG1,κ Biolegend 1:50 
CCR2 PE-Cy5 TG5 Mouse IgG2b Biolegend 1:20 
CCR2 APC K036C2 Mouse IgG2a Biolegend 1:40 
CCR5 PE 2D7 Mouse IgG2a 
BD 
Pharmingen 
1:20 
CCR6 PE 11A9 Mouse IgG1, κ 
BD 
Pharmingen 
1:20 
Intracellular 
marker  
staining 
IFN-γ PE-Cy7 B27 mouse IgG1 BioLegend 1:100 
TNF-α PE IPM2 mouse IgG1 Coulter 1:30 
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Table 2.4. Soluble mediators and blocking antibodies used in functional assay. 
 Reagent Supplier 
Functional assay 
Recombinant human TNF-α Miltenyi 
Recombinant human IFN-γ Peprotech 
HMB-PP 
A gift from Dr. Hassan Jomaa, 
Universitätsklinikum Giessen und 
Marburg, Germany 
DMRL 
A gift from Dr Boris Illarionov, 
Hamburg School of Food Science, 
Germany). 
Blocking assay 
Purified anti-human IL-1β antibody Clone H1b-27, Biolegend 
Purified anti-human IFN-γ antibody Clone B27, Biolegend 
Etanercept (sTNFR) Immunex 
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Figure 2.2. Flow diagram for gating strategy.  
The cells of interest were gated based on the appearance on side scatter and forward scatter area/high (SSC-
A/FSC-A); forward scatter area/high (FSC-A/FSC-H) were used to gate single cells and live-dead (fixable 
Aqua; Invitrogen) and FSC-A to select live cells. T-cells were defined as live cells and CD3+. Among these 
cells Vγ9+ T cells were defined as CD3+ Vγ9+ and MAIT cells as CD3+Vα7.2+CD161+. 
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2.10 Assessment of cytokines in culture supernatant by ELISA 
Cell-free peritoneal effluents were analysed on a SECTOR Imager 6000 (Meso Scale 
Discovery, Maryland, USA) for TNF-α, IFN-γ, IL-1β, CCL3, CCL4 and CXCL8 in 
collaboration with Dr. Ann Kift-Morgan (Institute of Infection & Immunity, Cardiff 
University). Conventional ELISA kits were used for the measurement of CCL2 
(eBioscience) and CCL20 (R&D Systems) in effluents with O.D. acquired using a Dynex 
MRX II reader. Cell culture supernatants were analysed using conventional ELISA kits for 
IFN-γ (Biolegend), TNF-α and CCL2 (eBioscience) as well as for CXCL8, CXCL10 and 
IL-6 (R&D Systems)with O.D. acquired using a Dynex MRX II reader. 
 
2.11 Real-time PCR 
2.11.1 RNA extraction from HPMCs 
In order to measure the mRNA expression of specific genes by HPMCs with different 
treatments, cells were lysed with TRIzol reagent (Invitrogen), which combines phenol and 
guanidine thiocyanate in a single phase to quickly inhibit RNase activity. The homogenate 
was separated to aqueous and organic phases by addition of chloroform (Sigma) for 5 min 
at RT followed by centrifugation at 12,000 g for 15 min at 4°C. RNA was precipitated from 
collected upper aqueous phase by addition of isopropanol (Sigma) with following 
centrifugation at 12,000 g for 10 min at 4°C. After precipitation, RNA was washed 3 times 
with 75% ethanol (Sigma) with centrifugation at 12,000 g for 5 min at 4°C each wash. 
Afterwards, the RNA pellet was air-dried for 15 min and rehydrated in 10 µl nuclease-free 
water. 1 µl of sample were used to measure the purity and concentration of RNA by 
NanoDrop 2000 spectrophotometer (Thermo Scientific). RNA was stored in all cases at -
80°C prior to subsequent experiments. 
2.11.2 Generation of cDNA 
mRNA was reverse-transcribed to cDNA using High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific). The RT master mix included: nuclease-free 
water, 10X RT buffer, 100 mM dNTPs, 40 U/µl RNase inhibitor (New England BioLabs ® 
Inc), 50 U/µl MultiScribe Reverse Transcriptase and 10X RT random primers. Next, 10 µl 
RT master mix were added to 10 µl RNA extract containing 0.5 µg RNA. The amplifications 
57 
 
were carried out with thermal cycles of 10 min at 25°C, 2 h at 37°C and 5 sec at 85°C, 
followed by a cooling step at 4°C. Generated cDNA was diluted with 60 µl water prior to 
use as a template for qPCR. 
2.11.3 Real-time Quantitative PCR 
mRNA quantitative polymerase chain reaction (qPCR) was carried out by mixing 300 nM 
forward and reverse mRNA specific PCR primer pairs (Table 2.5) with 10 µl Power SYBR® 
Green PCR Master Mix (Thermo Fisher Scientific) and 4.8 µl water. 16 µl mRNA specific 
master mix and 4 µl of diluted cDNA were added to each wells of Optical 96-Well Fast 
Plate (Thermo Fisher Scientific). The reaction was performed on ViiA7 Real-Time PCR 
System (Thermo Fisher Scientific) and the cycling parameters were: 10 min at 95°C, 40 
cycles of 15 sec at 95°C and 1 min at 60°C. Single PCR product amplification was 
confirmed by melting curve analysis. 
The comparative 2-∆CT method was used to calculate sample specific threshold cycle (Ct). 
The expression of target genes was normalized to the expressions of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) endogenous control. Relative expression to 1,000 
copies of the endogenous control was considered in this method. 
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Table 2.5. List of primer sequence used in real-time qPCR. 
Marker Reverse and Forward Primers (5’-3’) 
E-Cadherin 
F: TCCCAATACATCTCCCTTCACA 
R: ACCCACCTCTAAGGCCATCTTT 
ZO-1 
F: GGAGAGGTGTTCCGTGTTGT 
R: GGCTAGCTGCTCAGCTCTGT 
Occludin 
F: TAAATCCACGCCGGTTCCTGAAGT 
R: AGGTGTCTCAAAGTTACCACCGCT 
Claudin-1 
F: CGGGTTGCTTGCAATGTGC 
R: CCGGCGACAACATCGTGAC 
Fibronectin 
F: CCGAGGTTTTAACTGCGAGA 
R: TCACCCACTCGGTAAGTGTTC 
Collagen type I 
F: CATGTTCAGCTTTGTGGACCTC 
R: TTGGTGGGATGTCTTCGTCT 
Snail 
F: TTTACCTTCCAGCAGCCCTA 
R: GGACAGAGTCCCAGATGAGC 
α-SMA 
F: AACTGGGACGACATGGAAA 
R: AGGGTGGGATGCTCTTCAG 
GAPDH 
F: CCTCTGACTTCAACAGCGACAC 
R: TGTCATACCAGGAAATGAGCTTGA 
IL-6 
F: CGAGCCCACCGGGAACGAAA 
R: GGACCGAAGGCGCTTGTGGAG 
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2.12 Statistical analysis 
Statistical analyses were performed using Excel 2013, GraphPad Prism 6.0 or IBMS SPSS 
Statistics 20.0. All variables were tested for normal distribution using D'Agostino & Pearson 
omnibus normality test. Comparison between two non-paired normal distributed groups 
(parametric) was performed by one-sample t test, whereas paired t test was used for matched 
data. For the data that did not pass the normality test (non-parametric), Wilcoxon t test was 
performed for paired data and Mann-Whitney t test was used for unpaired data.  
Comparison among three or more groups was performed with ordinary one way-ANOVA 
for unpaired parametric data. Repeated measure one-way ANOVA for paired parametric 
data. While the comparison between matched non-parametric groups was performed by 
Friedman test, Kruskal-Wallis test was used for the comparisons between unpaired non-
parametric groups. Descriptive statistics were described as mean ± standard error of the 
mean (SEM) unless otherwise stated.  
Survival analysis was performed using the Kaplan-Meier approach and differences in 
overall survival between groups was assessed using the log-rank test. 
Outcomes associated with technique failure were predicted using multiple logistic 
regression analyses for both categorical and continuous variables. The analysis was 
conducted based on forward elimination of data and the chance of risk of a particular 
outcome was described as Odds Ratio. All statistical tests were two-tailed; differences were 
considered statistically significant as indicated in the figures and tables: *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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Chapter 3. Responses of unconventional T cells from peripheral blood 
and peritoneal dialysis effluent to bacterial extracts 
3.1 Introduction 
Bacterial infection with concomitant inflammation is a major risk factor limiting the choice 
of peritoneal dialysis (PD) as treatment for patients with end-stage renal failure. During this 
treatment the peritoneal membrane allows excess water and waste products to be discarded 
from blood to the dialysate solution by ultrafiltration. The permanent catheter placed in the 
peritoneal cavity allows regular exchange of PDE fluid. However, the catheter increases risk 
of bacterial infection, leading to peritoneal inflammation and membrane damage that result 
in progressive ultrafiltration failure (Cho and Johnson, 2014).  
Vγ9+ T cells and MAIT cells represent significant populations of lymphocytes in blood that 
uniquely possess the ability to respond to a large array of microbes by the capacity to 
recognize the microbial metabolite HMB-PP and vitamin B2, respectively. Indeed, both cell 
types respond to the majority of Gram− pathogens (e.g. E. coli, Klebsiella, Pseudomonas) 
and most Gram+ bacteria (e.g. C. striatum, S. aureus, Mycobacterium), whereas only MAIT 
cells became activated in presence of Staphylococcus species and Vγ9+ T cells in presence 
of Listeria species. However, both of them do not react to streptococci. Consequently, these 
two unconventional types of T cell complement each other in bacterial recognition. 
Most importantly, previous work in the laboratory showed that Vγ9/Vδ2 T-cells represent a 
sizeable proportion of peritoneal leukocytes that are able not only to predict episodes of PD-
related peritonitis caused by Gram-negative bacteria, but also to identify patients at 
increased risk of treatment failure (Davey et al., 2011a). In addition, MAIT cell numbers 
increase at sites of infection in diseases such as tuberculosis, and decrease in the blood of 
these patients (Le Bourhis et al., 2010; Gold et al., 2010). 
To validate the diagnostic, predictive and therapeutic value of local unconventional T cell 
populations (γδ T-cells, MAIT cells) in PD patients during episodes of peritonitis, this study 
aimed to analyse the function of these cells, from both peripheral blood and peritoneal 
dialysis effluent, in response to a broad range of Gram− and Gram+ pathogens.  
The specificity of peritoneal Vγ9/Vδ2 T-cells and MAIT cells for HMB-PP and vitamin B2 
metabolites, respectively, was demonstrated. Only bacteria positive for these two 
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metabolites (e.g. E. coli and C. striatum) activated γδ T cells and MAIT cells, and induced 
the release of TNF-α and IFN-γ, highlighting the importance of these cells in promoting 
inflammation during PD-associated infection. The data generated in the work described in 
this chapter provide insight into the relationship between microbial pathogens and 
inflammatory responses during peritoneal infection. 
 
3.2 Aims 
The aims of this chapter were: 
1. To identify Vγ9+ γδ T cells and MAIT cells in PBMC and PDE fluid. 
2. To study the responsiveness of peripheral blood and PDE Vγ9+ γδ T cells and MAIT 
cells to microbial ligands, and to a range of bacterial pathogens. 
3. To study the role of BTN3 and MR1 in unconventional T cell responses to bacterial 
pathogens. 
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3.3 Results 
3.3.1 Identification of Vγ9+ T cells and MAIT cells in both PBMC and PDE 
In order to study the role of unconventional T cells during PD-associated infections, I firstly 
tried to identify these lymphocytes in PBMC and in PDE of healthy and stable patients. In 
line with previous methods (Martin et al., 2009), I used an antibody against the invariant 
segment of the TCRα chain, Vα7.2-Jα33, together with an antibody against the marker 
CD161 to identify MAIT cells. HMB-PP responsive Vγ9/Vδ2 T cells were identified using 
an antibody against the Vγ9 chain of the TCR, since in the vast majority of cases the Vγ9 
chains pair with Vδ2 (Bonneville et al., 2010). As shown in Figure 3.1, Vα7.2+ CD161+ 
MAIT cells were identified in both PBMC and PDE. The frequency of MAIT cells was 
higher in PBMC than in PDE (p=0.06, mean 7.0 % ± 2.0 and 3.0 % ± 0.5, respectively). 
Similarly, the frequency of Vγ9+ γδ T cells was significantly higher in PBMC compared to 
PDE (p<0.0009, mean 6.5 % ± 1.0 and 2.6 % ± 0.6, respectively). 
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Figure 3.1. Identification of γδ T cells and MAIT cells in PBMC and PDE.  
(A) Representative FACS plot of Vγ9+ γδ T cells and Vα7.2+ CD161+ MAIT cells in peripheral blood of 
healthy volunteers (n=4) and in peritoneal effluent (PDE) of stable PD patients (n=45). (B) Frequencies of 
unconventional T cells amongst all T cells in PBMC and PDE are shown as ± SEM. Data were analysed by 
Mann Whitney t test.  
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3.3.2 Selective activation of γδ T cells and MAIT cells by HMB-PP and DMRL, 
respectively, in PBMC 
To study the peritoneal unconventional T cell response to bacterial extract pathogens, I first 
analysed activation of these cells by microbial metabolites HMB-PP ((E)-4-hydroxy-3-
methylbut-2-enyl pyrophosphate) and the vitamin B2 precursor DMRL (6,7-dimethyl-8-D-
ribityllumazine). As shown in Figure 3.2, upregulated CD69 expression was observed in 
peripheral Vγ9+ T cells, but not MAIT cells, in PBMC treated with ≥1 nM HMB-PP. In 
addition, γδ T cells alone showed a parallel (although less pronounced) increase in the CD25 
expression. When culturing PBMC with ≥10 µM DMRL, only MAIT cells upregulated 
CD69. I also observed a significant MAIT cell CD25 expression, but only when these cells 
where exposed to high concentrations of DMRL (Figure 3.2). These findings agree with 
previous investigations demonstrating specific but modest activation of MAIT cells by 
DMRL. Unfortunately, high bioactivity ligands such as 5-(2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-OP-RU; (Corbett et al., 2014)) were not available for the present 
studies. 
As described previously, Vγ9+ T cell response to HMB-PP and related compounds depends 
on the presence of the receptor CD277/BTN3A (Harly et al., 2012; Rhodes et al., 2015), 
whereas MAIT cells recognise antigens in association with the MHC class I related 
molecule MR1 (Le Bourhis et al., 2010; Treiner et al., 2003). Accordingly, the responses of 
Vγ9+ T cells and MAIT cells to HMB-PP and DMRL were abrogated in the presence of 
monoclonal antibodies against CD277 and MR1, respectively (Figure 3.3), confirming that 
these accessory molecules were necessary for full activation of unconventional T cells. 
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Figure 3.2. Response of peripheral unconventional T cells to microbial metabolites in vitro.  
Surface expression of CD69 and CD25 by Vγ9+ and Vα7.2+ CD161+ T-cells in PBMC stimulated overnight 
with HMB-PP (0.01-100 nM) or DMRL (0.3-100 µM). Data were analysed by two-way ANOVA with 
Bonferroni’s post-hoc tests and are shown as mean values ± SD, n=5. Significant differences are indicated: *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 3.3. Vγ9+ T cells and MAIT cells response to microbial metabolites is BTN3 and MR1 
dependent, respectively. 
Representative FACS plots of two donors showing CD69 expression by Vγ9+ T-cells and Vα7.2+ T-cells in 
PBMC stimulated overnight with 100 nM HMB-PP or 100 µM DMRL, in the absence or presence of anti-
BTN3 or anti-MR1 monoclonal antibodies. 
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3.3.3 Selective activation of peripheral Vγ9/Vδ2+ T cells and MAIT cells in the 
presence of bacteria producing HMB-PP and vitamin B2 
To study the role of unconventional T cells in the peritoneal immune response during PD 
related infection, I prepared low molecular weight fractions of bacterial extracts from 
clinical isolates Gram+ (E. faecalis, C. striatum, S. aureus, L. monocytogenes, S. 
pneumoniae) and Gram− (E. coli, K. pneumoniae, P. aeruginosa) species which possess or 
not the non-mevalonate and riboflavin pathways (Table 2.1, Materials and Methods).  
Firstly the ability of these extracts to activate peripheral unconventional T cells was tested. 
PBMC were cultured overnight with bacterial extracts, and cell activation was then assessed 
by flow cytometry and ELISA. As shown in Figure 3.4, up to 60 % of Vγ9+ γδ T cells 
upregulated CD69 in the presence of HMB-PP positive bacteria such as P. aeruginosa and 
K. pneumoniae, with a significant upregulation in response to E. coli and C. striatum ( 
p<0.05 and p<0.01, respectively). A similar response to HMB-PP+ bacteria was observed in 
Vγ9+ T cells that co-expressed CD69 and TNF-α or IFN-γ. In contrast, activation of γδ T 
cells was not seen in the presence of extracts from the HMB-PP deficient species E. faecalis 
(Figure 3.4). However, although not significant, Vγ9+ T cell activation was also observed 
in presence of the HMB-PP− bacteria S. aureus.  
In the same PBMC cultures, up to 60% of MAIT cells upregulated CD69 and released TNF-
α and IFN-γ in the presence of vitamin B2 positive bacteria K. pneumoniae, E.coli, C. 
striatum and S. aureus, but not P. aeruginosa (Figure 3.5). By contrast, only background 
activation of MAIT cells was observed in response to vitamin B2− E. faecalis. 
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Figure 3.4. Peripheral Vγ9/Vδ2+ T cells respond to HMB-PP producing bacterial extract, but not to 
HMB-PP deficient bacteria.  
CD69 surface expression and intracellular TNF-α and IFN-γ expression by Vγ9/Vδ2 T cells in PBMC cultured 
overnight in the presence of bacterial extracts from P. aeruginosa, K. pneumoniae, E. coli, C. striatum, S. 
aureus and E. faecalis , corresponding to final protein concentrations of 60 µg/ml (means ± SEM, n=4-5). 
Data were analysed by Kruskall Wallis test with Dunn’s post-hoc tests, and significant differences are 
indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 3.5. Peripheral MAIT cells respond to vitamin B2 producing bacterial extract but not to 
extract from vitamin B2 deficient bacteria.  
CD69 surface expression and TNF-α and IFN-γ intracellular expression by MAIT cells in PBMC cultured 
overnight in the presence of bacterial extracts from P. aeruginosa, K. pneumoniae, E.coli, C. striatum, S. 
aureus and E. faecalis bacterial extracts, corresponding to final protein concentrations of 60 µg/ml (means ± 
SD, n=4-5). Data were analysed by Kruskall Wallis test with Dunn’s post-hoc tests, and significant differences 
are indicated:: *, p<0.05; **, p<0.01; ***, p<0.001. 
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To confirm that full activation of unconventional T cells occurred in the context of antigen 
presenting cells, I isolated both Vγ9+ T cells and Vα7.2+ T cells from peripheral blood and 
cultured them with autologous monocytes. As shown in Figure 3.6, purified Vγ9+ T cells 
upregulated CD69 and secreted TNF-α and IFN-γ, not only in response to HMB-PP, but 
also when cultured with the HMB-PP+ bacteria K. pneumoniae and E. coli in the presence 
of autologous monocytes. By contrast, there was no such activation in the presence of HMB-
PP− E. faecalis. Similarly, MAIT cells co-cultured with autologous monocytes upregulated 
CD69 and produced TNF-α and IFN-γ in response to DMRL as control, and to vitamin B2 
producing bacteria. Of note, in these co-cultures purified MAIT cells also produced TNF-
α, but not IFN-γ, in the presence of vitamin B2 deficient E. faecalis (Figure 3.7), possibly 
due to indirect activation by activated monocytes. Overall, the amount of IFN-γ secreted by 
MAIT cells was lower compared to that released by γδ T cells in the same conditions. 
In summary, unconventional T cells were able to produce pro-inflammatory cytokines in 
response to bacterial extracts that contained HMB-PP and/or vitamin B2, but not in the 
presence of bacteria lacking these two metabolites (e.g. E. faecalis). These findings 
highlight the similar responsiveness of these two cell types to microbial metabolites. 
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Figure 3.6. MACS-purified Vγ9/Vδ2 T cells co-cultured with autologous monocytes respond to HMB-
PP producing bacteria but not to HMB-PP deficient bacteria.  
FACS plots show expression of CD69 and either TNF-α or IFN-γ by Vγ9+ T-cells in response to K. 
pneumoniae, E. coli and E. faecalis, and 100 nM HMB-PP as control (representative of three donors). 
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Figure 3.7. MACS-purified CD3+ Vα7.2+ T cells co-cultured with autologous monocytes respond to 
vitamin B2 producing bacteria but not to vitamin B2 deficient bacteria.  
FACS plots show expression of CD69 and either TNF-α or IFN-γ by Vα7.2+ CD161+ MAIT cells in response 
to K. pneumoniae, E.coli and E. faecalis, and 100 µM DMRL as control (representative of three donors). 
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3.3.4 Selective activation of γδ T cells and MAIT cells by HMB-PP and vitamin B2 
positive bacteria in PDE 
To study the potential role of unconventional T cells during PD associated infection I next 
assessed the activation profile of these cells in the presence of different bacterial extract. 
Firstly, I showed that peritoneal γδ T cells, but not MAIT cells, were able to respond to 
increasing concentrations of synthetic HMB-PP as assessed by CD69 upregulation and 
TNF-α production. By contrast, peritoneal MAIT cells, but not γδ T cells, produced TNF-α 
in response to synthetic DMRL. Due to the high background of CD69 expression on 
peritoneal MAIT cell, I did not observe significant upregulation of CD69 expression in 
response to DMRL (Figure 3.8).  
Next, peritoneal leukocytes derived from stable PD patients were cultured with different 
bacterial extracts. As shown in Figure 3.9, peritoneal Vγ9/Vδ2 T cells responded readily to 
HMB-PP producing Gram-negative (E. coli, K. pneumoniae, P. aeruginosa) and Gram-
positive bacteria (C. striatum, L. monocytogenes), but not to HMB-PP deficient E. faecalis 
and S. pneumoniae. Similarly to the peripheral Vγ9+ T cells, peritoneal Vγ9/Vδ2 T cells also 
responded to S. aureus. Failure to block this response with anti-BTN3 neutralizing 
antibodies (data not shown) suggested an indirect recognition of S. aureus, possibly via 
superantigens (Morita et al., 2001).  
Peritoneal MAIT cells responded to vitamin B2 positive bacteria E. coli, K. pneumoniae, C. 
striatum and S. aureus, but not to the vitamin B2− species L. monocytogenes, E. faecalis and 
S. pneumoniae with respect to TNF-α production (Figure 3.10). Peritoneal MAIT cell 
responses to vitamin B2+ P. aeruginosa failed to reach statistical significance. Compared to 
TNF-α production, IFN-γ responses generally followed similar trends but were less 
pronounced and at times did not reach statistical significance (Figure 3.10). Overall, these 
findings confirm that both peritoneal γδ T cells and/or peritoneal MAIT cells are able to 
respond to a broad range of bacterial pathogens that are associated with PD-related 
infections.  
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Figure 3.8. Peritoneal effluent derived unconventional T cell responses to microbial metabolites in 
vitro.  
Activation of Vγ9+ γδ T cells and Vα7.2+ CD161+ MAIT cells in peritoneal cells from stable PD patients 
following overnight stimulation with HMB-PP (n=4 individual patients) or with the vitamin B2 precursor 
DMRL (n=3), as analysed by flow cytometry and expressed as proportion of γδ or MAIT cells co-expressing 
CD69 and TNF-α (means ± SEM). Comparisons with the control group were made by repeated measures one 
way ANOVA, whereas multiple comparison between Vγ9+ T cells and MAIT cells were made by two-way 
ANOVA with Sidak’s multi comparison post hoc test. Significant differences are indicated: *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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Figure 3.9. Peritoneal γδ T cell responses to microbial metabolites.  
Activation of peritoneal Vγ9+ γδ T cells following overnight stimulation in the presence of extracts from 
different clinical isolates: E. coli, K. pneumoniae, P. aeruginosa and C. striatum (all HMB-PP+, in blue); and 
L. monocytogenes, S. aureus, E. faecalis and S. pneumoniae (all HMB-PP−, in red). (A). Summary of all data. 
Each data point represents an individual patient. Data were analysed by Kruskall Wallis test with Dunn’s post-
hoc tests (mean ± SEM, n= 21-27), significant differences are indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
(B) Representative FACS plots showing CD69 surface expression and intracellular TNF-α and IFN-γ 
expression by peritoneal Vγ9+ γδ T cells (representative of 21-27 individual donors). 
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Figure 3.10. Peritoneal MAIT cell responses to microbial metabolites.  
Activation of peritoneal MAIT cells following overnight stimulation in the presence of extracts from different 
clinical isolates E. coli, K. pneumoniae, P. aeruginosa, C. striatum, L. monocytogenes and S. aureus (all 
vitamin B2+, in blue); and E. faecalis and S. pneumoniae (vitamin B2−, in red). (A). Summary of all data. Each 
data point represents an individual patient. Data were analysed by Kruskall Wallis test with Dunn’s post-hoc 
tests (mean ± SEM, n=8-17). Differences were considered significant as indicated: *, p<0.05; **, p<0.01; ***, 
p<0.001. (B) Representative FACS plot of one donor showing CD69 surface expression and intracellular TNF-
α and IFN-γ expression by peritoneal MAIT cells (representative of 8-17 individual donors). 
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3.3.5 Peritoneal unconventional T cells are major producers of TNF-α and IFN-γ in 
response to microbial pathogens 
TNF-α is a pro-inflammatory cytokine that drives acute and chronic inflammation during 
episodes of peritonitis (Aroeira et al., 2007; Davey et al., 2011a). Previous work from our 
laboratory has also shown that, of all soluble factors present in peritoneal effluent, elevated 
levels of TNF-α at day 1 of peritonitis are associated with high rates of technique failure 
and mortality within three months following infection (Davey et al., 2011a). Here, after 
treatment of PDE leukocytes with E.coli extract (as example of an organism producing both 
HMB-PP and vitamin B2), responding Vγ9/Vδ2+ T cells and MAIT cells together made up 
a large fraction of TNF-α (median of 31.7%) and IFN-γ (median of 39.2%) producing T 
cells, despite considerable variability across individual PD patients (Figure 3.11 and 3.12A). 
Of note, IFN-γ was produced principally by γδ T cells compared to MAIT cells (median of 
33.0% vs 6.2 %, Figure 3.11 and 3.12A). By contrast, both cell types represented far lower 
proportions of lymphocytes amongst E. coli stimulated TNF-α− and IFN-γ− T cells (median 
of 7.7% and 8.2%, respectively, Figure 3.11 and 3.12A). Similar results were obtained using 
C. striatum extracts (data not shown).  
Next, I measured the amount of IFN-γ released by PDE cells into the culture medium in 
response to different Gram+ bacteria, and demonstrated that this cytokine was secreted only 
when the cells were exposed to extracts from bacteria possessing both HMB-PP and vitamin 
B2 (S. aureus and C. striatum), but not in the presence of E. faecalis extracts (HMB-PP− 
vitamin B2−, Figure 3.12B). Similar results were obtained for IFN-γ-induced chemokine 
CXCL10. By contrast, levels of CXCL8 were comparable in response to all three Gram+ 
bacteria (Figure 3.12B), confirming equal potential of the different organisms to stimulate 
peritoneal leukocytes other than unconventional T cells. Secretion of TNF-α was not 
assessed in these experiments, as any unconventional T cell-derived TNF-α would have 
been masked by TNF-α produced by peritoneal macrophages and neutrophils. In summary, 
unconventional T cells, while representing only a minor population of peritoneal T cells, 
are major producers of pro-inflammatory cytokines in response to a wide range of microbial 
pathogens. 
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Figure 3.11. In vitro responsiveness of peritoneal leukocytes to pathogenic bacteria.  
Intracellular staining of (A) TNF-α and (B) IFN-γ in peritoneal leukocytes cultured in the absence (medium; 
left panel) or presence of E. coli extract (middle panel), as analysed by flow cytometry within the CD3+ gate. 
Right panel, distribution of Vα7.2+ and Vγ9+ cells within all CD3+ cytokine+ peritoneal cells after stimulation 
with E. coli extract. Data shown are representative of 8-27 individual donors. 
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Figure 3.12. In vitro responsiveness of peritoneal leukocytes to pathogenic bacteria.  
(A) Proportion of Vα7.2+ and Vγ9+ cells amongst peritoneal T cells producing TNF-α and IFN-γ in response 
to E. coli, as analysed by flow cytometry in nine stable PD patients. ND, not done. (B) Overnight secretion of 
IFN-γ, CXCL10 and CXCL8 by peritoneal leukocytes in response to S. aureus, C. striatum and E. faecalis, as 
analysed by ELISA (median ± SEM, n=27). Data were analysed using Kruskal-Wallis tests combined with 
Dunn's multiple comparisons tests. Each data point represents an individual patient; asterisks indicate 
significant differences compared to medium controls: *, p<0.05; **, p<0.01; ***, p<0.001. 
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3.3.6 Blocking antibodies against BTN3 and MR1 modulate pro-inflammatory 
cytokine production by unconventional T cells 
During acute peritonitis, TNF-α and IFN-γ levels are frequently elevated (Lin et al., 2013). 
TNF-α and IFN-γ synergistically activate peritoneal tissue cells, thereby creating a positive 
feedback loop amplifying local chemokine and cytokine production during acute 
inflammation (Kawka et al., 2014; Visser et al., 1998). However, IFN-γ can have both pro- 
and anti-inflammatory effects, for instance in combination with IL-6, and regulate the 
recruitment of leukocytes to the site of infection (Fielding et al., 2014; McLoughlin et al., 
2003). Together with TGF-β and IL-1β, TNF-α drives epithelial to mesenchymal transition 
(EMT) of mesothelial cells, which in the long term may lead to inflammation-associated 
damage of the peritoneal membrane (Aroeira et al., 2007; Wang, 2013). 
As shown above, peritoneal γδ T cells and MAIT cells produced substantial amounts of 
TNF-α and IFN-γ in response to microbial pathogens. Given the impact of these two 
cytokines on leukocyte recruitment, resolution of the inflammatory response and local tissue 
damage, I performed blocking experiments to manipulate the amount of cytokines released 
by these cells in response to microbial pathogens. In the presence of anti-BTN3/CD277 
mAbs there was significantly reduced peritoneal Vγ9+ T cell CD69 expression, either alone 
or in combination with TNF-α or IFN-γ, in response to HMB-PP+ bacterial extracts (e.g. E. 
coli, K. pneumoniae, P. aeruginosa, C. striatum) (Figure 3.13 and 3.14) .  
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Figure 3.13. BTN3 dependent responses of peritoneal γδ T cells to Gram-positive and Gram-negative 
bacteria.  
Activation of total peritoneal leukocytes by bacterial extracts, in the presence or absence of anti-BTN3 
blocking antibodies, as analysed by flow cytometry within the Vγ9+ CD3+ cell gate. FACS plots show surface 
expression of CD69 and intracellular expression of TNF-α (left) or IFN-γ (right) after overnight stimulation; 
data are representative of independent experiments using five different donors.  
  
C
D
6
9
TNF-α
Medium
C.striatum
E.coli
Pseudomonas
Klebsiella
+ anti-BTN3
Vγ9+ CD3+ T cells
Medium
C.striatum
E.coli
Pseudomonas
Klebsiella
+ anti-BTN3
C
D
6
9
IFN-γ
82 
 
 
Figure 3.14. BTN3 dependent responses of peritoneal γδ T cells to Gram-positive and Gram-negative 
bacteria.  
Summary of all BTN3 blocking experiments performed, shown as expression of CD69 (top), co-expression 
of CD69 and TNF-α (middle) or CD69 and IFN-γ (bottom) by Vγ9+ T cells after overnight stimulation with 
bacterial extracts. Data were analysed using two-way ANOVA and Bonferroni's post hoc multiple 
comparisons tests. Each data point represents an individual patient; asterisks depict significant differences of 
anti-BTN3 treated samples compared to untreated controls. Significant differences are indicated: *, p<0.05; 
**, p<0.01; ***, p<0.001. 
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In the above paragraph I showed that PDE leukocytes secreted IFN-γ in response to HMB-
PP and vitamin B2 positive bacteria but not in the presence of bacteria negative for these 
metabolites, indicating that unconventional T cells may have been responsible for these 
patterns. Supporting this hypothesis, blocking of BTN3 induced a significant reduction of 
IFN-γ release by PDE cells (Figure 3.15). IFN-γ levels were also reduced following the 
addition of anti-MR1 antibodies, but not significantly. However, at least in the case of C. 
striatum, the addition of anti-BTN3 and anti-MR1 antibodies together had an additive effect 
on IFN-γ inhibition (Figure 3.15), indicating a minor but key contribution of peritoneal 
MAIT cells to the overall IFN-γ production. Collectively, these experiments showed that, 
of all leukocytes present in PDE, specific inhibition of the small population of 
unconventional T cells reduced the production of pro-inflammatory cytokines by these cells. 
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Figure 3.15. BTN3 and MR1 dependent secretion of IFN-γ by unconventional peritoneal T cells in 
presence of Gram-positive and Gram-negative bacteria.  
(A) IFN-γ ELISA of cell culture supernatants derived from PDE leukocytes cultured for 20 h with extracts 
from HMB-PP+ and vitamin B2+ bacteria K. pneumoniae, E.coli and C. striatum in the absence or presence of 
blocking antibodies against BTN3 and MR1, alone or in combination. (B) Effect of the presence of anti-BTN3 
and anti-MR1 blocking antibodies measured as relative inhibition of IFN-γ released by PDE leukocytes. (C) 
Effect of the presence of anti-BTN3 anti-MR1 antibodies and their respective isotype control measured as 
relative inhibition of IFN-γ released by PDE leukocytes in presence of C. striatum. Data were analysed by 
Kruskall Wallis test with Dunn’s post-hoc test (mean ± SEM). Significant differences are indicated: *, p<0.05; 
**, p<0.01; ***, p<0.001. 
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3.3.7 Pro-inflammatory cytokines released by PDE leukocytes in response to Gram+ 
and Gram− bacteria 
In addition to the clear association of peritoneal MAIT cells and Vγ9+ T cell responses in 
the presence of distinct groups of bacterial pathogens, local immune fingerprints at the site 
of infection are likely to comprise immune mediators produced by different types of immune 
and non-immune cells. Previous work in the host laboratory showed that peritoneal levels 
of cytokines IL-10, IL-β, TNF-α and IL-6 predicted culture-positive infections at day 1 of 
acute peritonitis (Lin et al., 2013). Elevated levels of IL-10, TNF-α and IL-β were detected 
during episodes of peritonitis caused by Gram− bacteria. 
To validate this distinct pattern of cytokine secretion in the presence of Gram− infections, 
PDE leukocytes from stable patients were cultured in the presence of different Gram− and 
Gram+ bacterial extracts. As shown in Figure 3.16, the most pronounced synthesis of IL-10 
by PDE cells occurred in the presence of Gram− K. pneumoniae, followed by E. coli and 
Gram+ C. striatum. TNF-α and IL-β production was similar for Gram− and Gram+ species. 
However, compared to the other Gram species, I did not observe a significant response in 
other cytokines release by cells in the presence of P. aeruginosa, one of the main bacteria 
responsible for Gram− infection (Figure 3.16).  
IL-17 is another pro-inflammatory cytokine produced during PD associated infection that is 
synthesized mainly by resident cells at the site of infection, such as CD4+ Th17 cells. A 
recent study by Rodrigues-Diez et al. showed that mice exposed to IL-17A develop long 
term peritoneal inflammation and fibrosis. Furthermore, IL-17A was present in peritoneal 
biopsies of inflamed tissue but absent in healthy individuals (Rodrigues-Díez et al., 2014). 
Given the importance of this cytokine during peritonitis, I analysed the presence of IL-17A 
in supernatant derived from PDE cells cultured in the presence of Gram+ and Gram− 
bacterial extracts. My data show that IL-17A production increased in response to each 
bacterial extract (E. coli, K. pneumoniae, P. aeruginosa, S. aureus, C. striatum, E. faecalis) 
with the greatest increase in response to Gram+ S. aureus. Collectively, these data confirm 
a contribution of peritoneal leukocytes to immune fingerprints in the presence of Gram+ and 
Gram− infections.  
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Figure 3.16. Cytokine secretion by PDE leukocytes in response to Gram-positive and Gram-negative 
bacteria.  
Overnight secretion of IL-10, TNF-α, IL-17 and IL-1β by peritoneal leukocytes in response to Gram-positive 
(S. aureus, C. striatum and E. faecalis) and Gram-negative (K. pneumoniae, P. aeruginosa and E. coli) 
bacterial extracts, as determined by ELISA. Data were analysed using Kruskal Wallis test with Dunn’s post-
hoc test (mean ± SEM, n=3-28). Significant differences are indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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3.4 Discussion 
In this Chapter I show for the first time how unconventional γδ T cells and MAIT cells may 
contribute to the amplification of inflammation during episodes of PD associated infection.  
PD infections caused by Gram− bacteria (e.g. E. coli, K. pneumoniae, Enterobacter) are 
typically less frequent than Gram+ infections (Ghali et al., 2011), but are associated with 
worse outcome (Chapter 1). A recent study has shown that peritoneal Vγ9/Vδ2 T cell 
frequency predicted Gram− infection at day 1 of infection, and the presence of these cells 
was associated with technique failure in 90 days (Lin et al., 2013). Here I confirmed that 
peritoneal Vγ9+ T cells were activated by HMB-PP+ bacteria but not by HMB-PP− 
pathogens, and release pro-inflammatory cytokines such as TNF-α and IFN-γ. 
Unexpectedly, γδ T cells were also activated in the presence of the HMB-PP− bacterium S. 
aureus, which might be BTN3 independent and instead mediated by superantigens such as 
staphylococcal enterotoxin A (SEA) (Morita et al., 2001). The vast majority of Gram− 
organisms causing peritonitis in PD patients are positive for both HMB-PP and vitamin B2, 
and are therefore likely to activate Vγ9+ T cells as well as MAIT cells. Here, both peripheral 
and peritoneal MAIT cells were specifically activated by the vitamin B2 metabolite, DMRL, 
and in response to extracts from vitamin B2 producing Gram− and Gram+ bacteria. MAIT 
cell responses to DMRL were not as pronounced as γδ T cell responses to HMB-PP. These 
modest responses were most likely due to the relatively modest bioactivity of DMRL 
compared to the true MAIT cell activators, 5-OP-RU 5-OE-RU (Corbett et al., 2014; Kjer-
Nielsen et al., 2012), but these molecules are not commercially available and could not be 
tested in the present studies. Nevertheless, I observed that in some patients MAIT cells also 
became positive for CD69 and IFN-γ in the presence of vitamin B2− bacteria such as E. 
faecalis. This is possibly due to activation of MAIT in the presence of IL-12 and IL-18 in 
an MR1 independent manner (Ussher et al. 2014). In this system E. faecalis may induce a 
TLR2 dependent activation of peritoneal monocytes, which in turn activates MAIT cells by 
secretion of IL-12 and IL-18.  
Davey et al. showed that elevated TNF-α at day 1 of peritonitis episodes is associated with 
technique failure and mortality (Davey et al., 2011a). In this chapter I demonstrated that 
peritoneal Vγ9/Vδ2 T cells and MAIT cells together represent up to 50% of TNF-α 
producing T cells of the PDE cells following stimulation with E.coli extract. This suggests 
that unconventional T cells, even if only present at small frequencies, are major producers 
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of pro-inflammatory cytokines in response to microbial stimulation. This has important 
implications for the orchestration of early immune responses at the site of infection.  
Another pro-inflammatory cytokine released by activated unconventional T cells is IFN-γ, 
which is responsible for both leukocyte recruitment to the site of infection and their 
subsequent clearance to ensure resolution (Glik and Douvdevani, 2006; McLoughlin et al., 
2003). Repeated episodes of infection or overproduction of IFN-γ will lead to a prolonged 
presence of neutrophils at the site of infection. In turn, neutrophils contribute to pathogen 
clearance via secretion of anti-microbial molecules, but the persistent presence of these cells 
can lead to the damage of the peritoneal membrane (Nathan, 2006). This means that the 
presence of IFN-γ at the wrong time and for too long at high concentration can lead to 
ultrafiltration failure (Davies, 2014). Furthermore, IFN-γ can induce fibrosis by excessive 
STAT1 activation and dysregulation of metalloprotease production (Fielding et al., 2014). 
I here showed that γδ T cells alone were able to contribute up to 50% and more of IFN-γ 
producing CD3+ T cells in the presence of bacterial extracts, and that blocking of BTN3 was 
able to reduce this IFN-γ production substantially.  
Alone or in combination TNF-α and IFN-γ produced by unconventional T cells are able to 
induce i) long-term survival and differentiation of neutrophils at the site of infection, which 
in turn are able to process antigens and prime CD4+ and CD8+ T cells (Davey et al., 2014); 
ii) differentiation of local monocytes into APCs (Eberl et al., 2009) and iii) activation of 
peritoneal tissue cells (Loghmani et al., 2002; Visser et al., 1998). All these processes may 
play a role in regulating local inflammatory responses at the site of infection with 
consequences for long term PD therapy failure, implying that the inactivation of this small 
population of unconventional T cells might have a significant impact on processes linked to 
fibrosis and ultrafiltration failure. 
Previous findings in our laboratory showed Gram-negative infections were associated with 
increased levels of IL-1β, IL-10 and TNF-α in the PDE of infected patients compared to 
culture-negative and Gram-positive infection (Lin et al., 2013). I here tested whether or not 
it was possible to confirm this pattern of activation in vitro and determine the underlying 
mechanisms.  
Gram− bacteria such as E. coli and K. pneumoniae induced more IL-10 in comparison to the 
Gram+ bacteria analysed. However, PDE leukocyte released similar amounts of IL-1β and 
TNF-α in the presence of Gram+ and Gram− bacteria. This can be explained by the difference 
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in PDE cell composition in stable patients and during Gram-negative infection. The latter is 
characterized by the presence of the potent bacterial ligand LPS, larger numbers of 
neutrophils and a lower proportion of monocytes/macrophages, which bear TLRs that 
respond promptly to LPS by releasing large quantities of cytokines. By contrast, Gram+ 
infections are characterized by the presence of Gram+ lipopeptides and large proportions of 
CD4 and CD8 T cells with lower TLR expression (Lin et al., 2013). This scenario is different 
to that in the stable patient, where the principal cell types are monocytes/macrophages 
followed by T cells and comparatively few neutrophils (Sharon Lewis and Clifford Holmes, 
1991). Therefore, the similar release of TNF-α and IL-1β observed in the presence of Gram+ 
and Gram− bacteria  can be explained by similar monocyte TLR activation (Kumar et al., 
2009) in presence of these bacteria (Davey et al. 2011). 
IL-17 is produced during PD associated infection, secreted mainly by CD4+ Th17 cells that 
are associated with inflammatory conditions such as rheumatoid arthritis and psoriasis 
(Niebuhr et al., 2011; Pène et al., 2008). The main function of this cytokine is to recruit 
neutrophils to the site of infection by regulating the release of CXCL8 and peptides with 
anti-microbial proprieties. Earlier studies showed association between IL-17 and peritoneal 
fibrosis in both mice and humans (Rodrigues-Díez et al., 2014). In addition, it has been 
shown that the balance between Th17 and regulatory T cells is crucial to maintain the 
integrity of the peritoneal membrane (Liappas et al., 2015). I here show that most Gram+ 
and Gram− bacteria induced IL-17 production by PDE cells, and S. aureus was particularly 
effective. These results are supported by previous studies reporting elevated IL-17 
production by PBMC cultured in the presence of S. aureus derived enterotoxins or 
supernatants (Islander et al., 2010). This effect was dependent on the presence of IL-1 
receptor and induced chiefly by CD4+ IL-17+ T cells (Haileselassie et al., 2013; Islander et 
al., 2010; Niebuhr et al., 2011). Moreover, since S. aureus is a vitamin B2 positive 
bacterium, another source of IL-17 may be MAIT cells. Indeed, once activated, these cells 
release IL-17 and express CCR6, RORC and IL-23R, which are associated with Th17 profile 
(Dusseaux et al., 2011). 
In summary in this chapter I showed a specific activation of peritoneal unconventional T 
cells in response to HMB-PP+ and vitamin B2+ organisms, resulting in the production of 
pro-inflammatory cytokines that can be modulated using monoclonal antibodies targeting 
the unconventional T cell presenting molecules BTN3 and MR1. 
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Chapter 4. In vivo analysis of Vγ9+ T cells and MAIT cells during acute 
PD associated infections 
4.1 Introduction 
In Chapter 3, pro-inflammatory cytokine release by peritoneal Vγ9+ T cells and MAIT cells 
in response to HMB-PP and/or vitamin B2 positive bacteria was shown. Moreover, it has 
been reported that in a cross-sectional cohort of PD patients Vγ9/Vδ2 T cells increase in 
frequency and number during infections caused by Gram-negative and HMB-PP producing 
bacteria (Davey et al., 2011a; Lin et al., 2013) confirming the ability of these cells to respond 
rapidly in acute infections. However, it is unclear whether this increase is caused by a 
preferential recruitment of Vγ9/Vδ2 T cells to the peritoneal cavity in certain infections 
and/or a result of ligand-specific local activation and expansion in response to the respective 
pathogens. 
In this Chapter, I performed an in vivo analysis of Vγ9+ T cells and MAIT cells during acute 
infections. Given the considerable biological variation between patients and the underlying 
pathologies, I analysed matched blood and PDE samples to examine systemic responses in 
blood and local responses in the peritoneal cavity, in stable PD patients before infection and 
again in the same individuals when presenting with acute peritonitis. Such matched 
investigations have never been attempted before, and highlight a unique advantage of 
studying individuals receiving PD. 
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4.2 Aims 
The aims of this Chapter were: 
1. To analyse expression of chemokines associated with cell migration during episodes 
of infection in PDE at day 1 of the infection. 
2. To analyse unconventional T cells in the peripheral blood of stable PD patients for 
expression of chemokine receptors implicated in migration. 
3. To analyse the frequencies of Vγ9/Vδ2 T cells and MAIT cells in the peritoneal 
cavity and in blood during episodes of PD associated infections. 
4. To analyse unconventional T cell composition in both blood and peritoneal cavity 
with respect to patient age. 
 
4.3 Results 
4.3.1 Peripheral unconventional T cells express inflammatory chemokine receptors 
PD associated peritonitis is characterised by a significant influx of leukocytes into the 
peritoneal cavity including unconventional T cells (Davey et al., 2011a, 2014; Glik and 
Douvdevani, 2006). This process involves adhesion of peripheral leukocytes to the 
endothelium, trans-endothelial migration and chemotaxis through the peripheral tissue 
(Bromley et al., 2008). This is mainly caused by the production of inflammatory chemokines 
by tissue resident cells. The balance among these chemokines is fundamental to avoid tissue 
fibrosis (Bromley et al., 2008; Charo and Ransohoff, 2006). 
As shown in Figure 4.1, PDE from patients presenting with episodes of PD related 
peritonitis at the University Hospital of Wales showed an increase in chemokines including 
CXCL8, CCL2, CCL3, CCL4 and CCL20 at day 1 of the infection, compared to the effluent 
from stable non-infected patients. To test whether this chemokine increase depended on the 
causative pathogen, I divided the peritonitis group into subgroups according to the 
metabolic signature of the identified species (HMB-PP+ vitamin B2+, HMB-PP− vitamin B2+ 
and HMB-PP− vitamin B2−, and no growth). As shown in Figure 4.2, no significant 
differences between these groups and no growth was found for CCL20 release. By contrast, 
multiple comparisons showed that CCL2, CCL3 and CCL4 are significantly increased in 
infection caused by HMB-PP+ and vitamin B2+ microbes compared to the no growth culture 
results (Figure 4.2). Therefore, an increase of these chemokines during infection caused by 
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HMB-PP+ and/or vitamin B2+ bacteria might lead to migration of peripheral unconventional 
T cells to the infection site. Moreover, increased neutrophil chemotactic factor CXCL8 was 
observed, most clearly in the HMB-PP+ and vitamin B2+ groups (Figure 4.2), supporting a 
role for this chemokine in the recruitment of neutrophils at the site of infection during Gram 
negative (HMB-PP and vitamin B2 positive) infections (Lin et al., 2013).  
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Figure 4.1. Peritoneal levels of pro-inflammatory chemokines in stable and infected PD patients.  
PDE was collected from stable PD patients and from patients presenting with acute peritonitis, and analysed 
for the presence of the neutrophil-attracting chemokine CXCL8 and the T cell and monocyte attracting 
inflammatory chemokines, CCL2, CCL3, CCL4 and CCL20. Data were analysed using Mann Whitney tests.  
Each data point represents an individual patient, error bars depict the median ± interquartile range. *, p<0.05; 
**, p<0.01; ***, p< 0.001; ****, p< 0.0001. 
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Figure 4.2. Peritoneal levels of inflammatory chemokines in infected PD patients.  
PDE was collected from stable PD patients and from patients presenting with acute peritonitis and analysed 
for neutrophil-attracting chemokine CXCL8 and the lymphocyte and monocyte attracting inflammatory 
chemokines CCL2, CCL3, CCL4 and CCL20. Infected patients were divided by the microbiological results 
in infections HMB-PP+ vitamin B2+ (blue), HMB-PP− vitamin B2+ (red), HMB-PP− vitamin B2− (green) and 
no growth (black). Data were analysed using Kruskal Wallis test with Dunn’s post hoc test, and comparisons 
were made with the no growth group. Each data point represents an individual patient, error bars depict the 
mean±SEM. *, p<0.05; **, p<0.01; ***, p< 0.001; ****, p< 0.0001. 
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Next, to test if Vγ9+ T cells and MAIT cells could potentially migrate to the infection site 
in response to these chemokines, expression of chemokine receptors CCR5 (for CCL4 and 
CCL3), CCR2 (for CCL2) and CCR6 (for CCL20) was measured on γδ T cells (CD3+ Vγ9+) 
and on MAIT cells (Vα7.2+ CD161+) from peripheral blood of stable PD patients. The flow 
cytometry analysis in Figure 4.3A shows significant upregulation of CCR5, CCR2 and 
CCR6 expression on Vα7.2+ CD161+ MAIT cells compared to their Vα7.2− CD161+ T cell 
counterparts. Similarly, Vγ9+ T cells showed a significantly increased expression of CCR5 
and CCR6 compared to the non-Vγ9+ cells. CCR2 was also present on γδ T cells, but the 
expression level was comparable to other CD3+ T cells (Figure 4.3A).  
These migratory profiles highlight the potential of blood Vγ9+ T cells and MAIT cells to 
migrate toward locally expressed CCL2, CCL3, CCL4 and CCL20 at the site of infection, 
in keeping with a substantial increase in absolute numbers of both Vγ9/Vδ2 T cells and 
MAIT cells during acute peritonitis compared to stable patients (Figure 4.3B). These 
findings indicate that unconventional T cells may be rapidly co-recruited from blood to the 
inflamed peritoneal cavity along with neutrophils, and complement the local pool of tissue-
resident Vγ9/Vδ2 T cells and MAIT cells already present in stable PD patients. 
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Figure 4.3. Migratory profile of peripheral blood Vγ9+ T cells and MAIT cells.  
(A) Peripheral blood samples from stable PD patients were analysed for chemokine receptor expression by 
flow cytometry on circulating Vγ9/Vδ2 T cells and MAIT cells. Panels show the percentage of CCR2+, CCR5+ 
and CCR6+ cells in Vα7.2+ CD161− and Vα7.2+ CD161+ CD3+ T cells (upper panels), and in Vγ9− and Vγ9+ 
CD3+ T cells (lower panels). (B) Peritoneal cells were collected from stable PD patients and from patients 
presenting with acute peritonitis, and examined by flow cytometry. Data shown are total cell counts and the 
total numbers of Vγ9
+
 CD3
+
 T cells and Vα7.2
+
 CD161
+
 MAIT cells within the peritoneal cell population. 
Data were analysed using Mann Whitney tests. Each data point represents an individual patient, error bars 
depict the mean ± SEM. *, p<0.05; **, p<0.01; ***, p< 0.001; ****, p< 0.0001. 
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4.3.2 Local enrichment of γδ T cells and MAIT cells during acute infection caused 
by bacterial pathogens producing HMB-PP and vitamin B2 
Previous work done in our laboratory showed a significant increase in the frequency of 
Vγ9/Vδ2 T cells in the peritoneal cavity of patients infected with HMB-PP+ and/or Gram 
bacteria compared to HMB-PP− infections (Davey et al., 2011a; Lin et al., 2013). However, 
it is unclear whether this increase is caused by preferential recruitment of Vγ9/Vδ2 T cells 
to the peritoneal cavity during such infections and/or this is a result of ligand-specific local 
activation and expansion in response to the respective pathogens. To address this question, 
the frequencies of Vγ9+ T cells and MAIT cells were measured in infected and stable 
patients and compared to the frequencies of the same cell types in blood.  
As shown in Figure 4.4A, no differences were found in the frequency of peripheral Vγ9+ T 
cells between stable and infected patients, nor in the frequency of Vγ9+ T cells between the 
peritoneal cavity and blood in the absence of infection. However, there was a significant 
enrichment of Vγ9+ T cells in the peritoneal cavity of patients presenting with peritonitis 
compared to the peripheral blood (median 1.74% vs 0.52%) but there was not difference in 
the frequency of peritoneal Vγ9+ T cells between stable and infected patients (Figure 4.4A).  
Unlike γδ T cells, MAIT cells were already present in a larger proportion in the peritoneal 
cavity of stable patients when compared with blood (median 1.8% vs. 0.56%). This 
proportion increased significantly during episodes of infection, but not in comparison with 
non-infection status in the peritoneal cavity (median 1.80% vs 1.5%) (Figure 4.4B).  
This analysis confirmed a significant difference in the Vγ9+ T cell frequency between HMB-
PP+ and HMB-PP− infection (median 2.6% vs 1.35%) suggesting increased recruitment 
and/or proliferation of these cells at the site of infection in response to HMB-PP+ bacteria. 
However, I did not find a similar difference with Vγ9+ T-cells in culture negative results 
(Figure 4.5A). The frequency of MAIT cells was measured in patients presenting with 
peritonitis caused by vitamin B2+ and vitamin B2− bacteria. Although not significantly 
different, the MAIT cell frequency was higher in vitamin B2+ infection than vitamin B2− 
infection (median 2.7% vs 1.2%, Figure 4.5B). In addition, the frequency of MAIT cells in 
vitamin B2+ infection was significantly higher compared to culture negative episodes of 
peritonitis (Figure 4.5B). 
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Figure 4.4. Vγ9+ T cell and MAIT cell frequencies in peripheral blood and peritoneal cavity of stable 
patients and patients with acute peritonitis.  
(A) Flow cytometry analysis of Vγ9+ T cell frequency in blood (n=41) and peritoneal cavity (n=44) of stable 
patients (blue), and in patients with acute peritonitis (n=15 and n=99, respectively, shown in red). (B) Scatter 
dot plot of MAIT cell proportions in blood and peritoneal cavity of stable patients (n=40 and n=42, 
respectively) and during peritonitis (n=15 and n=57, respectively). Data were analysed using Mann Whitney 
tests. Each data point represents an individual patient, *, p<0.05; **, p<0.01; ***, p< 0.001; ****, p< 0.0001. 
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Figure 4.5. Vγ9+ T cell and MAIT cell frequencies in the peritoneal cavity of patients with acute 
peritonitis.  
Flow cytometry analysis of Vγ9+ T cells and MAIT cells in the peritoneal cavity of PD patients with episodes 
of acute peritonitis that was either culture positive (red) or culture negative (black). (A) Scatter dot plot of 
Vγ9+ T cells in the peritoneal cavity during acute peritonitis according to the HMB-PP status of the causative 
organism (HMB-PP+, n=33; HMB-PP−, n=49; culture negative episodes, n=18). (B) MAIT cell frequency in 
the peritoneal cavity during acute peritonitis according to the vitamin B2 status of the causative organism 
(vitamin B2+, n=38; vitamin B2−, n=9; culture negative episodes, n=10). Data were analysed using Kruskal 
Wallis test with Dunn’s post hoc test. Each data point represents an individual patient, *, p<0.05; **, p<0.01; 
***, p< 0.001; ****, p< 0.0001. 
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Mindful of the biological variation between individuals (Figures 4.4 and 4.5) frequencies of 
Vγ9+ T cells and MAIT cells in the blood and peritoneal cavity of PD patients from a 
longitudinal study were then examined before and after episodes of acute peritonitis by 
studying matched samples from the same individuals.  
The proportions of Vγ9/Vδ2 T cells among all CD3+ T cells in blood and peritoneal cavity 
were comparable in the absence of infection, and on the day of presentation with acute 
peritonitis there was a trend towards elevated levels of Vγ9/Vδ2 T cells compared to blood 
(median 1.19% vs 0.52%, Figure 4.6). Although not statistically significant due to the low 
number of matched samples available for this study, this increase of local Vγ9/Vδ2 T cell 
levels compared to blood was apparent in patients infected with HMB-PP+ bacteria (4/4) 
but not in patients with HMB-PP− infections (Figure 4.6, upper panel), despite comparable 
peritoneal chemokine profiles between HMB-PP+ and HMB-PP− infections (Figure 4.2).  
There was a significant increase in local Vγ9/Vδ2 T cell levels in patients who developed 
acute peritonitis compared to the stable state (median 3.7% vs 1.56%, Figure 4.7). When 
the infected group was subdivided into infections caused by HMB-PP+ and HMB-PP− 
organisms, significantly increased levels of Vγ9/Vδ2 T cells were observed in matched 
patients with HMB-PP+ infection (median 5.6% vs. 1.9%) but not in patients infected with 
HMB-PP− bacteria (Figure 4.7). These findings suggest that Vγ9/Vδ2 T cells accumulate 
locally at the site of infection in response to HMB-PP+ but not HMB-PP−, organisms 
confirming the notion of a ligand-induced local expansion.  
Similar results were observed for peritoneal MAIT cells. While in stable PD patients the 
local MAIT cell levels in the peritoneal cavity were significantly higher than those in blood 
(median 1.85% vs. 0.77%), such differences between anatomical sites were much more 
pronounced in acutely infected individuals (median 3.30% vs. 0.40%, Figure 4.6). Further, 
peritoneal MAIT cells increased significantly in matched patients affected by vitamin B2+ 
infection but not in vitamin B2− compared to the blood levels (Figure 4.6). Similarly, 
peritoneal cavity MAIT cells increased during infection compared to the stable state (5.6% 
vs. 1.65%, Figure 4.7). This increase was significant in vitamin B2+ infection (5.64% vs 
1.53%) but not in infections by vitamin B2− organisms (Figure 4.7). 
In summary, these results confirm that Vγ9+ T cells and MAIT cells not only are able to 
enrich the site of infection during PD associated peritonitis but that they appear to expand 
and increase in the peritoneal cavity in response to bacteria producing the corresponding 
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ligands. The specificity of this responsiveness by local Vγ9+ T cells and MAIT cells implies 
that their frequency might be used as biomarker to discriminate HMB-PP and/or vitamin B2 
positive infection from infections where these metabolites are absent. 
 
 
Figure 4.6. Unconventional T cells in matched blood and PDE samples in stable PD patients and 
during acute peritonitis.  
Unconventional T cell levels in blood and effluent of stable (A, blue) and during episodes of acute peritonitis 
(B, red). Matched samples from the same individuals were analysed by flow cytometry for the proportion of 
Vγ9/Vδ2 T cells (identified as Vγ9+; upper panels) and MAIT cells (Vα7.2+ CD161+; lower panels), expressed 
as percentage of all CD3+ T cells. Samples were collected whilst patients were stable and again when they 
presented with acute peritonitis (day 1), before commencing antibiotic treatment. Vγ9+ T cells were measured 
in 26 stable and 16 matched infected patients, MAIT cell data are from 27 and 15 matched infected patients. 
Patients with confirmed infections were divided into HMB-PP and vitamin B2 status subgroups. Data were 
analysed using Wilcoxon matched-pairs signed rank tests.  Each data point represents an individual patient. *, 
p<0.05; **, p<0.01; ***, p< 0.001; ****, p<0.0001. 
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Figure 4.7. Unconventional T cells in matched PDE samples from PD patients before and during acute 
peritonitis.  
Unconventional T cell levels in peritoneal effluent of individuals when they were stable (blue) and when they 
presented with acute peritonitis (red), before commencing antibiotic treatment. Matched peritoneal effluents 
from the same individuals were analysed by flow cytometry for the proportion of Vγ9/Vδ2 T cells (identified 
as Vγ9+; upper panels, A and B) and MAIT cells (Vα7.2+ CD161+; lower panels, C and D), expressed as 
percentage of all CD3+ T cells. Vγ9+ T cells were measured in 20 individuals, MAIT cells in 17 individuals. 
Patients with confirmed infections were divided into HMB-PP and vitamin B2 status subgroups. Data were 
analysed using Wilcoxon matched-pairs signed rank tests. Each data point represents an individual patient. *, 
p<0.05; **, p<0.01; ***, p< 0.001; ****, p<0.0001. 
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4.3.3 Decreased frequencies of peritoneal MAIT cells and Vγ9/Vδ2 T cells in elderly 
patients 
Previous findings related to the measurement of γδ T cells and MAIT cells in peripheral 
blood showed an age-dependent decline of these cells in elderly individuals (Caccamo, 
2006; Colonna-Romano et al., 2002; Novak et al., 2014). The patients recruited for the 
present study had an average age of 68.4 years with SD ± 13.6 (Chapter 2). I therefore 
investigated whether the age of these patients might affect the frequencies of unconventional 
T cells in both blood and peritoneal cavity of stable and infected patients, as possible 
confounders of pathogen-specific immune profiles.  
As shown in Figure 4.8, the frequency of Vγ9+ T cells in blood of stable and infected patients 
were not correlated with age. The failure to confirm earlier findings in healthy individuals 
(Caccamo, 2006) may have been due to the skewed age profile of the PD patients in the 
present study as Vγ9+ T cells were reported to peak in younger adults at an age that was not 
represented sufficiently here. However, a significant negative correlation between Vγ9+ T 
cells in the peritoneal cavity in stable patients and age was observed (Figure 4.9).  
As shown in Figure 4.8, like Vγ9+ T cells, MAIT cells in blood of stable and infected patients 
were not correlated with age. Although no correlation of MAIT cell frequencies with age 
was found in stable PD patients, MAIT cells showed a significant decrease with age in the 
peritoneal cavity of infected patients (Figures 4.9), indicating that patient age might affect 
the incidence of unconventional T cells present at the peritoneal site. 
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Figure 4.8. Correlation between frequencies of blood unconventional T cells and patient age.  
Scatter plot showing correlations (Spearman's rank correlation coefficient) between frequency of blood MAIT 
cells (left column) and age in a cohort of stable patients (n=40, upper graph) and during acute peritonitis (n=15, 
lower graph). Right column, correlation of peripheral Vγ9/Vδ2 T cells with age in a cohort of stable patient 
(n=41, upper graph) and with acute peritonitis (n=15, lower graph). 
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Figure 4.9. Correlation between frequencies of peritoneal unconventional T cells and patient age.  
Scatterplot showing correlations (Spearman's rank correlation coefficient) between the frequency of peritoneal 
MAIT cells (left column) and age in a cohort of stable patients (n=42, upper graph) and during acute peritonitis 
(n=57, lower graph). Correlation of peritoneal Vγ9/Vδ2 cells (right column) with age in a cohort of stable 
patient (n=44, upper graph) and with acute peritonitis (n=99, lower graph). Correlation was determined using 
Spearman correlation coefficient. 
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4.4 Discussion 
Chemokines are small molecules that link local tissue activation to the recruitment of 
leukocytes including antigen specific T cells. At the time of infection, tissue cells and 
macrophages produce different chemokines upon triggering of pattern recognition receptors 
such as TLR2 and TLR4 (Luster, 2002). I observed an increase in expression of chemokines 
CCL2, CCL3 and CCL4 in HMB-PP and vitamin B2 positive infection, and parallel 
expression of chemokine receptor CCR5 and CCR2 on peripheral Vγ9+ and Vα7.2+ CD161+ 
T cells. The presence of these chemokine receptors on unconventional T cells and NKT 
cells has been described as a common feature of Th17 and effector CD8+ T cells (Bromley 
et al., 2008; Dusseaux et al., 2011; Glatzel et al., 2002). Once recruited to the site of 
infection, innate T cells release large amounts of IFN-γ and TNF-α which in turn amplify 
the local immune response. This observation may therefore provide a link between 
recruitment and/or presence of these cells at the site of infection and poor outcome when 
these cells are persistently activated. 
To further investigate the role of unconventional T cells in PD related infection, the 
frequency of both Vγ9+ T cells and MAIT cells was measured in two different cohorts of 
PD patients, before and after infection.  
For the first time I looked at the frequency of immune cells in the peripheral blood and in 
the peritoneal cavity, not only in a cross-sectional cohort of patients but also longitudinally 
in individuals before and after episodes of peritonitis.  
Previous studies have shown the capacity of unconventional T cells to migrate to perturbed 
tissue in different inflammatory diseases (Laggner et al., 2011; Magalhaes et al., 2015) and 
demonstrated a simultaneous reduction of these cells at the periphery. Here, an increase in 
unconventional T cells in the peritoneal cavity during episodes of infection was seen. The 
increase of pro-inflammatory chemokines like CCL3 and CCL4 during episodes of HMB-
PP and/or vitamin B2 positive infections, and the expression of chemokine receptor (e.g. 
CCR5) on unconventional T cells, suggest a recruitment of circulating T cells to the site of 
infection. Moreover, I found that this increase was ligand specific, with an enrichment of 
Vγ9+ T cells and MAIT cells, respectively, in HMB-PP and vitamin B2+ infections, but not 
in HMB-PP and vitamin B2 infections. This indicates that the increase is mainly antigen-
specific, possibly due to local cell proliferation and expansion.  
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In contrast to previous studies in other inflammatory diseases (Dunne et al., 2013; Laggner 
et al., 2011; Magalhaes et al., 2015) I did not find a decrease in circulating unconventional 
T cells during episodes of PD associated infections, but this does not mean that these cells 
are not recruited from the blood. The absence of difference observed might be due to a 
combinations of factors such as the advanced age of the patient cohort studied and the 
relatively small sample size. A previous study on a cohort of young psoriasis patients 
showed a decrease in peripheral Vγ9+ T cells from 4.21% to 2.16% when compared with 
healthy donors (Laggner et al., 2011) and other reports suggest that circulating 
unconventional T cell frequency decreases with age (Caccamo, 2006; Colonna-Romano et 
al., 2002; Lee et al., 2014; Novak et al., 2014). In this study, most patients were between 50 
and 80 years old, with a median of Vγ9+ T cells and MAIT cells in blood of 1.5% and 0.56%, 
respectively. Therefore the frequency of circulating unconventional T cells may already 
have dropped, and this could explain the absence of a further decrease of these cells in blood 
during episodes of peritoneal infection. Similarly i) the negative correlation between age 
and frequency of MAIT cells in the peritoneal cavity of infected patients, ii) the low 
percentage of these cells in the peritoneal cavity of stable patients (median 1.8%), and iii) 
the variability across PD patients could explain why I did not observe a significant 
difference between MAIT cells in stable and infected unpaired patients. To overcome some 
of these limitations I analysed matched patient samples and detected an overall increase of 
MAIT cells in the peritoneal cavity during episode of PD associated infection.  
In summary, the results presented in this Chapter highlight a ligand-specific expansion of 
Vγ9+ T cells and MAIT cells at the site of infection and the specific contribution of these 
cells in infection caused by HMB-PP+ and/or vitamin B2+ pathogens. Consequently, these 
data suggest an association between the presence of these unconventional T cells and poorer 
outcomes in acute peritonitis. 
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Chapter 5. Clinical outcomes depending on the capacity of the 
causative organism to produce ligands for Vγ9/Vδ2 T cells and MAIT 
cells 
5.1 Introduction 
Infection remains a major cause of morbidity and technique failure in PD patients. PD 
related peritonitis accounts for 20% of PD technique failure cases and 2-6% of all deaths 
(Cho and Johnson, 2014). The mechanisms that underpin the clinical severity of peritonitis 
episodes and their association with clinical outcomes remain poorly defined.  
The ANZDATA registry captures data from patients receiving renal replacement therapy in 
Australia and New Zealand, and is the largest and most comprehensive dataset of its kind 
in the world. The registry collects the incidence, prevalence and outcomes of dialysis and 
kidney transplant patients (Mcdonald and Russ, 2013; Mcdonald et al., 2012), and thereby 
supports health care planning and informs research (Mcdonald, Clayton, and Hurst 2012). 
In addition, the registry captures information about episodes of infection by recording the 
type of organism identified by microbiological culture and technique failure rates related to 
individual episodes. Around 13% of infections are recorded as culture negative, 11% are 
polymicrobial and the remaining 76% caused by a single organism. Single positive 
infections are mainly caused by Gram+ organisms (around 60% of all cases) such as 
coagulase-negative staphylococci (CoNS) followed by S. aureus, streptococci and 
enterococci. Gram− infection account for around 23% of single organism peritonitis 
episodes.  The most common Gram− organisms identified are E. coli followed by Klebsiella, 
Pseudomonas, Acinetobacter and Enterobacter (Cho and Johnson, 2014; Ghali et al., 2011; 
Jarvis et al., 2010). Moreover, similar levels and types of infections were also recorded in 
the UK registry (Chapter 1). 
Technique failure is defined as any PD related complication that leads to the permanent 
cessation of the therapy. The end of therapy can be the consequence of catheter removal, 
permanent switch from PD to HD, switch to HD for a period of at least 1 month (interim 
HD) and death (Quinn et al., 2010). Type of infection is a major risk factor for PD outcome. 
Upon diagnosis of peritonitis, empirical antimicrobial therapy covering both Gram+ and 
Gram− organisms is initiated before the nature of the causative pathogen is known, which 
generally takes several days due to the limitations of microbiological culture (Cho and 
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Johnson, 2014; Li et al., 2010). In many cases no organisms can be identified as result of 
suboptimal sample collection or culture method, or as consequence of a continued antibiotic 
use. Depending on the centre, culture negative results may account for up to 50% of all 
peritonitis cases (Fahim et al., 2010a). Conventional methods are therefore insufficiently 
robust and rapid to target therapy immediately when patients present with acute symptoms. 
As a result, patients may receive unnecessary and/or delayed treatment increasing the risk 
of opportunistic, chronic or recurrent infections and the spread of multidrug resistance. 
Previous work in the host laboratory has shown that peritoneal γδ T cell levels on the first 
day of peritonitis predict the presence of Gram− organisms and the risk of subsequent 
technique failure within the next 3 months (Lin et al., 2013). Studying three different cohorts 
of PD patients, including patients from the ANZDATA registry, it was also observed that 
HMB-PP positive infections were associated with worse outcomes (Davey et al., 2011a). 
Extending the earlier analysis by Davey 2011, which focused on catheter removal and 
mortality as outcome parameters and concentrated on the absence and presence of HMB-
PP production by the causative pathogens as discriminator, in this study a larger dataset 
from the ANZDATA registry (n=4,003 patients compared to n=2,424 patients as done by 
Davey 2011) was analysed, allowing consideration of transfer to interim or permanent HD 
as additional outcome parameters. Most importantly, I analysed the outcome data with 
respect to the HMB-PP and vitamin B2 status of the causative organism. Given the 
importance of MAIT cells as contributors to peritoneal inflammation via production of pro-
inflammatory cytokines in response to vitamin B2+ bacteria (Chapter 3), this approach 
allowed investigation of infections caused by vitamin B2+ bacteria as independent predictors 
of technique failure in 90 days.  
This Chapter shows that bacteria able to stimulate Vγ9/Vδ2 T cells and MAIT cells are 
associated with worse clinical outcomes, highlighting the implication of unconventional T 
cells in PD associated inflammation. 
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5.2 Aims 
The aims of this Chapter were: 
1. To analyse association of HMB-PP and/or vitamin B2 metabolism in the causative 
pathogen with technique failure. 
2. To analyse whether infections caused by Gram− or Gram+ bacteria positive for 
HMB-PP and Vitamin B2 were independent predictor of technique failure. 
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5.3 Results 
5.3.1  ANZDATA analysis: relation between technique failure and pathogen 
metabolic signature 
The following analysis is based on the ANZDATA records of 5,073 Australian patients who 
received PD and experienced peritonitis between 15 April 2003 and 29 December 2012. A 
total of 4,003 patients with first-time episodes of peritonitis were included in this analysis, 
excluding all patients with mixed infections, fungal infections, unrecorded culture results or 
undefined reasons for technique failure (Figure 5.1 and Table 5.2) 
 
 
 
Figure 5.1. Types of infections included in the ANZDATA registry from 2003 to 2012.  
4,003 patients from the ANZDATA registry grouped into culture-negative episodes (no growth, white) and 
confirmed infections caused by Gram+ HMB-PP+ vitamin B2+ bacteria (Corynebacterium, Mycobacterium, 
green), Gram+ HMB-PP− vitamin B2+ bacteria (Coagulase-negative Staphylococcus, Staphylococcus aureus, 
yellow), Gram+ HMB-PP− vitamin B2− bacteria (Streptococcus, Enterococcus, blue), Gram− HMB-PP+ 
vitamin B2+ bacteria (E. coli, Klebsiella, other coliform organisms, Pseudomonas, Acinetobacter, red) and 
rare organisms (e.g. Proteus, Serratia, Neisseria, Rhodococcus, Rothia and Kocuria, grey). 
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Table 5.1. ANZDATA registry bacteria grouped by Gram, HMB-PP and vitamin B2 status 
Metabolic 
signature 
Organism Number 
of episodes 
Culture negative  821 
Gram+, HMB-PP+, 
vitamin B2+ 
Corynebacterium species 67 
Mycobacterium tuberculosis 5 
Mycobacterium other 12 
Rhodococcus species 1 
Rothia mucilaginosa 1 
Kocuria kristinae 1 
Gram+, HMB-PP−, 
vitamin B2+ 
Coagulase-negative Staphylococcus epidermidis 618 
Coagulase-negative Staphylococcus, other 232 
Coagulase-negative Staphylococcus, unknown 231 
Staphylococcus aureus, methicillin resistant 86 
Staphylococcus aureus, non-MRSA 362 
Staphylococcus aureus, unknown sensitivity 70 
Gram+, HMB-PP−, 
vitamin B2 
Enterococcus 96 
Streptococcus viridans group 102 
Streptococcus, other 231 
Streptococcus, unknown 31 
Gram−, HMB-PP+, 
vitamin B2+ 
Acinetobacter species 81 
Citrobacter species 19 
E. coli species 342 
Enterobacter species 95 
Klebsiella species 194 
Neisseria species 14 
Proteus species 16 
Pseudomonas aeruginosa 111 
Pseudomonas maltophilia 5 
Pseudomonas cepacia 1 
Pseudomonas stutzeri 11 
Pseudomonas, other 44 
Pseudomonas, unknown 17 
Serratia species 80 
Roseomonas gilardii 2 
Pantoea agglomerans 1 
Pasteurella multocida 3 
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All patients presenting with first-time peritonitis were grouped according to the 
microbiological culture results into culture-negative and culture-positive episodes. The 
latter were subsequently divided into infections caused by Gram+ and Gram− bacteria, 
respectively, and then further with regard to HMB-PP and vitamin B2 metabolic status.  
The registry recorded 79.4% culture-positive episodes of peritonitis, amongst which 35.2% 
were infections caused by HMB-PP+ bacteria and 85.5 % by vitamin B2+ bacteria (Table 
5.2). 
 
Table 5.2. Characteristic of PD patients with acute peritonitis for outcome analysis. 
ANZDATA (Australia)  
Total number 4,003 
Age (mean ± SD) 59.9 ± 17.0 
Women (%) 43.0 
Days on PD (mean ± SD) 1,044 ± 796.9 
30th day mortality (%) 4.4 
90th day catheter removal (%) 14.1 
90th day transfer to permanent HD (%) 11.5 
90th day transfer to interim HD (%) 2.0 
90th technique failure in total (%) 17.9 
Culture-positive infections (%) 79.4 
   of which HMB-PP+ bacteria (%) 35.2 
   of which Vitamin B2+ bacteria (%) 85.5 
   of which Gram+, HMB-PP+, vitamin B2+ bacteria (%)  2.7 
   of which Gram+, HMB-PP−, vitamin B2+  bacteria (%) 50.2 
   of which Gram+, HMB-PP−, vitaminB2−  bacteria (%) 14.4 
   of which Gram-, HMB-PP+, vitamin B2+  bacteria (%) 32.5 
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I next assessed the clinical outcome after episodes of acute peritonitis. Cumulative survival 
curves for technique failure showed that up to 20% of the patients with culture positive 
infections had technique failure within 90 days. These results were significantly different 
from the survival curve of patients with culture negative peritonitis (p<0.0001, Figure 5.2). 
However, outcome mortality at 30 days was not significantly different between the two 
groups (Figure 5.2).  
 
  
Figure 5.2. Association of culture-positive status with clinical outcome.  
Australian PD patients from the ANZDATA registry with first-time peritonitis. Cumulative patient survival 
(right) and cumulative technique survival (left) of patients with acute peritonitis, grouped into culture-negative 
(dotted lines) and culture-positive episodes (solid lines). 
 
Next, I divided patients into Gram, HMB-PP and vitamin B2 status groups. Patients 
presenting with infections caused by Gram− HMB-PP+ vitamin B2+ (e.g. E. coli, 
Pseudomonas) and Gram+ HMB-PP+ vitamin B2+ bacteria (e.g. Corynebacterium, 
Mycobacterium) had overall technique failure rates of 35% and 23%, respectively, in 90th 
days (Figure 5.3). By contrast, only 10% of patients infected with Gram+ HMB-PP− vitamin 
B2− bacteria (e.g. Streptococcus, Enterococcus) and 12% of patients infected with Gram+, 
HMB-PP−, vitamin B2+ bacteria (e.g. Staphylococcus) had to discontinue PD in 90th days 
(Figure 5.3). 
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To determine specific association between technique failure and types of infection, I next 
looked at defined clinical outcome parameters including mortality after 30 days, catheter 
removal and transfer to permanent HD within 90 days after presenting with acute peritonitis. 
Figure 5.3 shows that in contrast to infections due to organisms lacking HMB-PP and 
vitamin B2, infections caused by HMB-PP and vitamin B2 positive bacteria were associated 
with high rates of catheter removal and subsequent HD transfer. Furthermore, I observed 
that patients with Gram− infections had higher 30th day mortality rates compared to patients 
infected with other organisms (Figure 5.3).  
 
Figure 5.3. Episodes of peritonitis caused by HMB-PP+ and vitamin B2+ bacteria are associated with 
poor clinical outcome.  
Cumulative technique survival (left, middle), cumulative patient survival (right, middle), catheter removal 
(left, bottom) and transfer to permanent HD (right, bottom) of patients with acute bacterial peritonitis, grouped 
into infections with Gram+ HMB-PP− vitamin B2+ (grey), Gram− HMB-PP+ vitamin B2+(red), Gram+ HMB-
PP+ vitamin B2+ (blue) and Gram+ HMB-PP− vitamin B2+ organisms (green). Comparisons were made using 
log-rank tests. *, p<0.05; **, p<0.01, ***, p< 0.001. 
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Collectively, these results suggested that the presence of HMB-PP and vitamin B2 can 
predict subsequent clinical outcome in patients presenting with acute PD associated 
infection. 
 
5.3.2  Episodes of peritonitis caused by HMB-PP and vitamin B2 producing bacteria 
are associated with poor clinical outcome 
To study the importance of HMB-PP and vitamin B2 status as predictors of peritonitis 
associated outcomes, I performed a binary logistic regression where Gram, HMB-PP and 
vitamin B2 status were considered as predictors of clinical outcome. As showed in Table 
5.3 patients infected with Gram− bacteria (e.g. E. coli, Klebsiella, Pseudomonas) producing 
HMB-PP and vitamin B2 had a four times higher risk of technique failure in 90 days when 
compared to patients with culture negative episodes (OR=4.3). This risk was also 
significantly higher for patients infected with Gram+ HMB-PP+ vitamin B2+ bacteria such 
as Corynebacterium and Mycobacterium, compared to patients with culture negative 
episodes (OR=2.4). However in this last group, as shown in Table 5.8, infections caused by 
Mycobacterium but not Corynebacterium species were associated with high risk of 
technique failure (OR= 19.2, p< 0.001).  
  
117 
 
 Table 5.3. Risk of technique failure within 90 days after presentation with acute peritonitis, 
depending on the causative pathogen. 
90th day  
technique failure 
Odds ratio 
(95%CI) 
p 
Reference: 
culture-negative 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
2.4 
(1.389-4.129) 
 
0.002 
Gram+ HMB-PP− 
Vitamin B2+ 
1.1 
(0.866-1.468) 
0.374 
Gram+ HMB-PP− 
Vitamin B2- 
0.9 
(0.662-1.381) 
0.812 
Gram− HMB-PP+ 
Vitamin B2+ 
4.3 
(3.318-5.500) 
*** 
Reference: 
culture-negative 
1  
HMB-PP+ 
4.1 
(3.194-5.271) 
*** 
HMB-PP− 
1.0 
(0.843-1.405) 
0.515 
Reference: 
culture-negative 
1  
Vitamin B2+ 
2.1 
(1.703-2.734) 
*** 
Vitamin B2− 
0.9 
(0.662-1.381) 
0.812 
Reference: 
HMB-PP− 
1  
Gram+ HMB-PP+ 
2.2 
(1.312-3.689) 
0.003 
Gram− HMB-PP+ 
3.9 
(3.263-4.721) 
*** 
Reference: 
Vitamin B2− 
1  
Gram+ Vitamin B2+ 
1.2 
(0.892-1.721) 
0.201 
Gram− Vitamin B2+ 
4.5 
(3.235-6.168) 
*** 
Reference: 
Gram− HMB-PP+ 
Vitamin B2+ 
1  
Gram+ HMB-PP+, 
Vitamin B2+ 
0.6 
(0.335-0.939) 
0.028 
Gram+ HMB-PP− 
Vitamin B2+ 
0.3 
(0.217-0.321) 
*** 
Gram+ HMB-PP− 
Vitamin B2− 
0.2 
(0.162-0.309) 
*** 
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Compared to culture-negative episodes of peritonitis, infections caused by Gram− HMB-PP+ 
vitamin B2+ bacteria were associated with a higher risk of permanent PD cessation for all 
four different types of technique failure investigated: 30th day mortality (OR=2.6; Table 
5.4), 90th day catheter removal (OR=4.4; Table 5.5), 90th day transfer to permanent HD 
(OR=3.4, Table 5.6) and 30th day transfer to interim HD (OR=9.0; Table 5.7).  
Infections caused by Gram+ HMB-PP+ vitamin B2+ bacteria were associated with higher 
risks of catheter removal (OR=3.2; Table 5.5) as well as transfer to permanent HD (OR=7.3; 
Table 5.6) and interim HD (OR=2.3; Table 5.7) but not with increased mortality (Table 5.4). 
By contrast, patients presenting infections caused by bacteria deficient for HMB-PP and 
vitamin B2 (e.g. Enterococcus and Streptococcus) did not carry a significantly enhanced 
risk of technique failure (Tables 5.4-5.8). 
5.3.3  Contribution of HMB-PP producing bacteria to clinical outcome 
The previous section identified an association of infections caused by Gram-negative and 
Gram-positive HMB-PP+ vitamin B2+ bacteria with poor clinical outcome. I next sought to 
determine the contributions of HMB-PP and vitamin B2 to overall outcome prediction.  
Patients with HMB-PP+ bacterial infection had a four times greater risk to discontinue PD 
therapy than HMB-PP− infection when compared to culture-negative results (Table 5.3). 
Taking different qualities of clinical outcomes as dependent variables and HMB-PP status 
as predictor, these analyses demonstrate that patients with infections caused by HMB-PP+ 
bacteria had higher risks of catheter removal (OR=4.4), mortality (OR=2.4) and of being 
transferred to interim (OR=8.9) or permanent HD (OR=3.3) (Tables 5.4-5.7). 
Using HMB-PP− infections as reference to assess outcomes in patients with either Gram− or 
Gram+ HMB-PP+ infections, HMB-PP+ bacteria were significantly associated with 
increased risk of technique failure such as catheter removal and transfer to permanent HD 
(Tables 5.5-5.6). In addition, Gram− but not Gram+ HMB-PP+ infections were associated 
with a higher risk of mortality in 30 days and interim HD (Table 5.4 and 5.7). 
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5.3.4  Contribution of vitamin B2 producing bacteria to clinical outcome 
I next tested whether or not the presence of vitamin B2 alone was an independent predictor 
of poor clinical outcome. To this end, I grouped culture positive infections into vitamin B2+ 
and vitamin B2− infections, according to the metabolic signature of the causative organism. 
As shown in Table 5.3, the odds of patients having technique failure as a result of an 
infection by a vitamin B2+ pathogen were two times greater than infections caused by 
vitamin B2− bacteria.  
Using vitamin B2− infections as reference to assess outcomes in patients with either Gram− 
or Gram+ vitamin B2+ infections, my analysis shows that patients with infections caused by 
Gram− vitamin B2+ bacteria had a higher risk of catheter removal (OR=4.4) as well as 
transfer to interim (OR=3.4) or permanent HD (OR=3.3) than patients with vitamin B2 
negative infections.  
Finally, when I used patients with infections caused by Gram− HMB-PP+ vitamin B2+ 
organisms as reference group, I found that all three Gram+ groups were associated with a 
lower risk of mortality (Table 5.4). In particular, infections caused by Gram+ HMB-PP− 
vitamin B2− species (Enterococcus, Streptococcus ) and Gram+ HMB-PP− vitamin B2+ 
species (Staphylococcus) species were associated with a lower risk of catheter removal and 
transfer to HD compared to the Gram− group (OR=0.27-0.35, Tables 5.4-5.7). Moreover, as 
shown in Table 5.8, infections caused by the Gram+ vitamin B2+ Coagulase-negative 
Staphylococcus bacteria are associated with a significantly lower risk of technique failure 
including mortality, catheter removal and transferred to permanent HD. 
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Table 5.4. Risk of mortality within 30 days after presentation with acute peritonitis, depending on the 
causative pathogen. 
30th day mortality  
Odds ratio 
(95%CI) 
p 
Reference: 
culture-negative 
1  
Gram+ HMB-PP+ 
 Vitamin B2+ 
0.262 
(0.043-2.360) 
0.262 
Gram+ HMB-PP− 
 Vitamin B2+ 
0.737 
(0.455-1.192) 
0.213 
Gram+ HMB-PP− 
Vitamin B2−- 
0.794 
(0.409-1.543) 
0.497 
Gram− HMB-PP+  
Vitamin B2+ 
2.6 
 (1.713-4.037) 
*** 
Reference: 
culture-negative 
1  
HMB-PP+ 
2.43  
(1.589-3.737) 
*** 
HMB-PP− 
0.75 
(0.474-1.184) 
0.217 
Reference: 
culture-negative 
1  
Vitamin B2+ 
 1.4 
(0.939-2.129) 
0.097 
Vitamin B2− 
0.8 
(0.409-1.543) 
0.497 
Reference: 
HMB-PP− 
1  
Gram+ HMB-PP+ 
0.424 
(0.058-3.098) 
0.398 
Gram− HMB-PP+ 
3.5 
(2.488-4.947) 
*** 
Reference: 
Vitamin B2− 
1  
Gram+ Vitamin B2+ 
0.9 
(0.480-1.688) 
0.742 
Gram− Vitamin B2+ 
3.3 
(1.832-5.985) 
*** 
Reference: 
Gram−, HMB-PP+ 
 Vitamin B2+ 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
0.12 
(0.017-0.877) 
0.037 
Gram+, HMB-PP− 
Vitamin B2+ 
0.3   
(0.193-0.407) 
*** 
Gram+ HMB-PP−  
Vitamin B2− 
0.3 
(0.167-0.546) 
*** 
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Table 5.5. Risk of catheter removal within 90 days after presentation with acute peritonitis, depending 
on the causative pathogen. 
90th day catheter  
removal 
Odds ratio 
(95%CI) 
p 
Reference: 
culture-negative 
1  
Gram+ HMB-PP+  
Vitamin B2+ 
3.2 
(1.812-5.637) 
*** 
Gram+ HMB-PP− 
 Vitamin B2+ 
1.2 
(0.895-1.637) 
0.215 
Gram+ HMB-PP− 
Vitamin B2- 
1.0 
(0.658-1.523) 
0.998 
Gram− HMB-PP+ 
Vitamin B2+ 
4.4 
(3.358-5.946) 
*** 
Reference: 
culture-negative 
1  
HMB-PP+ 
4.3  
(3.285-5.792 ) 
*** 
HMB-PP− 
1.2 
(0.868-1.558) 
0.312 
Reference: 
culture-negative 
1 1 
Vitamin B2+ 
2.3 
(1.789-3.074) 
*** 
Vitamin B2− 
1.0 
(0.658-1.523) 
0.998 
Reference: 
HMB-PP− 
1  
Gram+ HMB-PP+ 
2.7 
(1.618-4.670) 
*** 
Gram− HMB-PP+ 
3.8 
(3.141-4.700) 
*** 
Reference: 
Vitamin B2− 
1  
Gram+ Vitamin B2+ 
1.3 
 (0.896-1.883) 
0.167 
Gram− Vitamin B2+ 
4.4 
(3.108-6.415) 
*** 
Reference: 
Gram− HMB-PP+ 
Vitamin B2+ 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
          0.7 
(0.423-1.211) 
0.212 
Gram+ HMB-PP− 
Vitamin B2+ 
  0.3 
(0.219-0.336) 
*** 
Gram+ HMB-PP− 
Vitamin B2− 
0.2 
(0.156-0.322) 
*** 
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Table 5.6. Risk of transfer to permanent HD in 90 days after presentation with acute peritonitis, 
depending on the causative pathogen. 
90th day transfer  
to permanent HD 
Odd Ratio 
(95%CI) 
p 
Reference: 
culture-negative 
1  
Gram+ HMB-PP+  
Vitamin B2+ 
2.3 
(1.253-4.398) 
0.008 
Gram+ HMB-PP− 
 Vitamin B2+ 
1.0 
(0.763-1.437) 
0.775 
Gram+ HMB-PP− 
 Vitamin B2− 
1.0 
(0.655-1.551) 
0.971 
Gram− HMB-PP+ 
Vitamin B2+ 
3.4  
(2.506-4.550) 
*** 
Reference: 
culture-negative 
1  
HMB-PP+ 
3.3 
(2.449-4.425) 
*** 
HMB-PP− 
1.0 
(0.766-1.408) 
0.808 
Reference: 
culture-negative 
1  
Vitamin B2+ 
2.0  
(1.403-3.049) 
*** 
Vitamin B2− 
0.9   
(0.493-1.689) 
0.771 
Reference: 
HMB-PP− 
1  
Gram+ HMB-PP+ 
2.3 
(1.248-4.095 ) 
0.007 
Gram− HMB-PP+ 
 3.3 
(2.614-4.046) 
*** 
Reference: 
Vitamin B2− 
1  
Gram+ Vitamin B2+ 
1.1 
(0.748-1.617) 
0.629 
Gram− Vitamin B2+ 
 3.3  
(2.302-4.874) 
*** 
Reference: 
Gram− HMB-PP+ 
Vitamin B2+ 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
0.228 
(0.385-1.255) 
0.695 
Gram+ HMB-PP− 
Vitamin B2+ 
0.3 
(0.245-0.392) 
*** 
Gram+ HMB-PP− 
Vitamin B2− 
0.3 
(0.205-0.434) 
*** 
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Table 5.7. Risk of transfer to interim HD in 30 days after presentation with acute peritonitis, 
depending on the causative pathogen. 
Transferred to interim HD  
for at least 30 days 
Odd Ratio 
(95%CI) 
p 
Reference: 
culture-negative 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
7.3 
(1.606-33.143) 
0.010 
Gram+ HMB-PP− 
 Vitamin B2+ 
3.2 
 (1.125-9.353) 
0.029 
Gram+ HMB-PP− 
Vitamin B2− 
2.7 
(0.758-9.615) 
0.126 
Gram− HMB-PP+ 
Vitamin B2+ 
9.0 
(3.242-25.319) 
*** 
Reference: 
culture-negative 
1  
HMB-PP+ 
8.9  
(3.201-24.863) 
*** 
HMB-PP− 
3.1  
(1.099-8.873) 
0.033 
Reference: 
culture-negative 
1  
Vitamin B2+ 
5.5  
(2.021-15.235) 
0.001 
Vitamin B2− 
2.7  
(0.758-9.615) 
0.126 
Reference: 
HMB-PP− 
1  
Gram+, HMB-PP+ 
0.9 
(0.700-7.796) 
0.167 
Gram− HMB-PP+ 
 2.9  
(1.821-4.623) 
*** 
Reference: 
Vitamin B2− 
1  
Gram+ Vitamin B2+ 
1.3 
(0.526-3.105) 
0.588 
Gram− Vitamin B2+ 
3.4 
(1.420-7.933) 
0.006 
Reference: 
Gram− HMB-PP+ 
 Vitamin B2+ 
1  
Gram+ HMB-PP+ 
Vitamin B2+ 
0.805 
(0.245-2.648) 
0.721 
Gram+ HMB-PP− 
Vitamin B2+ 
0.4 
(0.218-0.589) 
*** 
Gram+ HMB-PP− 
Vitamin B2− 
0.3 
(0.126-0.704) 
0.006 
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Table 5.8. Risk of technique failure, catheter removal, transfer to HD and mortality after presentation with acute peritonitis, depending on the causative pathogen.  
Episodes Sig. OR Sig. OR Sig. OR Sig. OR Sig. OR
Reference culture negative 821
Coagulase-neg. Staphylococcus 1081 0.001 0.581 0.421 0.802 0.001 0.532 0.362 0.780 0.017 0.489 0.272 0.878 0.002 0.544 0.367 0.806 0.371 1.715 0.526 5.588
Staphylococcus aureus-MR 86 *** 4.521 2.767 7.389 *** 4.957 2.934 8.375 0.122 2.048 0.826 5.082 *** 3.472 1.96 6.148 *** 12.608 3.32 47.885
Staphylococcus aureus species 432 *** 2.201 1.604 3.02 *** 2.56 1.803 3.635 0.719 1.119 0.608 2.06 *** 2.013 1.384 2.928 0.004 5.337 1.689 16.861
Streptococcus-Enterococcus species 460 0.812 0.956 0.662 1.381 0.998 1.001 0.658 1.523 0.497 0.794 0.409 1.543 0.971 1.008 0.655 1.551 0.126 2.699 0.758 9.615
Corynebacterium species 67 0.873 0.936 0.415 2.109 0.792 1.125 0.469 2.701 0.389 0.414 0.055 3.086 0.359 0.574 0.175 1.879 0.004 9.574 2.097 43.706
Pseudomonas species 189 *** 8.458 5.907 12.11 *** 9.35 6.385 13.69 0.004 2.526 1.342 4.753 *** 5.42 3.622 8.112 *** 24.172 8.158 71.622
Acinetobacter species 81 0.185 1.534 0.815 2.885 0.042 1.989 1.026 3.859 0.618 0.691 0.162 2.952 0.26 1.53 0.73 3.206 0.06 5.171 0.932 28.676
 E. coli species 342 *** 4.858 3.568 6.615 *** 4.999 3.554 7.031 *** 3.313 2.002 5.483 *** 4.049 2.834 5.784 0.005 5.52 1.688 18.049
Klebsiella species 194 *** 3.338 2.287 4.871 *** 2.971 1.934 4.564 *** 3.139 1.735 5.679 *** 2.789 1.787 4.353 0.129 3.208 0.712 14.453
Enterobacter species 95 *** 3.185 1.939 5.232 *** 3.051 1.753 5.307 0.027 2.511 1.113 5.664 0.008 2.295 1.248 4.221 0.002 8.978 2.208 36.507
Serratia species 80 *** 3.237 1.904 5.504 *** 3.813 2.167 6.71 0.92 1.064 0.317 3.574 0.009 2.375 1.243 4.541 *** 13.617 3.58 51.789
Proteus species 16 0.019 3.646 1.239 10.73 0.024 3.813 1.196 12.154 0.081 3.901 0.847 17.968 0.018 4.081 1.278 13.028 0.999 0 0 .
Citrobacter species 19 *** 5.834 2.287 14.882 0.009 4.085 1.427 11.694 0.013 5.121 1.413 18.558 0.041 3.265 1.051 10.135 0.999 0 0 .
Neisseria species 14 0.999 0 0 . 0.999 0 0 . 0.999 0 0 . 0.999 0 0 . 0.999 0 0 .
Mycobacterium species 17 *** 19.253 6.632 55.893 *** 27.455 9.387 80.295 0.999 0 0 . *** 22.444 8.03 62.731 0.999 0 0 .
Other species 9 0.306 2.292 0.469 11.2 0.145 3.268 0.666 16.051 0.999 0 0 . 0.999 0 0 . 0.006 25.531 2.562 254.471
95% C.I.
Technique failure Mortality Transfer to permanent HD Transfer to interim HD
95% C.I.95% C.I.95% C.I.95% C.I.
Catheter removal
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5.4 Discussion 
PD is the principal form of home based dialysis therapy for patients with end-stage renal 
failure. Compared to haemodialysis, PD gives a better preservation of residual renal 
function and is more cost effective (Chaudhary et al., 2011; Tokgoz, 2009). Unfortunately, 
infection and associated inflammation remain the major reasons for treatment failure and 
death in PD patients (Cho and Johnson, 2014). However, the mechanisms that underlie the 
clinical severity of peritonitis episodes, and their link to outcomes, is poorly defined.  
I here re-analysed the ANZDATA registry that contains data on the outcomes of 1,579 
additional patients than a previous similar analysis on patient data recorded between 2003 
and 2008 (Davey et al., 2011a). This larger dataset allowed me to look in detail at prediction 
of different types of technique failure by the metabolic signature of the causative bacterial 
pathogen, including transfer to interim HD and permanent HD. While the previous analysis 
considered 90th day mortality (Davey et al., 2011a), I here focused on death within 30 days 
from the time of presentation with acute peritonitis as the more relevant time point 
(Boudville et al., 2012). Furthermore, in the current analysis I also considered how different 
types of metabolic signature can affect outcomes. 
As seen in Chapter 3, peritoneal Vγ9/Vδ2 T cell and MAIT cells are likely to contribute to 
peritoneal inflammation by production of large amounts of pro-inflammatory cytokines 
including TNF-α and IFN-γ. This conclusion is supported by the ANZDATA analysis. 
Indeed, Gram− HMB-PP+ vitamin B2+ are associated with poor clinical outcomes such as 
catheter removal, transfer to permanent and interim HD compared to infections by bacteria 
lacking these metabolites. This group of pathogens includes bacteria such as Pseudomonas, 
E. coli, Klebsiella and Enterobacter, which have previously been associated with worse 
outcomes (Jarvis et al., 2010; Siva et al., 2009). Moreover, Lin et al. showed that Gram− 
infections are characterized by increased pro-inflammatory cytokines IL-1β, IL-10 and 
TNF-α in the peritoneal cavity compared to Gram+ infection or culture negative episodes of 
peritonitis (Lin et al., 2013). Considering that peritoneal Vγ9/Vδ2 T cell and MAIT cells 
produce up to 50% of TNF-α after treatment with E. coli (Chapter 3), it is conceivable that 
these cells may contribute to detrimental outcomes caused by Gram negative bacteria during 
PD associated infection.  
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It was also observed that Gram+ HMB-PP+ vitamin B2+ bacteria are associated with elevated 
rates of catheter removal and transfer to permanent HD within 90 days after presentation 
with acute peritonitis. The poor clinical outcome in this patient group was due mainly to 
mycobacterial infections, whereas corynebacterial infections were not a significant 
predictor of technique failure. These findings concur with earlier reports on the relatively 
mild clinical course of coryneform infections (Barraclough et al., 2009), and on the high 
frequency of catheter removal in patients with mycobacterial infections (Ghali et al., 2011; 
Li et al., 2010). 
Access to the largest dataset yet produced for such analyses, I here confirmed that infections 
caused by HMB-PP+ bacteria are associated with poor outcomes in PD patients. This was 
true for episodes of peritonitis caused by both Gram+ and Gram− species, thereby identifying 
the production of HMB-PP by the causative organism as an effective predictive marker, and 
implying that Vγ9/Vδ2 T cell-driven responses may contribute to overall clinical outcome.  
In this analysis I also examined for the first time the impact of vitamin B2+ organisms on 
outcomes from PD associated peritonitis. The data indicate that while the presence of 
vitamin B2 was a significant predictor of technique failure, the associated risk was lower 
overall than that with HMB-PP positive infections (OR=2.1 vs OR=4.1). In addition, 
patients with Gram+ vitamin B2+ infections were more likely to continue PD therapy without 
interruptions over the next 90 days compared to patients with Gram+ HMB-PP+ infections. 
This observation was valid for all outcomes considered. The relatively benign course due to 
HMB-PP− vitamin B2+ peritonitis might be explained by the high prevalence of infections 
caused by the skin commensal bacterium Staphylococcus epidermidis and related 
coagulase-negative Staphylococcus species (CoNS) (67.6% of all infections in this group) 
and S .aureus species (32.2% of all infections in this group). S. aureus infections, in 
agreement with earlier studies (Fahim et al., 2010b; Govindarajulu et al., 2010), were 
associated with a considerably greater risk of technique failure and catheter removal than 
CoNS infections. Indeed, even if CoNS infections were more frequent, they were resolved 
with antibiotics within three weeks and were not associated with hospitalization, catheter 
removal and transfer to HD (Fahim et al., 2010b). 
These last results may support the hypothesis that I should not consider Vitamin B2 
metabolising organisms less pathogenic than HMB-PP+ bacteria, but that the nature of the 
immune response depends strictly on the type of pathogen, which as a consequence defines 
127 
 
outcome. Moreover, these findings indicate that the presence of the vitamin B2 pathway 
alone may not be sufficiently predictive of clinical outcome in PD patients, and may be 
masked by the stronger predictive power of HMB-PP.  
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Chapter 6. Activation of peritoneal mesothelial cells and fibroblasts by 
unconventional T cells 
6.1 Introduction 
During PD therapy, preservation of peritoneal membrane integrity is fundamental to long 
term treatment survival. Human peritoneal mesothelial cells (HPMC) are the most numerous 
cells lining the peritoneal cavity, form the first line of defence against bacteria in the 
peritoneal cavity and are able to maintain a chemotactic gradient to allow leukocyte 
infiltration during peritoneal inflammation (Yung and Chan, 2012). Chronic exposure to PD 
fluid and episodes of peritonitis can induce detachment of HPMC from the basement 
membrane through a process called mesothelial to mesenchymal transition (MMT), and 
migration of the cells undergoing MMT to the submesothelium (Selgas et al., 2006). 
With the loss of the mesothelium layer, PD fluid and bacteria invade the connective tissue 
and activate peritoneal fibroblasts (HPFB). The latter produce extracellular matrix 
components in the connective tissue, and persistent activation of these cells can contribute 
to peritoneal fibrosis (Witowski et al. 2015). In general, activated HPMC and HPFB 
contribute to increase pro-inflammatory cytokines and matrix proteins in the peritoneal 
cavity. Any structural changes to the peritoneal membrane will affect ultrafiltration 
capacity, and may ultimately lead to cessation of PD treatment (Lai and Leung, 2010).  
Previous studies have shown that HPMC and HPFB produce chemokines (e.g. CXCL10, 
CXCL8 and CCL2) and pro-inflammatory cytokines such as IL-6 in response to pro-
inflammatory cytokines like IFN-γ, IL-1β and TNF-α. As described in earlier chapters, Vγ9+ 
T cells and MAIT cells are major producers of TNF-α and IFN-γ in response to a range of 
bacterial pathogens. However, regulation of HPMC and HPFB by these unconventional T 
cells and the potential implications for clinical outcome have not yet been investigated.  
By isolating HPMC and HPFB from fresh omental specimens and culturing them with 
conditioned medium derived from activated unconventional T cells, I here demonstrated 
that unconventional T cells induce the release of pro-inflammatory chemokines and 
cytokines by peritoneal tissue cells, and induce striking morphological changes and 
alterations in the expression levels of epithelial and mesenchymal markers. These results 
point to the involvement of peritoneal tissue cells in the amplification of local inflammatory 
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responses during PD associated infection and their possible regulation by unconventional T 
cells.  
 
6.2 Aims 
The aims of this Chapter were: 
1. To examine activation of HPMC or HPFB by TNF-α and IFN-γ, and by conditioned 
medium (CoM) derived from activated γδ T cells and MAIT cells. 
2. To study HPMC and HPFB cytokine and chemokine release in response to Gram+ 
and Gram− bacteria, and PDE from stable or infected patients. 
3. To analyse expression of epithelial and mesenchymal markers implicated in 
peritoneal membrane integrity in response to activated unconventional T cell CoM. 
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6.3 Results 
6.3.1 Unconventional T cell CoM induced release of pro-inflammatory cytokines 
and chemokines by HPMC and HPFB. 
As shown in previous Chapters, unconventional T cells are present in the peritoneal cavity 
of stable PD patients and increase during episodes of acute peritonitis. I also found these 
cells are major producers of TNF-α and IFN-γ in response to bacterial extracts. To analyse 
activation of HPMC and HPFB by unconventional T cell cytokines during PD associated 
infection, CoM was obtained from activated Vγ9/Vδ2 T cells and MAIT cells. Vγ9+ T cells 
and Vα7.2+ T cells were isolated from PBMC and incubated with HMB-PP and anti-
CD3/CD28 beads, respectively, and, after 24 hours, cell-free supernatants were collected. 
While activated γδ T cells and MAIT cells yielded different concentrations, both 
supernatants were confirmed to contain substantial amounts of TNF-α and IFN-γ (Figure 
6.1A). 
Confluent HPMC and HPFB were growth synchronised by serum deprivation and cultured 
in the presence of γδ T cell or MAIT cell CoM for 24 hours. Under these conditions, both 
HPMC and HPFB released significant amounts of chemokines CCL2, CXCL8, CXCL10, 
and IL-6, at CoM dilutions as high as 1:16 (Figures 6.1B-C and 6.2).  
To confirm this chemokine and cytokine induction was not caused by the presence of FCS 
in the CoM, I cultured HPMC in the presence of defined concentrations of FCS as control. 
As shown in Figure 6.3, when I compared the amount of CCL2 and CXCL8 induced by 
CoM derived from unconventional T cells with the medium supplemented with 10% FCS, 
I observed that the latter induced 8 and 2 times less amount of these two chemokines, 
respectively. This confirmed that FCS did not have a major effect on chemokine production 
induced by CoM derived from unconventional T cells. 
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Figure 6.1. Effect of unconventional T cell CoM on CXCL8, CCL2, CXCL10 and IL-6 secretion by 
HPMC.  
Secretion of TNF-α and IFN-γ by FACS sorted Vγ9+ T cells and Vα7.2+ T cells stimulated overnight in the 
presence of 100 nM HMB-PP or anti-CD3/CD28 beads for 24 h, respectively, as detected by ELISA (A). 
Quiescent cells were exposed to either control medium (0) or to MAIT cell CoM (B) or γδ T cell CoM (C) at 
the dilutions shown for 24 h (means ± SEM from independent experiments, n = 4-7 omental donors). Data 
were analysed by RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's post hoc test 
respectively. Comparisons were made with control medium. Differences were considered significant as 
indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 6.2. Effect of unconventional T cell CoM on CXCL8, CCL2, CXCL10 and IL-6 secretion by 
HPFB. 
 Quiescent cells were exposed to control medium (0), MAIT cell CoM (A) or γδ T cell CoM (B) at the dilutions 
shown for 24 h (means ± SEM from independent experiments, n=4-7 omental donors). Data were analysed by 
RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's post hoc test respectively. Comparisons 
were made with control medium. Differences were considered significant as indicated: *, p<0.05; **, p<0.01; 
***, p<0.001. 
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Figure 6.3. Effect of complete medium containing different percentages of FCS on CXCL8, CCL2 and 
IL-6 secretion by HPMC.  
Quiescent cells were exposed to HPMC complete medium containing 0.1-10% FCS (black) for 24 hours and 
compared with the percentage of FCS contained in CoM derived from γδ T cells (red) or MAIT cells (blue). 
Means± SEM from 4-5 independent experiments. 
 
6.3.2 HPMC and HPFB release pro-inflammatory cytokines and chemokines in 
response to IFN-γ and TNF-α 
To investigate whether IFN-γ and TNF-α were responsible for the cytokine and chemokine 
release by HPMC and HPFB, I cultured them in the presence of increasing concentrations 
of the recombinant cytokines (Figure 6.4-5).  
HPMC showed a dose-dependent increase of CCL2 release with IFN-γ or TNF-α (Figure 
6.4A). As predicted (Robson et al., 2001), there was no induction of CXCL8 by IFN-γ , but 
TNF-α induced dose dependent CXCL8 release (Figure 6.4B). Similarly, production of IL-
6 increased significantly in response to TNF-α, but not IFN-γ (Figure 6.4C).  
HPFB treated with low concentrations of IFN-γ released IL-6 and CCL2 above background 
levels but this production did not increase at higher IFN-γ concentrations (Figure 6.5A-B). 
As seen before with HPMC, HPFB did not release relevant amounts of CXCL8 in response 
to IFN-γ (Figure 6.5C). TNF-α stimulation of HPFB resulted in a dose dependent production 
of IL-6, CCL2 and CXCL8 (Figure 6.5A-C).  
To establish whether combined stimulation of HPMC and HPFB with both IFN-γ and TNF-
α induced a synergistic production of chemokines and cytokines from these cells, I treated 
HPMC with a combination of a fixed concentration of IFN-γ (500 U/ml) plus different 
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concentrations of TNF-α (1-50 ng/ml). This resulted in significant synergistic up-regulation 
of CCL2 and IL-6, but not of CXCL8, by HPMC in comparison with the expected IFN-γ 
and TNF-α additive value (Figure 6.4A-C). 
Similarly, treatment of HPFB with a combination of IFN-γ and TNF-α resulted in a 
synergistic upregulation of IL-6 and CCL2 (Figure 6.5A-B). By contrast, IFN-γ tended to 
inhibit significantly CXCL8 release by HPFB when combined with TNF-α, in comparison 
with the amount induced by TNF-α alone (Figure 6.5C). CXCL10 production by HPFB was 
barely detectable after treatment with either TNF-α or IFN-γ, whereas there was significant 
upregulation of this chemokine when both cytokines were added together (Figure 6.6D). In 
summary, these results confirmed that TNF-α and IFN-γ derived from unconventional T 
cells can induce HPMC and HPFB activation, as well as cytokine and chemokines release 
from these cells. 
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Figure 6.4. Dose-dependent effects of recombinant IFN-γ and TNF-α on CXCL8, CCL2 and IL-6 
release by HPMC.  
(A-C, left) Quiescent cells were treated with increasing doses of either IFN-γ or TNF-α for 24 hours before 
quantification of chemokines and cytokines in culture supernatants. (A-C, right) Effect of recombinant IFN-γ 
and TNF-α alone and in combination on CXCL8, CCL2 and IL-6 secretion by HPMC. Data were analysed by 
RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's post hoc test, respectively. Comparisons 
were made with control medium. Comparisons between additive and combined cytokine effects were made 
using the Kruskal-Wallis test with Dunn's post hoc test. Data are expressed as the mean ± SEM from 4 to 7 
experiments with cells isolated from separate donors. Differences were considered significant as indicated: *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 6.5. Dose-dependent effect of recombinant IFN-γ and TNF-α on IL-6, CCL2, CXCL8, CCL10 
released by HPFB.  
(A-C, left) Quiescent cells were treated with increasing doses of either IFN-γ (1-5000 U/ml) or TNF-α (0.1-
50 ng/ml) for 24 hours before quantification of chemokines and cytokines in culture supernatants. (A-D, right) 
Effect of recombinant IFN-γ and TNF-α alone and in combination on IL-6, CCL2, CXCL8, and CXCL10 
secretion by HPFB. Data were analysed by RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's 
post hoc test, respectively. Comparisons were made with control medium. Comparison between the additive 
and the combined effect when cytokines were added together were made by Kruskal-Wallis test with Dunn's 
post hoc test. Data are expressed as the mean ± SEM from 4 to 7 experiments with cells isolated from separate 
donors. Differences were considered significant as indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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6.3.3 Pre-treatment of unconventional T cells CoM with sTNFR and anti-IFN-γ 
antibodies abrogates HPMC and HPFB activation 
To analyse activation of HPMC and HPFB by IFN-γ or TNF-α in unconventional T cell 
CoM, this last was pre-treated with anti-IFN-γ or sTNFR (etanercept), alone or in 
combination, before addition to HPMC and HPFB cultures. 
In the presence of CoM from γδ T cells or MAIT cells that was pre-blocked with anti-IFN-
γ, release of CCL2 and IL-6 by HPMC was reduced, but there was not effect on CXCL8 
production (Figures 6.6 and 6.7). Blocking of TNF-α alone had the greatest effect on 
production of IL-6, followed by CCL2, compared to the positive control (Figure 6.6A and 
6.7A). Although the measurement was not significant, the amount of CXCL8 was reduced 
between 4 and 10 fold in the presence of sTNFR (Figure 6.6B and 6.7B). 
HPMC cultured in the presence of γδ T cell or MAIT cell CoM pre-blocked with both 
sTNFR and anti-IFN-γ released a decreased amount of CCL2, IL-6 and CXCL8 (Figure 6.6 
and 6.7) in comparison to the positive control.  
HPFB cultured in unconventional T cell CoM blocked with sTNFR alone or in combination 
with anti-IFN-γ produced decreased IL-6 and CXCL8 (Figure 6.8A-B and 6.9A-B), whereas 
CCL2 was significantly reduced only when the two cytokines were blocked together 
(p<0.001, Figure 6.8A and 6.9A).  
CXCL10 was not detected when HPMC and HPFB were cultured in unconventional T cells 
CoM pre-treated with anti-IFN-γ alone or in combination with sTNFR (Figures 6.8B and 
6.9B). 
These data show that neutralisation of TNF-α and/or IFN-γ in γδ T and MAIT cell CoM 
potentially decrease the production of CCL2, CXCL8, CXCL10 and IL-6 by HPMC and 
HPFB, with CXCL8 and IL-6 secretion being particularly sensitive to inhibition of TNF-α, 
while CXCL10 secretion was mainly driven by IFN-γ. 
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Figure 6.6. Effect of TNF-α and IFN-γ blockade on induction of HPMC cytokine and chemokine 
secretion in response to CoM-γδ.  
CoM from FACS sorted Vγ9+ T cells stimulated overnight in the presence of HMB-PP was diluted 4-fold with 
control medium and supplemented with antibody against IFN-γ or sTNFR alone or in combination (all at 10 
µg/ml). HPMC were exposed to pre-treated CoM for 24 hours and the release of cytokines and chemokines 
was measured by ELISA. Data were analysed by RM one-way ANOVA or Friedman test with Holm-Sidak or 
Dunn's post hoc test, respectively. These data were compared with values detected in the absence of 
neutralising reagents. Data are expressed as the mean ± SEM from 4-7 experiments with HPMC isolated from 
separate donors. Differences were considered significant as indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 6.7. Effect of TNF-α and IFN-γ blockade on induction of HPMC cytokine and chemokine 
secretion in response to CoM-MAIT. 
 CoM from FACS sorted Vα7.2+ T-cells stimulated overnight in the presence of anti-CD3/CD28 beads was 
diluted 4-fold with control medium and supplemented with antibody against IFN-γ or sTNFR alone or in 
combination (all at 10 µg/ml). HPMC were exposed to the pre-treated CoM for 24 hours and the release of 
cytokines and chemokines was measured by ELISA. Data were analysed by RM one-way ANOVA or 
Friedman test with Holm-Sidak or Dunn's post hoc test, respectively. These data were compared with values 
detected in the absence of neutralising reagents. Data are expressed as the mean ± SEM from 4-7 experiments 
with HPMC isolated from separate donors. Differences were considered significant as indicated in the figure: 
*, p<0.05; **, p<0.01; ***, p<0.001.  
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Figure 6.8. Effect of TNF-α and IFN-γ blockade on induction of HPFB cytokine and chemokine 
secretion in response to CoM-γδ.  
CoM from FACS sorted Vγ9+ T cells stimulated overnight in the presence of HMB-PP was diluted 4-fold with 
control medium and supplemented with antibody against IFN-γ or sTNFR alone or in combination (all at 10 
µg/ml). HPFB were exposed to the pre-treated CoM for 24 hours and the release of cytokines and chemokines 
was measured by ELISA. Data were analysed by RM one-way ANOVA or Friedman test with Holm-Sidak or 
Dunn's post hoc test, respectively. These data were compared with value detected in the absence of neutralising 
reagents. Data are expressed as the mean ± SEM from 4-7 experiments with HPFB isolated from separate 
donors. Differences were considered significant as indicated in the figure: *, p<0.05; **, p<0.01; ***, p<0.001. 
  
141 
 
 
Figure 6.9. Effect of TNF-α and IFN-γ blockade on induction of HPFB cytokine and chemokine 
secretion in response to CoM-MAIT.  
CoM from FACS sorted Vα7.2+ T-cells stimulated overnight in the presence of anti-CD3/CD28 beads was 
diluted 4-fold with control medium and supplemented with antibody against IFN-g or sTNFR alone or in 
combination (all at 10 µg/ml). HPFB were exposed to the pre-treated CoM for 24 hours and the release of 
cytokines and chemokines was measured by ELISA. Data were analysed by RM one-way ANOVA or 
Friedman test with Holm-Sidak or Dunn's post hoc test, respectively. These data were compared with value 
detected in the absence of neutralising reagents. Data are expressed as the mean ± SEM from 4-7 experiments 
with HPFB isolated from separate donors. Differences were considered significant as indicated in the figure: 
*, p<0.05; **, p<0.01; ***, p<0.001. 
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6.3.4   HPMC and HPFB activation by PDE of patients with Gram− infections 
As described in the previous Chapter, γδ T cells and MAIT cell numbers increase in PD 
associated infection caused by HMB-PP+ and vitamin B2+ bacteria. Most of these bacteria 
are Gram− bacteria (e.g. E. coli, Acinetobacter, Enterobacter) and are associated with poor 
clinical outcomes (Chapter 5). Gram− infections in PD are characterized by increased 
numbers of neutrophils and monocytes in the peritoneal cavity, and elevated levels of 
cytokines such as IL-1β and TNF-α (Lin et al., 2013). TNF-α is produced by unconventional 
T cells in vitro in response to both synthetic ligands and Gram− bacterial extract (Chapter 
3). To determine if increased presence of pro-inflammatory cytokines during Gram− 
infection contributes to chemokine production by peritoneal HPMC and HPFB, I cultured 
these cells in the presence of PDE derived from stable patients or patients presenting with 
acute Gram− peritonitis (Table 6.1). 
When I stimulated HPMC with PDE from infected patients, production of CCL2 and 
CXCL8 was significantly induced compared to control cultures treated with PDE from 
stable patients (Figure 6.10A). 
Of note, the maximum amounts of CCL2 and CXCL8 were released after treatment of 
HPMC with PDE from patient P1 who presented with relatively high levels of TNF-α, IL-
1β and IFN-γ (Table 6.1). In contrast, I observed lower amounts of CXCL8 after treatment 
of HPMC with PDE from patient P2, who presented with relatively low levels of TNF-α, 
IL-1β and IFN-γ. 
I next sought to investigate which cytokines in the PDE were responsible for the induction 
of CCL2 and CXCL8 secretion by HPMC. To achieve this, PDE was pre-treated with 
sTNFR, anti-IFN-γ and anti-IL-1β, alone or in different combinations. As shown in Figure 
6.10B, I could significantly inhibit the secretion of CXCL8 and CCL2 (up to 34.7% ± 9.8 
and 25.4% ± 13, respectively), by a combined blocking of TNF-α and IL-1β. Other 
treatments showed various degrees of inhibition yet not significantly. Together these results 
highlight the importance of IL-1β and TNF-α in the acute inflammatory response to Gram− 
bacteria. 
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Table 6.1. Characteristics of PDE from patients with Gram− infections. 
 
  
 
Patients with peritonitis 
  P1 P2 P3 
Causative organism  Enterobacter E. coli Acinetobacter 
PDE cytokines/chemokines (pg/ml)    
CCL2  5027 8288 51 
CXCL8  65 2665 111 
IFN-γ 167 63 151 
TNF-α 1790 355 1154 
IL-1β 161 40 26 
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Figure 6.10. Effect of PDE on chemokine secretion by HPMC.  
(A) PDE from three infected patients (P1-P3) and three stable patients (P4-P6) was diluted 1:4 with culture 
medium and added to HPMC cultures for 24 hours. CCL2 and CXCL8 were measure by ELISA and results 
are adjusted by the dilution factor. (B) PDE from infected patients was supplemented with anti-IFN-γ, IL1-β 
or sTNFR alone or in different combinations. Resting HPMC were then exposed to pre-blocked PDE for 24 
hours. Data are expressed as the mean ± SEM from 3-4 experiments with cells isolated from separate donors. 
Data were analysed by Friedman test with Dunn’s post hoc test. Comparisons were made with values detected 
in absence of antibodies. Differences were considered significant as indicated: *, p<0.05; **, p<0.01; ***, 
p<0.001. 
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6.3.5 HPMC release cytokines and chemokines in response to Gram+ and Gram− 
bacteria  
HPMC are the first cells to encounter microbes during episodes of PD associated infections. 
These infections are caused most frequently by Gram+ Staphylococcus species, and cells 
respond to S. epidermidis by releasing chemokines and cytokines (Colmont et al., 2011).  
Infections caused by Gram− bacteria, even if less frequent, are more severe. However, the 
role of HPMC in response to Gram− bacteria has received comparatively little attention, 
despite the fact that Gram− infections are generally associated with poorer clinical outcomes. 
To define the potential impact of bacterial infections on local tissue, I here studied HPMC 
responses to a range of Gram− (E. coli, K. pneumoniae, P. aeruginosa) and Gram+ (E. 
faecalis, C. striatum, S. aureus) bacteria. HPMC produced IL-6, CXCL8 and CCL2 
following treatment with either Gram+ or Gram− extracts (Figure 6.11). This response was 
significant when cells were cultured in the presence of E. coli and P. aeruginosa extracts, 
in comparison with other organisms (Figure 6.11).  
As shown in Figure 6.12, similar results were obtained when using HPFB as responder cells. 
Taken together, these results suggest that both types of bacteria contribute to activation of 
peritoneal epithelial and stromal cells, and that Gram− bacteria are able to trigger a more 
severe response compared to Gram+ microbes, as evidenced by more pronounced secretion 
of inflammatory chemokines and cytokines. 
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Figure 6.11. Effect of Gram+ and Gram− bacterial extracts on CXCL8, CCL2 and IL-6 release by 
HPMC.  
Quiescent HPMC were exposed to Gram− (P. aeruginosa, K. pneumoniae, E. coli) or Gram+ (S. aureus, E. 
faecalis, C. striatum) bacterial extracts at a protein concentration of 100 µg/ml for 24 hours. ELISA was 
performed after 24 hours. Data are expressed as the mean ± SEM from 4 to 5 experiments with cells isolated 
from separate donors. Data were analysed by Friedman test with Dunn’s post hoc test. Differences were 
considered significant as indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
 
 
Figure 6.12 Effect of different Gram+ and Gram− bacterial extracts on CXCL8, CCL2 and IL-6 
release by HPFB.  
Quiescent HPFB were exposed to Gram− (P. aeruginosa, K. pneumoniae, E. coli) or Gram+ (S. aureus, E. 
faecalis, C. striatum) bacterial extracts at a protein concentration of 100 µg/ml for 24h. ELISA was performed 
after 24h. Data are expressed as the mean ± SEM from 4 to 5 experiments with cells isolated from separate 
donors. Data were analysed by one-way ANOVA, comparisons were made with medium controls. Differences 
were considered significant as indicated: *, p<0.05; **, p<0.01; ***, p<0.001. 
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6.4 Effect of unconventional T cell derived cytokines on epithelial and 
mesenchymal marker expression by HPMC 
6.4.1 Unconventional T cell induced morphological changes in HPMC 
Repeated episodes of peritonitis together with a long term PD effluent exposure can result 
in peritoneal fibrosis and ultrafiltration dysfunction. TNF-α is one of the cytokines 
implicated, together with TGF-β, IL-1β and IL-6, in mesothelial to mesenchymal transition 
of HPMC, which can lead to long term peritoneal membrane damage (Aroeira et al., 2007; 
López-Cabrera, 2014). In the experiments above, when HPMC were co-cultured with CoM 
derived from γδ T cells or MAIT cells, they underwent striking changes from an epithelial-
like appearance to a spindled fibroblastic shape within 24 hours (Figure 6.13A). This effect 
was similar to the one observed when HPMC were cultured in the presence of IFN-γ and 
TNF-α (Figure 6.14). These morphological changes were diminished when TNF-α and/or 
IFN-γ were neutralized in unconventional T cell CoM prior to addition to HPMC (Figure 
6.13B). These findings imply that TNF-α and IFN-γ derived from activated unconventional 
T cells might at least contribute to induction of morphological changes in the peritoneal 
membrane during PD associated infection.  
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Figure 6.13. Morphologic HPMC changes in the presence of unconventional T cell CoM.  
(A) Images were captured using a light microscope with a ×20 objective lens following 24 hours of culture in 
RPMI-1640 medium or conditioned medium derived from MAIT cells or γδ T cells. (B) CoM derived from 
MAIT cells was +/- pre-treated with sTNFR and anti-IFN-γ blocking antibody and added to HPMC cultures 
for 24 hours. Representative of 3 experiments.  
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Figure 6.14. Morphologic HPMC changes induced by TNF-α and IFN-γ.  
Images were captured using a light microscope with a ×20 objective lens following 24 hours of culture in the 
presence of 5 ng/ml of TNF-α and IFN-γ, alone or in combination, in the absence of FCS. Representative of 3 
experiments.  
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6.4.2 TNF-α induced significant changes in HPMC epithelial markers 
To study the effects of TNF-α on the modulation of epithelial and mesenchymal markers 
associated with peritoneal membrane failure I firstly cultured HPMC with increasing 
concentrations of TNF-α. I then examined expression of epithelial and mesenchymal 
markers that are associated with mesothelial to mesenchymal transition (MMT) at the 
mRNA level. As shown in Figure 6.15, I found a decrease in mRNA expression of epithelial 
markers implicated in cell-cell junctions such as E-cadherin, ZO-1 and occludin. Among 
the mesenchymal markers, I observed a significant downregulation of collagen-1 expression 
but not of the others marker, including fibronectin, α-SMA and SNAIL (Figure 6.15).  
SNAIL is implicated in the switch between the epithelial and the mesothelial phenotype and 
usually affects the expression of E-cadherin by TNF-α through the protein kinase B (Wu 
and Zhou, 2010). To check if an early upregulation of SNAIL was also responsible for the 
downregulation of E-cadherin in my system, I incubated HPMC with 5 ng/ml of TNF-α and 
measured the expression of mesenchymal markers at different time points. Figure 6.16 
shows that there were no changes in the expression of SNAIL at early time points (less than 
24 hours). Similarly, no changes were observed for α-SMA, whereas collagen-1 
significantly increased after 6 hours and then decreased again after 48 hours. Although not 
significantly, fibronectin expression also showed a tendency to increase after 12 and 48 
hours in the presence of TNF-α (Figure 6.16). In summary, these data show a possible 
contribution of TNF-α to the modulation of expression levels of epithelial markers 
implicated in the MMT process. However, the same effect was less evident with regard to 
key mesenchymal markers.  
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Figure 6.15. Relative expression of epithelial and mesenchymal HPMC markers in response to TNF-α. 
HPMC expression of epithelial markers E-cadherin, ZO-1, occludin, claudin-1 (left panels), and mesenchymal 
markers fibronectin, collagen-1, SNAIL and α-SMA (right panels) was detected by RT-qPCR following 
exposure to TNF-α for 48 hours at the concentrations shown. Data were expressed as expression levels relative 
to 1,000 copies of GAPDH, and are shown as mean ± SEM of 3 independent experiments. Data were analysed 
by RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's post hoc test, respectively. Comparison 
were made with control medium. Differences were considered significant as indicated: *, p<0.05; **, p<0.01; 
***, p<0.001, ****p<0.0001. 
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Figure 6.16. Relative expression of HPMC mesenchymal markers in response to TNF-α over 48 hours.  
Expression of mesenchymal markers fibronectin, collagen-1, SNAIL and α-SMA by HPMC were detected by 
RT-qPCR relative to GAPDH, after co-culturing HPMC with 5 ng/ml of TNF-α at the time points shown. Data 
are expressed as mean ± SEM of 3 independent experiments. Data were analysed by two-way ANOVA with 
Sidak post-hoc test, comparisons were made with control medium at each time point. Differences were 
considered significant as indicated: *, p<0.05; **, p<0.01; ***, p<0.001, ****p<0.0001. 
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6.4.3 Synergistic modulation of epithelial and mesenchymal markers by TNF-α and 
IFN-γ 
Since CoM from activated unconventional T cells contained between 5 and 10 ng/ml each 
of TNF-α and IFN-γ, I next analysed expression of epithelial and mesenchymal markers in 
HPMC cultured with 5 ng/ml of TNF-α and IFN-γ either alone or in combination. 
As shown in Figure 6.17, E-cadherin was downregulated by TNF-α, and this effect was 
more pronounced when TNF-α was combined with IFN-γ (Figure 6.17). The same effect 
was observed for the expression of ZO-1 and claudin-1, and was more pronounced for 
occludin (Figure 6.17). Of the mesenchymal markers, a significant downregulation of 
collagen-1, α-SMA and SNAIL was observed when TNF-α and IFN-γ were added together 
(Figure 6.17).  
. 
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Figure 6.17. Relative expression of epithelial and mesenchymal markers by HPMC in the presence of 
TNF-α and IFN-γ.  
Expression of the epithelial markers E-cadherin, ZO-1, occludin, claudin-1 (left panel), and the mesenchymal 
markers fibronectin, collagen-1, α-SMA and SNAIL (right panel) by HPMC was detected by RT-qPCR 
relative to GAPDH after 24 hours following exposure to the indicated concentrations of TNF-α and IFN-γ, 
alone or combination. The results are expressed as the mean ± SEM of 6 independent experiments. Data were 
analysed by RM one-way ANOVA or Friedman test with Holm-Sidak or Dunn's post hoc test, respectively. 
Comparison were made with the condition in absence of blocking antibody. Differences were considered 
significant as indicated in the Figures: *, p<0.05; **, p<0.01; ***, p<0.001, ****p<0.0001. 
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Next, HPMC were cultured for 24 hours in the presence of unconventional T cell CoM to 
test the effect of unconventional T cell-released cytokines on expression of epithelial and 
mesenchymal markers. As shown in Figure 6.18, E-cadherin and occludin were significantly 
downregulated in the presence of CoM derived from MAIT cells, whereas no one of the 
epithelial marker were significantly decreased in the presence of CoM derived from γδ T 
cells (Figure 6.18), maybe due to the relatively small number of experiments performed.  
Under the same conditions, both γδ T cell and MAIT cell CoM induced a significant 
upregulation of fibronectin alone amongst mesenchymal markers (Figure 6.19).  
Given the profound production of IL-6 by HPMC in response to TNF-α and IFN-γ, the 
mRNA level of IL-6 was used as a positive control in these cultures. As shown in Figure 
6.20A, the expression of IL-6 was increased 20-fold compared to the untreated control when 
TNF-α and IFN-γ were combined. A similar level of IL-6 was detected when HPMC were 
cultured in the presence of CoM derived from unconventional T cells (Figure 6.20B).  
Collectively, these results define a potential mechanism by which the presence of TNF-α 
and IFN-γ released by unconventional T cells during acute inflammatory responses might 
contribute to peritoneal membrane damage during PD associated infections. 
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Figure 6.18. Relative expression of epithelial markers in HPMC in the presence of CoM derived from 
unconventional T cells.  
Expression of the epithelial markers E-cadherin, ZO-1, occludin, claudin-1 after 24 hours of co-culture with 
conditioned medium derived from γδ T cells (left panel) or MAIT cells (right panel). Expression levels were 
detected by RT-qPCR relative to GAPDH. Each data point represents an individual. Data were analysed by 
Wilcoxon matched pairs tests. Differences were considered significant as indicated in the figure: *, p<0.05; 
**, p<0.01; ***, p<0.001, ****p<0.0001. 
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Figure 6.19. Relative expression of mesenchymal markers in HPMC in the presence CoM derived 
from unconventional T cells.  
Expression of mesenchymal markers fibronectin, collagen-1, SNAIL and α-SMA, relative to GAPDH in 
HPMC were detected by RT-qPCR, after 24 hours of co-culture with conditioned medium derived from γδ T 
cells (left panel) or MAIT cells (right panel). Data were analysed by Wilcoxon matched pairs test. Differences 
were considered significant as indicated in the figure: *, p<0.05; **, p<0.01; ***, p<0.001, ****p<0.0001. 
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Figure 6.20. Relative expression of IL-6 mRNA in HPMC in presence of TNF-α, IFN-γ or CoM 
derived from unconventional T cells.  
Expression IL-6 mRNA relative to GAPDH in HPMC was detected by RT-qPCR, following 24 h of co-culture 
with TNF-α and/or IFN-γ (A) or with conditioned medium derived from γδ T cells or MAIT cells (B). The 
results are expressed as the mean ± SEM of 6 independent experiments. Data were analysed by RM one-way 
ANOVA with Holm-Sidak post-hoc test. Comparisons were made with control medium. For CoM data were 
analysed by Wilcoxon matched pairs test. Differences were considered significant as indicated in the Figures: 
*, p<0.05; **, p<0.01; ***, p<0.001, ****p<0.0001. 
  
159 
 
6.5  Discussion 
In this Chapter I showed for the first time that activated unconventional T cells not only 
interact with other immune cells during episodes of infection (Davey et al., 2014; Eberl and 
Moser, 2009) but also contribute to the production of pro-inflammatory mediators by 
peritoneal tissue cells and induce phenotypic and morphological alterations in primary 
HPMC. 
The balance in the production of chemokines CXCL8, CCL2 and CXCL10 is important to 
fight infection at its onset and subsequently to resolve inflammation. Neutrophils are the 
first cells to migrate to the peritoneal cavity during infection, normally their recruitment is 
regulated by CXCL8 (Luster, 2002). Here I showed that CoM derived from both γδ and 
MAIT cells induced production of CXCL8 by both HPMC and HPFB via a mechanism 
regulated by TNF-α but not IFN-γ. These results concur with previous studies showing IFN-
γ regulated the switch from PMN to MNC recruitment, downregulating CXCL8 induced by 
TNF-α (Robson et al. 2001; Proost et al. 2006; Topley, et al. 1993).  
IL-6 increases with PD treatment and PD associated infection (Lambie et al., 2013; Topley 
et al., 1993a) and has pro- and anti-inflammatory effects in combination with IFN-γ 
(Fielding et al., 2014; Jones, 2005). In this study, IL-6 was produced by HPMC and HPFB 
following treatment with unconventional T cell CoM in a primarily TNF-α dependent 
process. It is likely that IFN-γ sensitises peritoneal cells to the subsequent action of TNF-α, 
for example by upregulating TNF-α’s receptors, and this could explain the synergistic effect 
induced by IFN-γ and TNF-α when combined together (Kawka et al., 2014; Topley et al., 
1993a).  
Induction of IL-6 production by unconventional T cells can in turn, together with sIL-6R 
released by recruited neutrophils, have a positive feedback on chemokines produced by 
HPMC. Furthermore, together with IFN-γ, IL-6 can modulate the switch from recruitment 
of polymorphonuclear to mononuclear cells to the site of infection (Hurst et al., 2001; 
McLoughlin et al., 2003). The presence of IFN-γ is also responsible for resident tissue cell 
secretion of CXCL10, a chemokine responsible for leukocyte migration to the infection site 
(Luster, 2002). Here, CXCL10 was not induced by IFN-γ alone, possibly due to the 
suboptimal concentration used in these experiments, but was released in the presence of 
CoM derived from both unconventional T cells. Blocking experiments confirmed that this 
effect was dependent on the presence of IFN-γ in the supernatant. These results agree with 
160 
 
those from an earlier study where IL1-β and TNF-α induced CXCL10 by HPMC only when 
combined with IFN-γ (Visser et al., 1998).   
As described in Chapter 4, CCL2 increases in the peritoneal cavity during episodes of acute 
infection. CCL2 is generally responsible for mononuclear cell recruitment to the site of 
infection and is produced mainly by tissue cells such as mesothelial cells and fibroblasts 
following IL-1β and IFN-γ activation (Topley et al., 1996; Witowski et al., 2001, 2009). I 
here observed, that activated unconventional T cells can trigger CCL2 from tissue stromal 
cells and this effect is caused by both IFN-γ and TNF-α present in the CoM (Glik and 
Douvdevani, 2006; Visser et al., 1998). Unconventional T cells express CCR2, these 
findings therefore suggest that these cells (i) may be recruited to the site of infection in 
response to locally secreted CCL2; (ii) once at the site, become activated by microorganisms 
producing the corresponding ligands and release IFN-γ and TNF-α at the site of infection, 
and (iii) induce a positive feedback loop enhancing the production of further chemokines 
by local tissue cells. 
Next, I observed that PDE effluents from patients with Gram− infection triggered 
significantly higher CXCL8 and CCL2 production, and that this effect was caused in part 
by IL-1β and TNF-α in the effluent. This is in agreement with a previous study in the host 
laboratory (Lin et al., 2013), where in contrast to Gram+ results, Gram− infection were 
characterized by an increased influx of neutrophils to the peritoneal cavity and increased 
PDE concentrations of IL-1β and TNF-α. The release of IL-1β and TNF-α is mainly induced 
by the endotoxin LPS, present on the outer cells wall of Gram− bacteria, following binding 
of TLR on resident macrophages during PD associated infection (Kumar et al., 2009). 
Indeed, simultaneous secretion of IL-1β and TNF-α is responsible for synergistic 
upregulation of inflammatory chemokines (e.g. CXCL8, CCL2 and RANTES) by both 
mesothelial cells and fibroblasts (Loghmani et al., 2002; Topley et al., 1993b; Visser et al., 
1998), confirming involvement of these chemokines in recruitment of leukocytes to the site 
of infection.  
During episodes of peritoneal infection, it is likely that mesothelial cells are amongst the 
first cells to encounter pathogens. PD associated infections most commonly caused by 
Gram+ organisms such as S. epidermidis, S. aureus, Streptococcus and Enterococcus, and 
less frequently by Gram− bacteria, the latter being associated with poorer outcomes (Chapter 
5). In this study I showed that HPMC not only participate in the peritoneal inflammation in 
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the presence of Gram+ bacterial extract (Colmont et al., 2011), but also become activated in 
the presence of Gram− microbial extracts. In particular, when Gram+ and Gram− bacteria 
were compared, I observed increased release of pro-inflammatory chemokines and 
cytokines in the presence of E. coli and P. aeruginosa. It has been shown that HPMC release 
inflammatory mediators like IL-6 after treatment with TLR2 agonists and cell free 
supernatant from S. epidermidis, but that they do not express the receptor for the Gram− 
associated pathogen molecule LPS (TLR4) nor response to LPS in vitro (Colmont et al., 
2011). However, the molecular compositions of LPS may vary between genera such that 
LPS derived from E. coli and Klebsiella might bind not only to TLR4, but also to TLR2, 
triggering a different modality of infection resolution (Oliveira-Nascimento et al., 2012). 
Colmont et al. showed that HPMC cells respond to flagellin (Colmont et al., 2011), a 
component present in flagellated bacteria such as E. coli and P. aeruginosa, and a potent 
agonist of TLR5 (Hayashi et al., 2001). This may explain the profound induction of HPMC 
pro-inflammatory chemokines by these organisms, and their association with technique 
failure in PD associated infection (Feng et al., 2014; Siva et al., 2009).  
I observed a similar pattern of activation by HPFB. HPFB activation was more evident in 
the presence of Gram− bacterial extracts than Gram+ extracts. This activation may was 
caused by the presence of TLR2 and TLR4 on HPFB (Abe et al., 2014). Gram− bacteria may 
trigger stronger inflammatory response by HPFB thanks to the presence of LPS and porins 
(Loghmani et al., 2002; Perfetto et al., 2003). Indeed, these PAMPs activate transcription 
factor NF-κB, which induces an array of genes implicated in inflammation (Medzhitov, 
2001). Moreover, fibroblast activation by Gram− bacteria such as P. aeruginosa might be 
induced independently by TLR activation. For instance, it has been demonstrated that 
elastase induces secretion of CXCL8 from dermal fibroblasts by binding to the epidermal 
growth factor receptor (Azghani et al., 2014).  
Finally, the present findings demonstrate that TNF-α and IFN-γ produced by activated 
unconventional T cells induced morphological and phenotypical changes in mesothelial 
cells that are usually associated with EMT. This process starts with the dissociation of the 
intercellular junctions as a result of downregulation of epithelial markers E-cadherin, 
claudins, occludins, ZO-1 and upregulation of mesenchymal markers α-SMA, collagen-1, 
fibronectin and the transcription factor SNAIL (Thiery and Sleeman, 2006). E-cadherin 
expression is fundamental to maintain the integrity of the peritoneal membrane. E-cadherin 
secures adhesion between cells by binding β-catenin and p120 catenin in the cytoplasm, 
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these molecules are also associated with the actin cytoskeleton via α-catenin (Lamouille et 
al., 2014). Destabilization of E-cadherin results in the β-catenin degradation or translocation 
to the nucleus, where it acts as transcription factor. These processes are regulated by SNAIL, 
which is upregulated via the ERK/NF-κB pathway in both cancer and peritoneal membrane 
associated EMT (Strippoli et al., 2008; Wu and Zhou, 2010).  
In the present study, TNF-α induced downregulation of epithelial markers such as E-
cadherin and occludin, an effect increased in conjunction with IFN-γ. This concurs with 
previous studies in which epithelial cells lost apical-basolateral polarity and acquired a 
migratory phenotype following downregulation of E-cadherin and upregulation vimentin 
and N-cadherin (Hanada et al., 2003; Lv et al., 2015). Synergistic downregulation of these 
epithelial markers in the presence of TNF-α and IFN-γ might result from crosstalk between 
signalling pathways activated by these two cytokines such as NF-κB by TNF-α, and 
JAK/STAT by IFN-γ (Ohmori et al., 1997; Wang et al., 2013).  
E-cadherin expression is repressed by SNAIL, which can be induced by pathways like WNT 
and PI3K-AKT acting on GSK3β or phosphorylation by transcription factors Notch and NF-
κB (Lamouille et al., 2014), and TNF-α can induce SNAIL dependent E-cadherin 
upregulation (Strippoli et al., 2008; Wu and Zhou, 2010; Yanez-Mo et al., 2003). This 
contrasts with my findings where I did not observe an upregulation of SNAIL induced by 
TNF-α. It may be the case that TNF-α was able to regulate other transcriptional factor 
responsible of EMT process such as TWIST, ZEB-1 and ZEB-2 but not SNAIL (Wang, 
2013). This may also explain why I observed downregulation of most mesenchymal markers 
after 24 hours and upregulation of fibronectin only with conditioned medium from 
unconventional T cells. Indeed, fibronectin can be induced by transcription factors such as 
SNAIL and TWIST. The downregulation of mesenchymal markers could also be explained 
by the anti-fibrotic activity of TNF-α and IFN-γ in the regulation of tissue gene expression. 
It has been shown that these two cytokines inhibit expression of collagen and fibronectin on 
epithelial fibroblasts, opposing the effects of TGF-β-SMAD3 pathways (Ghosh et al., 2001; 
Hatamochi et al., 1994). TGF-β, the most potent pro-fibrotic factor, is induced in the 
presence of glucose degradation products from PD solutions and in episodes of peritonitis, 
and is able to drive EMT (Aroeira et al., 2007; LEASK, 2004; Selgas et al., 2006). It has 
been shown that TNF-α accentuates the ability of TGF-β to suppress epithelial markers and 
increase MMP secretion (Borthwick et al., 2012). However, TNF-α did not change or reduce 
the expression of mesenchymal markers when combined with TGF-β (Borthwick et al., 
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2012). Therefore, increased level of TNF-α at the site of infection, together with elevated 
levels of TGF-β and IL-6, could drive EMT. This means that is fundamental the balance 
between these molecules for infection resolution and tissue regeneration during PD 
associate infection. 
Overall, these findings identify unconventional T cell-derived TNF-α and IFN-γ as major 
stimulators of peritoneal tissue cells, likely to enhance local inflammation and contribute to 
the recruitment of further monocytes, neutrophils and lymphocytes to the site of infection. 
Moreover, the magnitude of inflammatory chemokines produced by peritoneal tissue cells 
in the presence of Gram− bacteria might help explain the difference in clinical outcome 
between Gram+ and Gram− bacterial infection. 
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Chapter 7. General discussion and future work 
7.1 General discussion 
Novel methods for the early diagnosis of peritonitis in PD are urgently needed. Ideally, with 
such diagnostic tools, patients at risk of technique failure could be identified earlier thus 
helping improve patient outcomes. Infection and associated inflammation remain the major 
reasons for treatment failure and death of PD patients (Piraino et al., 2011). Diagnosis of 
infection by microbiological culture results is inefficient, slow and often unclear, leading to 
a widespread use of broad-spectrum antibiotics to cover both Gram+ and Gram− infections. 
This may contribute to prolonged treatments, chronic/recurrent infections, catheter removal 
and mortality. Moreover, inappropriate antibiotic prescription may contribute to the 
emergence of anti-microbial resistant “superbugs”, which are spreading at an alarmingly 
high rate (Arias and Murray, 2009). 
During infections, the immune system interacts with microbe-associated molecules at 
various levels leaving a pathogen-specific signature of immunological biomarkers (Lin et 
al., 2013). Such “immune fingerprints” could be exploited to discriminate between different 
types of pathogens, which might consequently help design novel tests for infection 
diagnosis. For instance, pattern associated molecules (HMB-PP, vitamin B2 derivatives) 
can be recognised by Vγ9/Vδ2 T cells and MAIT cells via the non-polymorphic presenting 
molecules BTN3 and MR1, respectively (Liuzzi et al., 2015). In this thesis, it was shown 
that Vγ9/Vδ2 T cells and MAIT cells are able to respond specifically to HMB-PP+ and/or 
vitamin B2+ organisms by the release of pro-inflammatory cytokines. Moreover, it was 
observed that high levels of Vγ9/Vδ2 T cells and MAIT cells were associated with HMB-
PP+ and vitamin B2+ infections in the peritoneal cavity at day 1 of acute peritonitis. This is 
particularly important given that infections caused by HMB-PP+ and/or vitamin B2+ 
pathogens (e.g. E. coli, Pseudomonas, Mycobacterium) are responsible for poor outcomes 
in PD. In particular, an assessment of the frequency of these unconventional T cells 
combined with the proportions of other immune cells (e.g. neutrophils, monocytes and CD4+ 
T cells) and concentrations of soluble mediators (e.g. TNF-α, IL-1β, IFN-γ, CXCL-10, IL-
22) might help design a diagnostic test that is able to identify the causative pathogen at day 
1 of the infection (Lin et al., 2013; Liuzzi et al., 2015). Such a combination would not only 
help discriminate between Gram+ and Gram− infections but also between certain subgroups 
such as Gram+ HMB-PP+ vitamin B2+ (e.g. Mycobacterium, Corynebacterium), Gram+ 
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HMB-PP− vitamin B2+ (e.g. Staphylococcus) and Gram+ HMB-PP− vitamin B2− species 
(e.g. Streptococcus, Enterococcus). Ultimately, the use of such a diagnostic tool would help 
prescribe antibiotic more prudently and hence lead to better patient outcomes. 
Previous work in the Eberl laboratory showed that the presence of Vγ9/Vδ2 T cells at the 
site of infection is not only able to predict Gram− infection but also to identify patients at 
high risk of technique failure within the first 3 months after infection. Here, the analysis of 
peritonitis outcomes from the ANZDATA registry demonstrated the association of HMB-
PP and vitamin B2 positive infections with poor outcomes. This finding suggests that, if the 
infection is not resolved in time, both Vγ9/Vδ2 T cells and MAIT cells may contribute to 
the amplification of local inflammation and long-term membrane damage.  
In order to better understand the role of unconventional T cells during inflammation and 
long-term membrane damage, the activation of Vγ9+ T cells and MAIT cells in the presence 
of HMB-PP and vitamin B2 positive and negative bacterial extracts was studied. 
Specifically, in this study it was demonstrated that (i) γδ T cells and MAIT cells together 
account for up to 50% of peritoneal T cells releasing TNF-α in response to E.coli bacterial 
extract; (ii) under the same conditions, peritoneal Vγ9/Vδ2 T cells alone contribute to up to 
60% of IFN-γ production; and (iii) unconventional T cells derived TNF-α and IFN-γ are 
potent stimulators of peritoneal mesothelial cells and fibroblasts. The stimulation of 
peritoneal γδ T cells and MAIT cells results in the induction of the pro-fibrotic cytokine IL-
6 as well as chemokines such as CCL2, CXCL8 and CXCL10 and triggers phenotypical 
changes in mesothelial cells (Figure 7.1). TNF-α, actually tends to increase at the site of 
infection and is associated with technique failure and mortality in PD patients (Davey et al., 
2011a).  
Of note, the crosstalk between unconventional T cells and peritoneal immune and stromal 
cells in response to HMB-PP and/or vitamin B2 producing bacteria can be manipulated 
experimentally at various check points, by (i) blocking antibodies against the TCR, thus 
preventing recognition of HMB-PP by Vγ9/Vδ2 T cells and vitamin B2 by MAIT cells; (ii) 
adding antibodies to block the accessory molecules MR1 for MAIT cells and BTN3 for 
Vγ9/Vδ2 T cells; and (iii) neutralisation of soluble TNF-α, which is important for γδ T cell 
proliferation. It is also released by neutrophil and monocytes in the presence of LPS, and 
acts as survival factor for all three types of cells (Figure 7.1) (Davey et al., 2011a, 2014).  
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Figure 7.1. Amplification of inflammation by peritoneal γδ T cells and MAIT cells.  
Neutrophils are able to engulf invading microbes and release microbial metabolites such as HMB-PP and 
vitamin B2 into the microenvironment, which become visible to Vγ9/Vδ2 T cells in the context of BTN3A1 
and to MAIT cells in the context of MR1. At the same time, monocytes provide contact-dependent signals 
necessary for unconventional T cells activation (e.g. LFA-1-ICAM-1 interaction). Once activated at the site 
of infection, recruited or resident Vγ9/Vδ2 T cells and MAIT cells release the pro-inflammatory cytokines 
TNF-α and IFN-γ. In turn, TNF-α supports local γδ T cell expansion and acts as a monocyte and neutrophil 
survival signal. TNF-α also induces the release of the chemokines such CCL2 and CXCL8 from human 
peritoneal mesothelial cells (HPMC) and human peritoneal fibroblasts (HPFB). CCL2 is also induced in the 
presence of IFN-γ at the site of infection. IFN-γ but not TNF-α trigger the release of CXCL10 from both 
HPMC and HPFB. Once released, CCL2 and CXCL10 are responsible for the recruitment of mononuclear 
cells such as monocytes and T cells to the site of infections. CCL2 is also responsible for the recruitment of 
peripheral Vγ9/Vδ2 T cells and MAIT cells to the peritoneal site. CXCL8 is responsible for the recruitment 
of neutrophils to the site of infection and is also released by neutrophils themselves after activation by 
microbial metabolites (e.g. LPS). Under the same conditions, neutrophils release the soluble form of the 
interleukin-6 receptor (sIL-6R). The pro-inflammatory cytokine IL-6 is released by activated monocytes and 
macrophages as well as HPMCs and HPFBs which may have recruited sIL-6R. In this way the IL-6/IL-6R 
complex signals will suppress the production of CXC chemokines and promote the production of mononuclear 
chemokines such as CCL2 and CCL5.  
  
167 
 
The assessment of Vγ9/Vδ2 T cells and MAIT cells as cellular biomarkers in PD may also 
give an indication on appropriate antimicrobial treatments to control infections caused by 
“superbugs”. Indeed, the spreading of antibiotic resistance limits the treatment choice for 
PD patients at day 1 of the infection. Vancomycin-resistant E. faecium (VRE) and 
methicillin-resistant S. aureus (MRSA) bacteria present a therapeutic challenge among the 
Gram positive bacteria (Arias and Murray, 2009; Reynolds, 2009). Similarly, Gram− 
bacteria can become resistant to almost all β-lactamase due to the spread of enzymes such 
as New Delhi metallo-β-lactamase (NDM) among these species (Jacoby and Munoz-Price, 
2005). It has been found that up to 36% of E. coli peritonitis were caused by β-lactamase 
resisting strains and were associated with poor response to single antibiotic treatment (Feng 
et al., 2014). In addition, with the rise of new β-lactamases the detection of resistant bacteria 
by microbiological culture can be suboptimal (Jacoby and Munoz-Price, 2005). This means 
that new effective antibiotics are needed and available agents need to be used more 
prudently. In this respect, it is noteworthy that most Gram− bacteria are also HMB-PP 
positive (Liuzzi et al., 2015). The production of this metabolite can be abrogated by the use 
of the antibiotic fosmidomycin (Jomaa, 1999). Most importantly, fosmidomycin was found 
to be effective against Gram− bacteria that are β-lactamase resistant (Davey et al., 2011c). 
Of note, a possible future use of this antimicrobial in PD might not only help inhibit the 
growth of HMB-PP positive bacteria but also possess anti-inflammatory properties by 
abrogation of the HMB-PP dependent Vγ9/Vδ2 T activation.  
Many pathogenic bacteria are dependent on the biosynthesis of riboflavin (vitamin B2) 
(Mack and Grill, 2006). The enzymes catalysing the last two steps in the riboflavin pathway 
(lumazine and riboflavin synthases, respectively) have been studied in detail and found to 
be conserved among all organisms (Morgunova et al., 2010). Since a number of inhibitors 
of these two enzymes have already been identified (Mack and Grill, 2006), the riboflavin 
pathway represents a promising target to design novel anti-infective agents and to inhibit 
the vitamin B2 dependent MAIT cell activation in vivo. Taken together, the presence of 
increased levels of Vγ9/Vδ2 T and MAIT cells at day 1 of acute infections may thus give 
both an indication on the severity of the infection and directions on the choice of treatment. 
In summary, the findings in this thesis elucidate a potential mechanism for the amplification 
of acute inflammatory response by unconventional T cells in PD. Vγ9/Vδ2 T cells and 
MAIT cells are recruited specifically to the site of infection in response to HMB-PP+ and 
vitamin B2+ bacteria, respectively. Once at the site of infection, they may contribute to the 
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amplification of peritoneal inflammation by releasing IFN-γ and TNF-α and orchestrating 
antimicrobial responses. However, in the case of an unresolved infection, unconventional T 
cells might also be pathogenic, affecting long-term peritoneal membrane damage and 
consequently technique survival. This suggests that a diagnostic test that would be able to 
identify unconventional T cells at day 1 of the infection would not only give information as 
to the type of causative organism present in the peritoneal cavity but would also be able to 
tell whether the patient is at increased risk of subsequent technique failure. 
This clinical model offers a number of opportunities to study the immune response into 
acute infections caused by Gram+ and Gram− bacteria as well as fungi. Most other acute 
diseases, for instance respiratory or urinary tract infections, do not show such a wide 
spectrum of organisms. Moreover, access to anatomical locations other than blood is usually 
limited, especially during acute disease, and the collection of samples from the site of 
inflammation is rarely possible. In contrast, in PD patients peritoneal effluent can be 
sampled repeatedly and non-invasively providing unrestricted access to the site of infection. 
The immunological profile of stable PD patients allows to establish pre-infection baseline 
parameters in individuals prone to develop peritonitis later on. Collectively, this study 
demonstrated that PD can be used as model for investigations into local immune responses 
and monitoring individuals before, during and after defined microbial infections. 
 
7.2 Future work 
The aim of my research was to study how unconventional T cells contribute to the 
amplification of inflammation during PD associated infection. In particular, it was studied 
how activated unconventional T cells influence the activation of peritoneal mesothelial cells 
and fibroblasts. However, further work is necessary to clarify whether peritoneal 
mesothelial cells and fibroblasts have an impact on unconventional T cell activation in the 
presence of microbial metabolites such as HMB-PP and vitamin B2, or bacterial extracts in 
general. For instance, it might be that peritoneal mesothelial cells, equally as other epithelial 
cells, express antigen presenting molecules (e.g. BTN3 and MR1) and have properties of 
antigen uptake followed by unconventional T cell stimulation and activation (Hausmann et 
al., 2000; Jeffery et al., 2016). 
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Another open question is as to where exactly unconventional T cells are localised in the 
peritoneal cavity. Are they in contact with mesothelial cells? Do they migrate to the 
connective tissue? Future studies are necessary to try to identify these cells in sections of 
omentum and peritoneum tissue of patients that were either stable or had a history of 
peritonitis. Such a study would not only clarify the exact localisation of these cells but also 
confirm the presence of unconventional T cells in the peritoneal cavity depending on the 
causative pathogen.  
It remains to be investigated as to how much these findings on the use of unconventional T 
cells as diagnostic tool in PD can be applied to monitoring the course of the disease and the 
response to treatment. Many questions remain in this regard: do the frequency of 
unconventional T cells remain stable over time in the absence of infection? Is the presence 
of unconventional T cells during the stable phase affected by the previous history of 
infections? Does the composition of peritoneal immune cells return to pre-infections 
baseline levels?  
Moreover, future studies are needed to define the mechanisms that underline microbial 
pattern recognition by unconventional T cells. This raises the questions: how do 
unconventional T cells’ TCRs interact with non-polymorphic presenting molecules? Which 
molecules are involved in antigen uptake and intracellular trafficking allowing antigen 
presentation? Do unconventional T cells use different TCRs to recognise different 
pathogens? 
In the future, the use of immune fingerprints in PD may be extended to other local or 
systemic infections such as sepsis at the time of patient care. Uunconventional T-cells play 
a pivotal role in the orchestration of early inflammatory responses, and emerging 
mechanistic insights have started to unlock the secrets of innate-like recognition encoded 
by specific portions of the TCR repertoire. The highly constrained genetic and microbial 
elements inherent within each of these various systems therefore offer unique molecular 
targets for the development of novel and universally applicable diagnostics and therapeutics.
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APOCALYPSE NOW: THE END OF
MODERN MEDICINE AS WE KNOW IT
Gentlemen, it is the microbes who will
have the last word. [Messieurs, c’est les
microbes qui auront le dernier mot].
– Louis Pasteur, 1822–1895
The last 200 years have seen a dramatic
reduction in the prevalence and sever-
ity of microbial infections, due to the
implementation of groundbreaking mea-
sures ranging from improved sanitation
and hygiene and the introduction of asep-
tic techniques to the development of suc-
cessful vaccines and the discovery of effec-
tive antibiotics. Devastating infections that
were common until the late nineteenth cen-
tury such as cholera, diphtheria, plague,
syphilis, tuberculosis, and typhoid came
into the reach of effective control, at least
in developed countries, and with a min-
imized risk of wound infections surgical
procedures began to revolutionize modern
medicine. Antibiotics, in particular, radi-
cally transformed the treatment and pre-
vention of microbial infections and have
saved millions of lives since their intro-
duction (1). However, antibiotic usage is
invariably linked to the selective pressure
it exerts on the target organism to develop
escape strategies (2).
We are at present witnessing how the
pendulum begins to swing backwards,
with anti-microbial resistances develop-
ing on an unprecedented global scale.
New classes of Gram-positive and Gram-
negative “superbugs” are emerging and
spreading at an alarming rate, some of
which are virtually insusceptible to all
available drugs (3–5). The once apocalyp-
tic vision of a “post-antibiotic era” where
common infections and minor injuries
may result untreatable and eventually fatal
is rapidly becoming a real possibility (1,
2, 6, 7), heralding what Margaret Chan,
Director-General of the WHO, in 2012
called “the end of modern medicine as we
know it.” The appearance of multidrug-
resistant bacteria has been identified by
the WHO, the Centers for Disease Con-
trol and Prevention (CDC) in the USA and
their European counterpart, the ECDC,
as one of the major global health chal-
lenges humankind is facing in the twenty-
first century (8–10). According to Sally
Davies, the UK Chief Medical Officer,
“there are few public health issues of
greater importance than anti-microbial
resistance in terms of impact on society”
(11).
There is now an urgent call for anti-
microbial stewardship programs that aim
to prescribe antibiotics more prudently,
and to tailor their use to defined patient
groups who will benefit most. The fact
that the prevalence of resistance appears
to correlate directly with antibiotic con-
sumption across different countries (12)
argues in favor of the immediate effec-
tiveness of such tightly controlled pro-
grams. As highlighted in a recent Outlook
issue in Nature, “the potential to save lives
with faster and more targeted diagnoses,
decrease unnecessary and often incorrect
prescriptions, and even help identify early
on where bacterial resistance could occur,
will have a drastic effect on the way patients
are treated” (13).
MISSION IMPOSSIBLE: THE
FUNDAMENTAL FLAWS OF
CONVENTIONAL DIAGNOSIS
When it concerns the search for
pathogenic organisms suspected in
the diseased body, in the first
instance bacteria, then during con-
ventional microscopic examination
carried out without special prepa-
rations and artifices one encoun-
ters the most substantial, at times
virtually insurmountable, obstacles.
[Wenn es sich nun darum han-
delt, die im erkrankten Körper ver-
mutheten pathogenen Organismen,
zunächst Bacterien, aufzusuchen, so
begegnet man bei der gewöhn-
lichen ohne besondere Vorbereitun-
gen und Kunstgriffe ausgeführten
mikroskopischen Untersuchung den
erheblichsten, stellenweise geradezu
unübersteiglichen Hindernissen]. –
Robert Koch, 1843–1910 (14)
More than a century after Robert Koch’s
landmark discovery of the causative agents
of anthrax, cholera, and tuberculosis,
the diagnosis of suspected infections still
depends largely on the definitive identifi-
cation of the likely pathogen in biological
samples. However, standard microbiolog-
ical culture is inefficient and slow (typi-
cally >1–2 days, for a confirmed diagnosis
of tuberculosis >4 weeks), and in many
cases no organism can be grown despite
Abbreviation: HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate.
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clinical signs of infection, indicating that
conventional diagnostic methods are not
specific and/or rapid enough to target
therapy (15–17). Early management of
patients with acute symptoms who require
immediate medical intervention, includ-
ing virtually all hospital-based infections,
thus remains largely empirical. As direct
consequence, the fundamental uncertainty
about the real cause underlying the clinical
signs observed leads to inappropriate and
unnecessary treatments exposing patients
to drug-related side effects; raising the
risk of opportunistic, chronic, or recurrent
infections; and contributing to the emer-
gence and spread of multidrug resistance
(1–7). This dilemma eventually results
in potentially avoidable patient morbid-
ity/mortality, and imposes a considerable
burden on health care systems and societies
(8–11). There remains an unmet clinical
need for rapid and accurate diagnostic tests
for patients with acute infections. Accord-
ing to Kessel and Sharland (18), “new tech-
nology focusing on rapid diagnosis of spe-
cific bacteria and resistance genes, along
with combination biomarkers indicating
bacterial or viral infections, especially if
adapted to near patient testing, could have
a major impact on targeting appropriate
antibiotic treatment.”
In order to circumvent the almost
insurmountable obstacles of a rapid and
accurate identification of the causative
pathogen by traditional microbiological
techniques, efforts are being made to
utilize state-of-the-art molecular meth-
ods. Approaches based on the detec-
tion of microbial nucleic acids, cell wall
constituents, or other unique features
of distinct pathogens by PCR, chro-
matography, or mass spectrometry cer-
tainly complement culture-based tests
and speed up microbial identification,
yet they require considerable resources
and may not be applicable to primary
care or home settings (19–23). More-
over, they do not provide information
about the pathogenicity of the identi-
fied species and its interaction with the
host. Of note, neither microbiological nor
molecular methods discriminate between
pathogens causing disease, asymptomatic
carriage, and sample contaminants, and
thus even positive test results require exten-
sive interpretation by the treating physician
(24–26).
There is a plethora of disease-related
markers that are commonly assessed by
clinicians to aid a correct diagnosis, rang-
ing from basic blood and urine parameters
to indicators of tissue damage, tumor pro-
gression and autoimmunity, among others.
However, there is a conspicuous paucity
of biomarkers for accurate diagnosis of
microbial disease. Current biomarkers of
inflammation such as C-reactive protein
(CRP) or procalcitonin (PCT) are often
not sensitive or specific enough and are
only poor surrogates for acute infections
(22, 27, 28). The vast majority of research
on novel diagnostics has so far focused on
identifying individual factors and assess-
ing their performance in isolation. Yet,
it may come as no surprise that none of
these proposed parameters have reached
sufficient discriminatory power on their
own, given the complex and multifactorial
processes underlying local and systemic
inflammatory responses to a broad range
of pathogens (29, 30). As a result, neither
the direct identification of the causative
pathogen nor the measurement of cur-
rently used biomarkers of inflammation is
sufficiently accurate or rapid for a reliable
point-of-care diagnosis of acute microbial
infection.
QUANTUM OF SOLACE: EXPLOITATION
OF PATHOGEN-SPECIFIC HOST
RESPONSES FOR NOVEL DIAGNOSTICS
The immune system appears to have
originated as a set of effector cells
having multiple distinct receptors
that discriminate self from infec-
tious non-self by recognition of pat-
terns found exclusively on microor-
ganisms. – Charles A. Janeway, Jr.,
1943–2003 (31)
Key to developing better and stratified
approaches to treating infection is a
detailed understanding of the intricate
host–pathogen relationships in disease, in
order to exploit the unique sophistica-
tion of the human immune system for
diagnostic and therapeutic purposes (32,
33). In a radical departure from current
practice, our research is based upon the
premise that each type of infection evokes a
distinct pathogen-specific host response –
what we refer to as “immune fingerprint.”
A patient’s early anti-microbial response
itself is likely to provide far more detailed
insight into the true cause and sever-
ity of acute infections than conventional
methods, independently of the subsequent
clinical course of the disease (34). The
human immune system is a highly complex
network of interdependent cellular and
humoral players that has evolved over mil-
lions of years in order to survey the body for
potentially hazardous structures and initi-
ate an appropriate defense. The commu-
nication with invading micro-organisms
thus occurs at multiple levels, giving rise
to a plethora of biomarkers of potential
relevance for diagnostic purposes. Differ-
ent pathogens interact uniquely with dif-
ferent components of the innate immune
system due to the efficient self/non-self dis-
crimination based on conserved microbial
signals such as non-methylated bacterial
DNA, bacterial flagella, and cell wall con-
stituents. These structures are typically rec-
ognized by members of the Toll-like recep-
tor family and/or other pattern recogni-
tion receptors expressed by sentinel cells
(35–37). However, there is also emerg-
ing evidence that certain types of innate
or “unconventional” T-cells such as γδ T-
cells and mucosal-associated invariant T
(MAIT) cells are able to detect common
microbial metabolites through their T-cell
receptors, by sensing intermediates of the
non-mevalonate and riboflavin biosynthe-
sis pathways that are unique to certain types
of microorganisms (38, 39).
Vγ9/Vδ2 T-cells represent a unique
subpopulation of human T-cells (40, 41)
that appears to have a particularly cru-
cial role in contributing to immune fin-
gerprints of diagnostic relevance (34). This
is due to their exquisite responsiveness to
the microbial isoprenoid precursor (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMB-PP) that is produced by the
majority of Gram-negative pathogens and
a large proportion of Gram-positive species
such as Clostridium difficile, Listeria mono-
cytogenes, and Mycobacterium tuberculosis,
while it is not found in other bacteria
including staphylococci and streptococci
as well as fungi (42–44). The rapid and
sensitive response of Vγ9/Vδ2 T-cells to a
broad range of pathogens evokes Janeway’s
criteria for a “pathogen-associated mol-
ecular pattern” in that HMB-PP is an
invariant metabolite in many different
species that is essential in the microbial
physiology but absent from the human
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host (43, 45). Bacterial extracts prepared
from HMB-PP producing species typically
activate Vγ9/Vδ2 T-cells much stronger
than extracts prepared from HMB-PP
deficient micro-organisms (42, 44, 46),
and peripheral and/or local Vγ9/Vδ2 T-
cell levels are often elevated in patients
infected with defined HMB-PP producing
pathogens (43, 47). Elegant proof of con-
cept for this responsiveness comes from
the demonstration that HMB-PP produc-
ing wildtype L. monocytogenes activate
Vγ9/Vδ2 T-cells far better, both in vitro
(48) and in primate models in vivo (49),
than genetically engineered L. monocyto-
genes that are identical to the parental
strain except for an inability to pro-
duce HMB-PP. Similarly, overexpression of
HMB-PP synthase through genetic manip-
ulation increases the stimulatory poten-
tial of bacteria such as E. coli, L. mono-
cytogenes, M. tuberculosis, and Salmonella
enterica on Vγ9/Vδ2 T-cells in vitro (42,
46, 48, 50, 51) and in vivo (52). Our
own data demonstrate that even in het-
erogeneous patient cohorts infected with
a whole spectrum of diverse bacteria,
differences in Vγ9/Vδ2 T-cell frequencies
between patients with microbiologically
confirmed infections caused by HMB-PP
producing and HMB-PP deficient species
remain apparent. This is true both for peri-
toneal dialysis patients with acute peritoni-
tis as an exemplar of localized immune
responses restricted to the peritoneal cav-
ity (34, 46, 53), as well as on a sys-
temic level in the peripheral blood of
critically ill patients with severe sepsis
(54). Most importantly, studies in patients
with acute peritonitis suggest that a diag-
nostic test measuring local Vγ9/Vδ2 T-
cells on the first day of presentation
with acute symptoms may not only indi-
cate the presence of Gram-negative (pre-
dominantly HMB-PP producing) bacteria
but also identify patients at an increased
risk of inflammation-related downstream
complications (34).
The exquisite responsiveness of
Vγ9/Vδ2 T-cells and other unconven-
tional T-cells to microbial metabolites
shared by certain pathogens but not
by others identifies these cell types as
key constituent of diagnostically relevant
immune fingerprints at the point of care.
This is especially the case when Vγ9/Vδ2
T-cell levels are assessed locally and when
they are combined with other powerful dis-
criminators such as peritoneal proportions
of neutrophils, monocytes, and CD4+
T-cells in the inflammatory infiltrate as
well as intraperitoneal concentrations of
certain soluble immune mediators (34)
(Figure 1). Such a combination with
further parameters provides additional
information as to the precise nature of
the causative pathogen, for instance to
distinguish between immune responses
induced by Gram-negative (LPS produc-
ing) and Gram-positive (LPS deficient)
bacteria, and is also likely to help increase
sensitivity owing to the age and gender-
dependent variability of Vγ9/Vδ2 T-cell
levels (55). Pathogen-specific immune
fingerprints that discriminate between
certain subgroups of patients (e.g., with
Gram-negative vs. Gram-positive bacterial
infections) can be determined within hours
of presentation with acute symptoms, long
before traditional culture results become
available, and by guiding early patient
FIGURE 1 | Local immune fingerprints in peritoneal dialysis patients on the day of presentation with acute peritonitis. Shown are cellular and humoral
biomarkers that are associated with the presence of Gram-positive or Gram-negative bacteria and that may be exploited for novel diagnostic tests (34).
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management and optimizing targeted
treatment will contribute to improv-
ing outcomes and advancing antibiotic
stewardship. It remains to be investigated
how much these findings on diagnostic
immune fingerprints in peritoneal dialysis
patients can be extended to other local
or systemic scenarios to diagnose infec-
tions at the point of care, and whether
they can also be applied to monitoring the
course of the disease and the response to
treatment.
Applied research on γδ T-cells has so
far focused predominantly on their use for
novel immunotherapies against different
types of cancers (56–58). Thirty years after
the unexpected cloning of the TCRγ chain
(59, 60) and 20 years after the first descrip-
tion of microbial “phosphoantigens” as
specific activators of human Vγ9/Vδ2 T-
cells (61, 62), the diagnostic potential of γδ
T-cells is only beginning to unfold (34, 47,
63, 64).
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Microbe-Specific Unconventional T Cells Induce Human
Neutrophil Differentiation into Antigen Cross-Presenting
Cells
Martin S. Davey,*,1,2 Matt P. Morgan,*,†,1 Anna Rita Liuzzi,* Christopher J. Tyler,*
Mohd Wajid A. Khan,* Tamas Szakmany,*,‡ Judith E. Hall,* Bernhard Moser,* and
Matthias Eberl*
The early immune response to microbes is dominated by the recruitment of neutrophils whose primary function is to clear invading
pathogens. However, there is emerging evidence that neutrophils play additional effector and regulatory roles. The present study
demonstrates that human neutrophils assume Ag cross-presenting functions and suggests a plausible scenario for the local gen-
eration of APC-like neutrophils through the mobilization of unconventional T cells in response to microbial metabolites. Vg9/
Vd2 T cells and mucosal-associated invariant T cells are abundant in blood, inflamed tissues, and mucosal barriers. In this study,
both human cell types responded rapidly to neutrophils after phagocytosis of Gram-positive and Gram-negative bacteria pro-
ducing the corresponding ligands, and in turn mediated the differentiation of neutrophils into APCs for both CD4+ and CD8+
T cells through secretion of GM-CSF, IFN-g, and TNF-a. In patients with acute sepsis, circulating neutrophils displayed a similar
APC-like phenotype and readily processed soluble proteins for cross-presentation of antigenic peptides to CD8+ T cells, at a time
when peripheral Vg9/Vd2 T cells were highly activated. Our findings indicate that unconventional T cells represent key con-
trollers of neutrophil-driven innate and adaptive responses to a broad range of pathogens. The Journal of Immunology, 2014,
193: 3704–3716.
N
eutrophils are the first cells that are recruited to sites
of microbial infection. Although classically viewed as
terminally differentiated cells, there is emerging evi-
dence that neutrophils represent key components of the effector and
regulatory arms of the innate and adaptive immune system (1–3).
As such, neutrophils regulate the recruitment and function of
various cell types and interact with immune and nonimmune cells.
Intriguingly, neutrophils directly affect Ag-specific responses by
facilitating monocyte differentiation and dendritic cell maturation,
and by interacting with T cells and B cells (4–10). Murine neu-
trophils have been shown to present Ags to both CD4+ and CD8+
T cells (11–13), and to differentiate into neutrophil–dendritic cell
hybrids in vitro and in vivo (14, 15). In humans, neutrophils with
a phenotype consistent with a possible APC function, including
expression of MHC class II, have been found in diverse inflam-
matory and infectious conditions (16–22). This notwithstanding,
direct Ag presentation by neutrophils has to date not been dem-
onstrated in patients, especially with respect to an induction of
Ag-specific CD8+ T cell responses upon cross-presentation of
exogenous proteins.
The physiological context underlying the differentiation of
neutrophils into APCs and the implications for Ag-specific immune
responses remain unclear. Unconventional T cells such as human
gd T cells, NKT cells, and mucosal-associated invariant T (MAIT)
cells represent unique sentinel cells with a distinctive respon-
siveness to low m.w. compounds akin to pathogen and danger-
associated molecular patterns (23–25). Such unconventional
T cells represent a substantial proportion of all T cells in blood
and mucosal epithelia, accumulate in inflamed tissues, and con-
stitute an efficient immune surveillance network in inflammatory
and infectious diseases as well as in tumorigenesis. Besides or-
chestrating local responses by engaging with other components of
the inflammatory infiltrate (26–29), unconventional T cells are
also ideally positioned in lymphoid tissues to interact with freshly
recruited monocytes and neutrophils (30–32). We previously
showed that human gd T cells enhance the short-term survival of
neutrophils but did not characterize these surviving neutrophils on
a phenotypical and functional level (28). In this work, we studied
the outcome of such a crosstalk of human neutrophils with both gd
T cells and MAIT cells in vitro and translated our findings to
patients with severe sepsis. We demonstrate that neutrophils with
APC-like features can be found in blood during acute infection,
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and that the phenotype and ex vivo function of circulating sepsis
neutrophils was replicated in vitro upon priming of neutrophils by
human gd T cells and MAIT cells. Our findings thus provide
a possible physiological context and propose a cellular mechanism
for the local generation of neutrophils with APC functions, in-
cluding their potential to cross-present soluble Ags to CD8+
T cells, in response to a broad range of microbial pathogens.
Materials and Methods
Subjects
This study was approved by the South East Wales Local Ethics Committee
under reference numbers 08/WSE04/17 and 10/WSE04/21 and conducted
according to the principles expressed in the Declaration of Helsinki and
under local ethical guidelines. Sampling of adult patients with sterile
systemic inflammatory response syndrome (SIRS) or with acute sepsis
(defined as patients with SIRS in conjunction with a proven or suspected
infection) was carried out within the United Kingdom Clinical Research
Network under study portfolio UKCRN ID 11231, “Cellular and Bio-
chemical Investigations in Sepsis.” All study participants provided written
informed consent for the collection of samples and their subsequent
analysis. A waiver of consent system was used when patients were unable
to provide prospective informed consent due to the nature of their critical
illness or therapeutic sedation at the time of recruitment. In all cases,
retrospective informed consent was sought as soon as the patient recovered
and regained capacity. In cases in which a patient died before regaining
capacity, the initial consultee’s approval would stand.
Sepsis patients had a proven infection as confirmed by positive culture of
at least one relevant sample according to the local microbiology laboratory
overseen by Public Health Wales, and developed at least three of the four
following SIRS criteria over the previous 36 h: 1) temperature from any site
.38˚C or core ,36˚C; 2) heart rate of .90 beats/min (unless individual
had a medical condition or was receiving treatment preventing tachycar-
dia); 3) respiratory rate of.20 breaths/min, arterial PaCO2,32 mmHg, or
mechanical ventilation for an acute process; and 4) total WBC .12,000
cells/mm3 or,4,000 cells/mm3 or differential WBC count showing.10%
immature (band) forms (n = 37; age range 35–82 y, median 63 y; 51%
female). Patients with sterile SIRS developed at least three of the four
SIRS criteria but had no suspected or proven microbial infection (n = 14;
age range 26–70 y, median 48 y; 21% female). All patients with sepsis or
SIRS had at least one documented organ failure on recruitment to the study
and were either mechanically ventilated, on inotropic support, or received
acute renal replacement therapy. Healthy donors served as controls for the
patient cohorts (n = 10; age range 31–68 y, median 59 y; 20% female).
Individuals were excluded from the study if pregnant or breastfeeding;
suffering from documented severe immune deficiency or severe liver
failure; admitted postcardiac arrest; treated with high-dose steroids or
immunosuppressant drugs for the last 6 mo; or unlikely to survive for the
duration of the study period regardless of treatment.
Media, reagent, and Abs
Culture medium was RPMI 1640 medium supplemented with 2 mM
L-glutamine, 1% sodium pyruvate, 50 mg/ml penicillin/streptomycin, and
10% FCS (Invitrogen). Synthetic (E)-4-hydroxy-3-methyl-but-2-enyl py-
rophosphate (HMB-PP) was provided by H. Jomaa (Justus-Liebig Uni-
versity Giessen); synthetic 6,7-dimethyl-8-D-ribityllumazine (DMRL) was
provided by B. Illarionov (Hamburg School of Food Science). Staphylo-
coccus aureus toxic shock syndrome toxin-1 (TSST-1) was purchased from
Toxin Technology; Mycobacterium tuberculosis purified protein derivate
(PPD) was purchased from Statens Serum Institut (Copenhagen, Den-
mark). Salmonella abortus equi LPS, brefeldin A, and BSA-FITC were
purchased from Sigma-Aldrich. Recombinant IFN-g, TNF-a, and GM-
CSF was purchased from Miltenyi Biotec. Human T-activator CD3/
CD28 Dynabeads, CFSE, and 10-kDa dextran-FITC were purchased
from Life Technologies.
The following mAbs were used for surface labeling: anti-CD3 (UCHT1,
SK7, HIT3a), anti-CD4 (SK3, RPA-T4), anti-CD8 (SK1, HIT8a, RPA-T8),
anti-CD11c (S-HCL-3), anti-CD14 (M5E2, MOP9), anti-CD15 (HI98),
anti-CD16 (3G8), anti-CD25 (M-A251), anti-CD27 (M-T271), anti-CD31
(WM-59), anti-CD32 (FLI8.26), anti-CD45RO (UCHL1), anti-CD49d
(9F10), anti-CD50 (TU41), anti-CD54 (HA58), anti-CD56 (B159), anti-
CD62L (DREG-56), anti-CD64 (10.1), anti-CD69 (FN50), anti-CD70
(Ki24), anti-CD71 (M-A712), anti-CD72 (J4-112), anti-CD83 (HB15e),
anti-CD86 (2331), anti-CD209 (DCN46), anti–HLA-DR (L243), anti–
TCR-Vd2 (B6.1), anti-CCR4 (1G1), anti-CCR5 (2D7), anti-CCR7 (3D12),
and anti-CXCR3 (1C6) from BD Biosciences; anti–TCR-Vb2 (MPB2D5),
anti–TCR-Vg9 (Immu360), and anti-CD40 (mAB89) from Beckman
Coulter; anti-CD11a (HI111), anti-CD66b (G10F5), anti-CD154 (24-31),
anti-CD161 (HP-3G10), anti–HLA-ABC (w6/32), and anti–TCR-Va7.2
(3C10) from BioLegend; anti-CD11b (ICRF44), anti-CD14 (61D3), anti-
CD19 (SJ25C1), anti-CD25 (BC96), anti-CD45RA (HI100), and anti-
CD80 (2D10.4) from eBioscience; anti–HLA-A2 (BB7.2) from Serotec;
and anti-CCR9 (248601) and anti-CCR10 (314305) from R&D Systems;
together with appropriate isotype controls. Intracellular cytokines were
detected using anti–IFN-g (B27, BD Biosciences; 4S.B3, eBioscience)
and anti–TNF-a (6401.1111, BD Biosciences; 188, Beckman Coulter).
Blocking reagents used included anti-Va7.2 (3C10; BioLegend); anti–
TCR-Vg9 (Immu360; Beckman Coulter); anti-TLR4 (HTA125; eBio-
science); anti-CD277 (103.2; D. Olive, Universite´ de la Me´diterrane´e,
Marseille, France); anti–MHC-related protein 1 (MR1) (26.5; T. Hansen,
Washington University School of Medicine, St. Louis, MO); anti–IFN-g
(25718) and anti–GM-CSF (3209) (BioLegend); and soluble TNFR
(sTNFR) p75-IgG1 fusion protein (etanercept/Enbrel; Amgen).
Cells
Total leukocytes from healthy donors and patients were isolated from
heparinized blood by mixing with HetaSep (StemCell Technologies),
followed by sedimentation of RBCs (Supplemental Fig. 1A). Neutrophils
were purified from whole blood or Lymphoprep (Axis-Shield) separated
granulocytes by HetaSep sedimentation, followed by negative selection
using the EasySep neutrophil enrichment kit (StemCell Technologies)
(33), resulting in purities of .99.2% CD142CD66b+CD15+ and ,0.1%
contaminating monocytes (Supplemental Fig. 1B). Total CD3+ T cells
(.98%) were isolated from PBMC using the pan T cell isolation kit II
(Miltenyi Biotec); CD4+ and CD8+ T cells (.98%) were obtained using
the corresponding EasySep kits (StemCell Technologies). Vg9+ T cells
(.98%) were purified using anti–Vg9-PE-Cy5 (Immu360; Beckman
Coulter) and anti-PE microbeads (Miltenyi Biotec); Va7.2+ T cells
(.98%) were purified using anti–Va7.2-PE (3C10; BioLegend) and
anti-PE microbeads. Alternatively, Vg9+ CD3+ gd T cells or Va7.2+
CD161+ CD3+ MAIT cells were sorted to purities .99% using a FACS-
Aria II (BD Biosciences).
Bacteria
Clinical isolates of Enterobacter cloacae, Enterococcus faecalis, Klebsiella
pneumoniae, and S. aureus (28) were grown in liquid Luria-Bertani broth
and on solid Columbia blood agar (Oxoid). The distribution of the non-
mevalonate and riboflavin pathways across microbial species was deter-
mined based on the absence or presence of the enzymes HMB-PP synthase
(EC 1.17.7.1) and DMRL synthase (EC 2.5.1.78) in the corresponding
genomes, according to the Kyoto Encyclopedia of Genes and Genomes
(http://www.genome.jp/kegg).
T cell culture
PBMC were stimulated with 0.1–100 nM HMB-PP or 0.1–100 mMDMRL.
Vg9+ T cells or Va7.2+ T cells were cocultured with autologous mono-
cytes at a ratio of 1:1, in the presence of 25% (v/v) cell-free supernatants
from neutrophils that had phagocytosed live bacteria, as described previ-
ously (28). For blocking experiments, anti–TCR-Va7.2, anti–TCR-Vg9,
anti-CD277, and anti-MR1 were used at 1–20 mg/ml.
Neutrophil culture
Freshly isolated neutrophils were cultured for up to 48 h in the absence or
presence of autologous Vg9/Vd2 T cells or MAIT cells at a ratio of 10:1,
and 10 nM HMB-PP or anti-CD3/CD28 dynabeads (1 bead per T cell).
Alternatively, neutrophils were cultured with 25–50% (v/v) conditioned
medium obtained from purified Vg9/Vd2 T cells or MAIT cells stimulated
for 24 h with anti-CD3/CD28 dynabeads (1 bead per cell) or 100 nM HMB-
PP. Other stimuli included 100 ng/ml LPS and 100 U/ml recombinant IFN-
g, TNF-a, and/or GM-CSF. sTNFR p75-IgG1 fusion protein, anti–IFN-g,
and anti–GM-CSF were used at 10 mg/ml. Neutrophil survival and acti-
vation were assessed by flow cytometry, after gating on CD15+ cells and
exclusion of Vg9+ or Va7.2+ cells where appropriate. For morphological
analyses, neutrophils were centrifuged onto cytospin slides, stained with
May-Gr€unwald-Giemsa solution, and analyzed by light microscopy.
Functional assays
Endocytosis and APC functions were assessed as before (34–38). Freshly
purified neutrophils and neutrophils cultured for 24 h in the presence or
absence of unconventional T cell–conditioned medium were incubated
with 500 mg/ml 10-kDa dextran-FITC or BSA-FITC for up to 60 min at
4˚C or 37˚C. Endocytic uptake was measured immediately by flow cytom-
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etry; the specific uptake of each reagent was calculated by subtracting the
background MFI at 4˚C from the MFI obtained at 37˚C.
For MHC class II–restricted presentation of Ags, activated neutrophils
were generated by 48-h culture with a combination of IFN-g, GM-CSF,
and/or TNF-a, or with unconventional T cell–conditioned medium. Neu-
trophils were pulsed with 10 ng/ml TSST-1 for 1 h. After extensive
washing, neutrophils were mixed with autologous CD4+ T cells at a ratio of
1:1; 1 h later 10 mg/ml brefeldin A was added and cultures were incubated
for an additional 4 h. Activation of TSST-1–responsive Vb2+ CD4+ T cells
was assessed by intracellular cytokine staining and analysis by flow
cytometry (35). To assess CD4+ and CD8+ T cell responses to complex Ag
preparations, neutrophils were pulsed with 1–10 mg/ml PPD for the last
18 h of the 48-h culture phase. After extensive washing, neutrophils were
mixed with CFSE-labeled autologous CD3+ T cells at a ratio of 1:1 and
incubated for 7 d. CFSE dilution in the CD4+ and CD8+ T cell populations
was assessed by flow cytometry, after exclusion of CD66b+ cells.
For MHC class I–restricted Ag presentation, Ag-specific HLA-A2–re-
stricted CD8+ T cell lines were generated using the immunodominant
peptide of influenza matrix protein, M1(p58–66) (GILGFVFTL), as de-
scribed before (37, 38). M1(p58–66)-specific responder CD8+ T cells used
in APC assays were .95% pure, as confirmed by tetramer staining (data
not shown). Activated neutrophils from HLA-A2+ donors were generated
as above, using unconventional T cell–conditioned medium or recombi-
nant cytokines, and pulsed for 1 h with 0.1 mM peptide. For cross-
presentation assays, 0.01–1 mM recombinant influenza M1 protein was
added during the last 18 h of the 48-h neutrophil culture period. Fresh
neutrophils from HLA-A2+ sepsis patients were incubated with 0.01–1 mM
recombinant influenza M1 protein for 18 h or cultured in medium for 17 h
prior to addition of 0.1 mM M1(p58–66) peptide for an additional 1 h. In
each case, following extensive washing, neutrophils were incubated with
HLA-A2+ peptide-specific CD8+ T cells at a ratio of 1:1; after 1 h, 10 mg/
ml brefeldin was added and cultures were incubated for an additional 4 h.
Activation of CD8+ T cells was assessed by intracellular cytokine staining
and analyzed by flow cytometry, after exclusion of CD66b+ cells.
Flow cytometry
Cells were acquired on an eight-color FACSCanto II (BD Biosciences) and
analyzed with FlowJo (Tree Star). Single cells of interest were gated based
on their appearance in side and forward scatter area/height, exclusion of
live/dead staining (fixable Aqua; Invitrogen), and surface staining. Apo-
ptotic cells were identified using annexin-V (BD Biosciences).
ELISA
Cell culture supernatants were analyzed on a Dynex MRX II reader, using
ELISA kits for IL-17A (R&D Systems) as well as IFN-g and TNF-a
(eBioscience). Cell-free plasma samples and unconventional T cell–con-
ditioned media were analyzed on a SECTOR Imager 6000 using the ul-
trasensitive human proinflammatory 9-plex kit (Meso Scale Discovery).
Statistics
Data were analyzed using two-tailed Student t tests for normally dis-
tributed data and Mann–Whitney tests for nonparametric data (Graph-
Pad Prism). Differences between groups were analyzed using one-way
ANOVA with Bonferroni’s posttests or with Kruskal–Wallis and Dunn’s
posttests; two-way ANOVA was used when comparing groups with in-
dependent variables.
Results
Unconventional human T cells respond to neutrophil-released
microbial metabolites
Vg9/Vd2+ gd T cells recognize the isoprenoid precursor HMB-PP,
which is produced via the nonmevalonate pathway by a broad
range of Gram-negative and Gram-positive bacteria (27, 39).
Va7.2+ CD161+ MAIT cells show a very similar responsiveness
to an overlapping, but distinct spectrum of microorganisms by
sensing intermediates of the microbial vitamin B2 biosynthesis
(Table I) (40–43). We therefore sought to investigate the antimi-
crobial responses of these two types of unconventional T cells side
by side. In this study, Vg9/Vd2 T cells, but not MAIT cells,
responded to HMB-PP, as judged by induction of CD69 expres-
sion (Fig. 1A). In contrast, the riboflavin precursor DMRL in-
duced a dose-dependent activation of MAIT cells, but not Vg9/
Vd2 T cells. Blocking experiments confirmed a requirement for
butyrophilin 3A/CD277 for Vg9/Vd2 T cells and the MHC-related
protein MR1 for MAIT cells (Fig. 1B), in support of current
models of Ag recognition (41–45).
We previously identified a crucial role for neutrophils in facil-
itating access to HMB-PP by Vg9/Vd2 T cells (28). As control,
purified Vg9+ T cells readily responded to neutrophils after
phagocytosis of clinically relevant bacteria, in accordance with the
distribution of the nonmevalonate pathways across the different
pathogens (Table I). Strikingly, purified Va7.2+ T cells showed
very similar responses depending on the utilization of the ribo-
flavin biosynthesis pathway by the phagocytosed species. Acti-
vated Vg9+ T cells and Va7.2+ T cells upregulated CD69
(Fig. 1C) and secreted IFN-g (Fig. 1D), but not IL-17A (data not
shown). The response of Va7.2+ T cells to microbial compounds
was confined to the CD161+ bona fide MAIT cell population
(Fig. 1C, 1D). Both Vg9/Vd2 T cells and MAIT cells failed to
respond to neutrophil-released microbial compounds in the pres-
ence of anti-CD277 and anti-MR1, respectively (Fig. 1D), and in
the absence of autologous monocytes (Fig. 1E), highlighting a
requirement for presentation by accessory cells. These findings
reveal a remarkable similarity in the responsiveness of Vg9/Vd2
T cells and MAIT cells to microbial metabolites.
Patients with acute sepsis caused by HMB-PP–producing
pathogens display elevated levels of activated gd T cells
To resolve the existence of APC-like neutrophils in human infectious
disease and determine a possible link with antimicrobial uncon-
ventional T cell responses, we recruited adult patients with newly
diagnosed severe sepsis and characterized their circulating leuko-
cytes phenotypically and functionally. As proof of principle for
the involvement of unconventional T cells in early inflammatory
responses, patients with acute sepsis revealed a substantial activation
of Vg9/Vd2 T cells, as judged by CD69 expression, but not SIRS
patients who served as noninfected controls (Fig. 1F, Supplemental
Fig. 1A). Of note, we found a significant increase in the absolute
counts and the proportion of Vg9/Vd2 T cells among all circulating
T cells between patients with microbiologically confirmed infec-
tions caused by HMB-PP–producing as opposed to HMB-PP–de-
ficient species (Fig. 1F). These clinical findings evoke earlier
studies in patients with acute peritonitis (28) and further support the
notion of a differential responsiveness of unconventional T cells to
defined pathogen groups that can be detected both locally at the site
of infection (46) and systemically in blood (Fig. 1F).
Unconventional human T cells induce prolonged neutrophil
survival and activation
We recently showed that Vg9/Vd2 T cells trigger short-term (,20 h)
survival of autologous neutrophils (28). In this study, highly
purified neutrophils cocultured for extended periods with activated
Vg9/Vd2 T cells or MAIT cells displayed a prolonged survival, as
judged by exclusion of amine reactive dyes and retention of sur-
face CD16 (FcgRIII) for at least 48 h (Fig. 2A). A similar effect
was observed when incubating purified neutrophils with Vg9/Vd2
T cell or MAIT cell–conditioned culture supernatants, indicating
a significant contribution of soluble factors in mediating the ob-
served effects (Fig. 2B). In contrast to the highly active metabolite
HMB-PP as specific activator of Vg9/Vd2 T cells, the MAIT cell
activator used in the current study, DMRL, only possesses a rela-
tively modest bioactivity. The true MAIT cell activator is far more
potent than DMRL and active at subnanomolar concentrations, but
not commercially available and difficult to synthesize chemically
(41, 43). Most stimulation experiments with purified MAIT cells
were therefore conducted with anti-CD3/CD28–coated beads.
Importantly, use of either anti-CD3/CD28 beads or HMB-PP to
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activate Vg9/Vd2 T cells elicited identical neutrophil responses
(Fig. 2A–C and data not shown). Surviving neutrophils possessed
a highly activated morphology, as judged by the presence of hyper-
segmented nuclei (Fig. 2C). The antiapoptotic effect of unconven-
tional T cells was confirmed by the preservation of the total number
of neutrophils present after 48 h of culture and the lack of annexin-V
binding (Fig. 2D). As confirmation of their activated status, surviving
neutrophils showed pronounced upregulation of CD11b and CD66b
expression and complete loss of CD62L (Fig. 2E).
Unconventional T cell–primed neutrophils have a unique
APC-like phenotype
Circulating neutrophils in healthy people do not express CD40,
CD64 (FcgRI), CD83, or HLA-DR, yet all these surface mark-
ers were found on unconventional T cell–primed neutrophils
(Fig. 2F). Moreover, these neutrophils also showed a marked
upregulation of CD54 (ICAM-1) and HLA-ABC (Fig. 2F), sug-
gestive of a possible function of unconventional T cell–primed
neutrophils as APCs for both CD4+ and CD8+ T cells.
The chemokine receptors CCR7, CCR9, and CCR10 remained
undetectable under those culture conditions (data not shown),
arguing against trafficking of APC-like neutrophils to noninflamed
lymph nodes, the intestine, or the skin. In contrast, APC-like
neutrophils displayed enhanced expression levels of CXCR3 and
CCR4 (data not shown), indicative of an increased responsiveness
to inflammatory chemokines and supporting a local role during
acute inflammation.
Neutrophils stimulated with defined microbial compounds on
their own, in the absence of Vg9/Vd2 T cells or MAIT cells, failed
to acquire a similar phenotype. Most notably, neutrophils cultured
for 48 h in the presence of LPS did not show increased levels of
HLA-ABC, HLA-DR, CD40, CD64, or CD83 compared with
neutrophils cultured in medium alone (data not shown), empha-
sizing the crucial and nonredundant contribution of unconven-
tional T cells and their specific ligands to the acquisition of APC
characteristics by neutrophils.
Circulating neutrophils in sepsis patients display an APC-like
phenotype
To resolve the existence of APC-like neutrophils in human infectious
disease, we characterized circulating leukocytes in sepsis patients as
a means to access neutrophils that had recently been activated in
different infected tissues. Sepsis neutrophils displayed a strikingly
altered phenotype compared with neutrophils from healthy individ-
uals and SIRS patients and were characterized by markedly higher
expression of CD40, CD64, and CD86 (Fig. 3A). We also found
increased surface levels of CD83 and HLA-DR on circulating
neutrophils in some patients with sepsis, although this was not sig-
nificant across the cohort as a whole. Of note, there was a correlation
between the expression of CD64 and HLA-DR on sepsis neu-
trophils, supporting a link between neutrophil activation and APC
phenotype (Fig. 3B). These findings indicate the presence of APC-
like neutrophils in sepsis patients, despite the generally presumed
immune suppression in those individuals, as judged by reduced
HLA-DR expression levels on monocytes (data not shown) (47).
Neutrophil survival and APC marker expression are mediated
via unconventional T cell–secreted cytokines
To identify the unconventional T cell–derived factor(s) exerting the
observed effects on neutrophils, we quantified proinflammatory
Table I. Distribution across clinically relevant microbial pathogens of key biosynthetic pathways that
produce metabolites targeted by human unconventional T cells
Nonmevalonate Pathway
(Vg9/Vd2 T Cell Activation)
Vitamin B2 Synthesis
(MAIT Cell Activation)
Gram-negative bacteria
Acinetobacter baumannii + +
Chryseobacterium gleum 2 +
Enterobacter cloacae + +
Escherichia coli + +
Haemophilus influenzae + +
Helicobacter pylori + +
Klebsiella pneumoniae + +
Legionella pneumophila 2 +
Neisseria meningitidis + +
Pseudomonas aeruginosa + +
Shigella dysenteriae + +
Gram-positive bacteria
Bacillus anthracis + +
Clostridium difficile + +
Corynebacterium diphtheriae + +
Enterococcus faecalis 2 2
Listeria monocytogenes + 2
Mycobacterium tuberculosis + +
Propionibacterium acnes + +
Staphylococcus aureus 2 +
Streptococcus pyogenes 2 2
Other bacteria
Borrelia burgdorferi 2 2
Leptospira interrogans + +
Mycoplasma genitalium 2 2
Mycoplasma penetrans + 2
Treponema pallidum 2 2
Yeasts, fungi
Aspergillus fumigatus 2 +
Candida albicans 2 +
Crytococcus neoformans 2 +
Saccharomyces cerevisiae 2 +
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mediators in the culture supernatants. These experiments revealed
a dominant production (.1000 pg/ml on average) of GM-CSF,
IFN-g, and TNF-a by activated Vg9/Vd2 T cells and MAIT cells,
but only very low levels (,25 pg/ml) of IL-1b, IL-6, and CXCL8,
indicating that both unconventional T cell populations share
a similar cytokine profile (Fig. 4A). Experiments using blocking
reagents identified an involvement of GM-CSF, IFN-g, and TNF-a
in promoting neutrophil survival by both Vg9/Vd2 T cells and
MAIT cells (Fig. 4B). Whereas neutralization of each individual
cytokine on its own had a partial effect, combined blocking of
GM-CSF and IFN-g was most effective in inhibiting neutrophil
survival, with blocking of TNF-a having little additive effect. In
contrast, CD66b upregulation was mainly triggered by TNF-a
(Fig. 4B). Of note, the effect of unconventional T cells on neu-
trophils could be mimicked in part by using recombinant GM-CSF,
IFN-g, and TNF-a. In this respect, only neutrophils cultured
with a combination of all three cytokines exhibited a morphol-
ogy characterized by hypersegmented nuclei (Fig. 4C). TNF-a
was particularly important for the induction of CD40, CD54,
CD66b, and MHC class I expression (Fig. 4D). Taken together,
FIGURE 1. Unconventional human T cell responses to microbial metabolites in vitro and in vivo. (A) CD69 surface expression by Vg9+ T cells and
Va7.2+ CD161+ T cells in PBMC stimulated overnight with HMB-PP or DMRL (means 6 SD, n = 5). Data were analyzed by two-way ANOVA with
Bonferroni’s post hoc tests. (B) Representative FACS plots of two donors showing CD69 expression by Vg9+ T cells and Va7.2+ T cells in PBMC stimulated
overnight with 100 nM HMB-PP or 100 mM DMRL, in the absence or presence of anti-CD277 or anti-MR1 mAb. (C) CD69 expression by MACS-purified
Vg9+ T cells or Va7.2+ T cells cocultured overnight with autologous monocytes in the presence of supernatants from neutrophils after phagocytosis of
Klebsiella pneumoniae (representative of three donors). (D) IFN-g secretion by MACS-purified Vg9+ T cells or Va7.2+ T cells cocultured overnight with
autologous monocytes in the presence of supernatants from neutrophils after phagocytosis of different bacteria: HMB-PP2 DMRL+, Staphylococcus aureus;
HMB-PP2 DMRL2, Enterococcus faecalis; and HMB-PP+ DMRL+, Enterobacter cloacae and K. pneumoniae (means 6 SD, n = 3–4 donors). Differences
between mAb-treated and untreated cultures were analyzed using Mann–Whitney tests. (E) CD69 expression by FACS-sorted Vg9+ T cells or Va7.2+
CD161+ T cells cocultured overnight with or without autologous monocytes in the presence of supernatants from neutrophils after phagocytosis of E. cloacae
(representative of two donors). (F) Surface expression by CD25 and CD69 on circulating Vg9+ T cells in healthy controls and in patients with SIRS or sepsis.
Each data point represents an individual; lines and error bars depict medians and interquartile ranges. Data were analyzed using Kruskal–Wallis tests and
Dunn’s multiple comparison tests; comparisons were made with sepsis patients. (G) Proportion of Vg9+ T cells among all circulating T cells and absolute
counts of circulating Vg9+ T cells (in cells/ml blood) in sepsis patients with microbiologically confirmed infections caused by HMB-PP–producing (E. coli,
Enterobacter aerogenes, Haemophilus influenzae, K. pneumoniae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, anaerobic Gram-negative ba-
cilli, diphtheroid bacteria) or HMB-PP–deficient organisms (Aspergillus fumigatus, Candida spp., Staphylococcus spp., Streptococcus pneumoniae). Data
were analyzed using Mann–Whitney tests. Differences were considered significant as indicated: *p , 0.05, **p , 0.01, ***p , 0.001.
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these experiments identify microbe-responsive unconventional
T cells as a rapid physiological source of GM-CSF, IFN-g, and
TNF-a and imply that the unique combination of cytokines se-
creted by unconventional T cells is key for the observed impact
on neutrophils.
The particular requirement for TNF-a in the acquisition of the
full APC phenotype is especially noteworthy when considering
the cytokine/chemokine profiles in acutely infected patients.
Plasma proteins that were highly elevated in sepsis patients in-
cluded TNF-a as well as IL-6 and CXCL8 (Fig. 4E). Of note,
there was a trend toward higher levels of TNF-a in patients with
HMB-PP–positive infections (p = 0.09; data not shown). A pro-
portion of individuals with sepsis also had increased plasma levels
of GM-CSF, IFN-g, and IL-1b, although this was not significant
across the whole cohort (Fig. 4E). These findings confirm that the
blood of sepsis patients contains proinflammatory mediators im-
plicated in driving survival and activation of neutrophils, including
their differentiation into APCs.
Unconventional T cell–primed neutrophils readily take up
soluble Ags
We next tested the capacity of APC-like neutrophils to take up
soluble Ags. Although freshly isolated neutrophils were not very
efficient at endocytosing FITC-labeled BSA and dextran (10,000
Da) as model compounds, short-term exposure to Vg9/Vd2 T cell–
conditioned medium led to a greatly enhanced uptake (Fig. 5A).
With unconventional T cell–primed neutrophils kept in culture for
24 h before addition of BSA-FITC, Ag endocytosis was confined
FIGURE 2. Survival, activation, and expression of APC markers by unconventional T cell–primed neutrophils. (A) Neutrophil survival judged by re-
tention of CD16 expression and exclusion of live/dead staining after 48-h coculture with FACS-sorted Vg9/Vd2 T cells or MAIT cells, in the absence or
presence of anti-CD3/CD28 beads. FACS plots are representative of three donors and depict total neutrophils after gating on CD15+ Vg92 or CD15+
Va7.22 cells. (B) Neutrophil survival after 48-h culture in the presence of HMB-PP–activated Vg9/Vd2 T cell or anti-CD3/CD28–activated MAIT cell–
conditioned medium (representative of three donors). (C) Morphological analysis of surviving neutrophils after 48-h culture in the absence or presence of
HMB-PP–activated Vg9/Vd2 T cell or anti-CD3/CD28–activated MAIT cell–conditioned medium (representative of two donors). Original magnification
3400. (D) Neutrophil survival after 48-h culture in the absence or presence of HMB-PP–activated Vg9/Vd2 T cell or anti-CD3/CD28–activated MAIT
cell–conditioned medium. Shown are means 6 SD for the proportion of CD16high cells (n = 9–10), the total number of neutrophils (n = 3), and annexin V
staining on CD16high neutrophils (n = 3). Expression of (E) activation markers and (F) APC markers on freshly isolated neutrophils and CD16high neu-
trophils after 48-h culture in the absence or presence of HMB-PP–activated Vg9/Vd2 T cell– or anti-CD3/CD28–activated MAIT cell–conditioned medium.
Data shown are means 6 SD and representative histograms from three individual donors. Data were analyzed by one-way ANOVAwith Bonferroni’s post
hoc tests; comparisons were made with medium controls. Differences were considered significant as indicated: *p , 0.05, **p , 0.01, ***p , 0.001.
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to the CD16high APC-like population, whereas no such uptake was
seen in the apoptotic CD16low population (Fig. 5B). In contrast,
neutrophils cultured in medium alone showed no specific uptake
of BSA in the CD16high population. These data indicate that un-
conventional T cells promote the uptake of exogenous Ags as
a prerequisite for Ag processing and presentation by neutrophils.
Unconventional T cell–primed neutrophils are efficient APCs
for CD4+ and CD8+ T cells
The functionality of cell surface–expressed HLA-DR on activated
neutrophils was confirmed using the S. aureus superantigen,
TSST-1, which cross-links MHC class II molecules with the TCR
of CD4+ T cells expressing a Vb2 chain (35). Neutrophils exposed
to Vg9/Vd2 T cell–conditioned medium or to a combination of
GM-CSF, IFN-g, and TNF-a were both capable of presenting
TSST-1 to autologous Vb2+ CD4+ T cells (Fig. 5C). When using
the complexM. tuberculosis Ag, PPD, which requires intracellular
processing, unconventional T cell–primed neutrophils displayed
a striking capacity to trigger proliferation of both CD4+ and CD8+
T cells (Fig. 5D). Sequestration of TNF-a during the neutrophil-
priming period by addition of sTNFR diminished both CD4+ and
CD8+ T cell responses (Fig. 5E) as further confirmation of the key
role for unconventional T cell–derived TNF-a in the acquisition of
APC features by neutrophils.
Unconventional T cell–primed neutrophils cross-present Ags to
CD8+ T cells
Following up from the striking induction of PPD-specific CD4+ and
CD8+ T cell responses, we assessed the potential of APC-like
neutrophils to trigger CD8+ T cell responses, by taking advan-
tage of HLA-A2–restricted responder T cell lines specific for
M1(p58–66), the immunodominant epitope of the influenza
M1 protein (36–38). Using the M1(p58–66) peptide, which can be
pulsed readily onto cell surface–associated MHC class I molecules
for direct presentation to CD8+ T cells, unconventional T cell–
primed neutrophils showed a significantly improved Ag presen-
tation, compared with freshly isolated neutrophils (Fig. 6A) and in
agreement with the elevated levels of MHC class I molecules on
APC-like neutrophils. Importantly, only unconventional T cell–
primed neutrophils, but not freshly isolated neutrophils, were also
able to induce robust responses by M1(p58–66)-specific responder
CD8+ T cells when utilizing the full-length M1 protein (Fig. 6A),
a 251-aa–long Ag that requires uptake, processing, and loading of
M1(p58–66) onto intracellular MHC class I molecules for cross-
presentation to CD8+ T cells (36–38). Control experiments sup-
ported the need for Ag uptake and processing, as recombinant M1
protein could not be pulsed directly onto neutrophils, demon-
strating the absence of potential degradation products in the M1
protein preparation that might be able to bind directly to cell
surface–associated MHC class I molecules on neutrophils or CD8+
T cells (Fig. 6B). Neutrophils cultured for 48 h in the presence of
GM-CSF and IFN-g were also capable of enhanced presentation
of M1(p58–66) peptide to M1-specific CD8+ T cells. However,
only neutrophils generated by incubation with a combination of
GM-CSF, IFN-g, and TNF-a readily processed the full-length M1
protein (Fig. 6A), demonstrating that TNF-a plays a pivotal role in
the acquisition of a fully competent APC phenotype and function
by neutrophils.
FIGURE 3. APC-like phenotype of circulating neutrophils during acute sepsis. (A) Surface expression of the indicated markers on circulating neutrophils
in patients with SIRS (n = 14) or sepsis (n = 37) and in healthy controls (n = 10). Each data point represents an individual; lines and error bars depict
medians and interquartile ranges. Data were analyzed using Kruskal–Wallis tests and Dunn’s multiple comparison tests; comparisons were made with sepsis
patients. (B) Correlation between surface expression of CD64 and HLA-DR on circulating neutrophils in healthy controls and in patients with SIRS or
sepsis. Lines depict linear regression and 95% confidence bands as calculated for sepsis neutrophils. Differences were considered significant as indicated:
*p , 0.05, **p , 0.01, ***p , 0.001.
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Circulating neutrophils from sepsis patients are capable of
cross-presenting Ags to CD8+ T cells
It has not yet been established whether neutrophils are capable of
triggering Ag-specific T cell responses in vivo. To translate our
findings on APC-like neutrophils to the situation in acute infec-
tions, we isolated untouched neutrophils from sepsis patients to
purities of 99.2–99.8%. Our experiments show that sepsis neu-
trophils and control neutrophils had a similar capacity to activate
M1-specific responder CD8+ T cells when pulsed with the peptide
itself (Fig. 6C). Strikingly, only sepsis neutrophils, but not control
neutrophils, were also able to take up the full-length M1 protein
and cross-present the M1(p58–66) peptide to responder CD8+
T cells (Fig. 6C, 6D), consistent with the differences in APC
marker expression between patients and healthy individuals.
These findings indicate that in acute sepsis neutrophils acquire an
APC-like phenotype with the capacity to induce Ag-specific CD8+
T cell responses that is reminiscent of neutrophils primed by
unconventional T cells (Fig. 7).
Discussion
To our knowledge, the present study is the first demonstration that
human neutrophils can assume Ag cross-presenting properties.
Although our work does not formally demonstrate a causal link for
the interaction of unconventional T cells and neutrophils in vivo, it
does suggest a plausible scenario for the generation of APC-like
neutrophils during acute infection. Our data support a model in
which different types of unconventional T cells respond rapidly to
neutrophils after phagocytosis of a broad range of bacteria at the
site of infection, and in turn mediate the local differentiation of
bystander neutrophils into APCs for both CD4+ and CD8+ T cells
(Fig. 7). APC-like neutrophils may be particularly relevant for
local responses by tissue-resident memory and/or freshly recruited
FIGURE 4. Effect of unconventional T cell–derived cytokines on neutrophil survival and APC marker expression. (A) Secretion of the indicated
mediators into the culture supernatant by FACS-sorted Vg9/Vd2 T cells or MAIT cells stimulated overnight in the presence of HMB-PP or anti-CD3/CD28
beads, respectively, as detected using multiplex ELISA (means + SD, n = 2–3). (B) Neutrophil survival (as proportion of CD16high cells) and CD66b
expression on CD16high neutrophils after 48-h culture in the presence of HMB-PP–activated Vg9/Vd2 T cell– or anti-CD3/CD28 MAIT cell–conditioned
medium and neutralizing agents against GM-CSF, IFN-g, and/or TNF-a (means + SD, n = 3). Data were analyzed by one-way ANOVAwith Bonferroni’s
post hoc tests; comparisons were made with isotypes. (C) Morphological analysis of surviving neutrophils after 48-h culture in the absence or presence of
GM-CSF, IFN-g, and/or TNF-a (representative of two donors). Original magnification 3400. (D) Neutrophil survival and expression of the indicated
markers on CD16high neutrophils after 48-h culture in the absence or presence of recombinant GM-CSF, IFN-g, and/or TNF-a (means + SD, n = 3). Data
were analyzed by one-way ANOVA with Bonferroni’s post hoc tests; comparisons were made with medium controls. (E) Plasma levels of IL-1b, IL-6,
CXCL8, GM-CSF, IFN-g, and TNF-a in SIRS and sepsis patients (in pg/ml). Each data point represents an individual; lines and error bars depict medians
and interquartile ranges. Differences between the two groups were analyzed using Mann–Whitney tests. Differences were considered significant as in-
dicated: *p , 0.05, **p , 0.01, ***p , 0.001.
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effector CD4+ and CD8+ T cells at the site of infection, rather than
the priming of naive CD4+ and CD8+ T cells in secondary lym-
phoid tissues. Expression of the lymph node homing receptor
CCR7 by activated neutrophils was reported before (30) but could
not be confirmed in the current study (data not shown). Still, APC-
like neutrophils may also gain access to inflamed draining lymph
nodes through the action of inflammatory chemokines (7–10).
Irrespective of the anatomical context, APC-like neutrophils may
contribute to protective immune responses, by fighting the “first
hit” infection as a result of inducing Ag-specific CD4+ and CD8+
T cells and by harnessing the T cell compartment against potential
“second hit” infections. However, it is also thinkable that such an
early induction of cytotoxic CD8+ T cells may add to the systemic
inflammatory response and ultimately lead to tissue damage and
organ failure. Whereas the generation of APC-like neutrophils is
likely to occur locally in the context of infected tissues, in severe
inflammatory conditions, including sepsis, such APC-like neu-
trophils may eventually leak into the circulation and become de-
tectable in blood. Larger stratified approaches are clearly needed
to define the role of APC-like neutrophils in different infectious
scenarios, locally and systemically, in clinically and microbio-
logically well-defined patient subgroups.
The presence of cross-presenting neutrophils in patients with
sepsis is intriguing and may point to an essential role of APC-like
neutrophils in acute disease. Sepsis patients who survive the pri-
mary infection often show signs of reduced surface expression of
HLA-DR on monocytes and a relative tolerance of monocytes to
LPS stimulation (47). As consequence of what is generally per-
ceived as a loss of immune function, many patients are susceptible
to subsequent nosocomial infections, including reactivation of
FIGURE 5. Efficient endocytosis of exogenous molecules and presentation of microbial Ags by unconventional T cell–primed neutrophils. (A) Endo-
cytosis of FITC-labeled BSA and 10-kDa dextran by freshly isolated neutrophils incubated for 60 min at 4˚C or at 37˚C in the absence or presence of HMB-
PP–activated gd T cell supernatant. FACS plots are representative of two to three donors; specific uptake of FITC-labeled BSA and dextran by freshly
isolated neutrophils was determined over 30 and 60 min (means + SD, n = 2–3). (B) Endocytosis of FITC-labeled BSA over 60 min by neutrophils that had
been cultured overnight in the absence or presence of HMB-PP–activated gd T cell supernatant. FACS plots are representative of three healthy donors;
specific uptake of FITC-labeled BSA by gd T cell–primed neutrophils was determined over 30 and 60 min (means + SD, n = 2–3). Data were analyzed by
two-way ANOVA with Bonferroni’s post hoc tests; comparisons were made with (A) medium controls or (B) CD16low cells. (C) IFN-g production by
superantigen-specific CD4+ Vb2+ T cells in response to autologous neutrophils cultured for 48 h in medium or in the absence or presence of HMB-PP–
activated Vg9/Vd2 T cell–conditioned medium or a combination of IFN-g, GM-CSF, and TNF-a prior to pulsing with 10 ng/ml TSST-1 (representative of
two donors). (D) Proliferation of CD4+ and CD8+ T cells in response to freshly isolated neutrophils and neutrophils cultured for 48 h in the presence of
HMB-PP–activated Vg9/Vd2 T cell– or anti-CD3/CD28–activated MAIT cell–conditioned medium. Neutrophils were pulsed with 10 mg/ml PPD for 18 h
prior to addition of CFSE-labeled bulk CD3+ T cells; CFSE dilution of responder T cells was assessed after 7 d of coculture (representative of three donors).
(E) Proliferation of CFSE-labeled CD4+ and CD8+ T cells in response to PPD-pulsed freshly isolated neutrophils and neutrophils cultured for 48 h in the
presence of HMB-PP–activated Vg9/Vd2 T cell–conditioned medium with and without sTNFR. CFSE dilution of responder T cells was assessed after 7 d
of coculture (means + SD, n = 3). Data were analyzed by one-way ANOVAwith Bonferroni’s post hoc tests; comparisons were made with Vg9/Vd2 T cell +
sTNFR–treated neutrophils. Differences were considered significant as indicated: *p , 0.05, **p , 0.01, ***p , 0.001.
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latent viruses that are associated with high mortality rates (48, 49).
Trials specifically targeted at reversing this apparent monocyte
deactivation have shown promising clinical results (50). However,
our present findings suggest that HLA-DR expression by circu-
lating monocytes is a poor surrogate marker for a systemic
immune suppression and rather indicate that, contrary to the
proposed general loss of function, certain cells such as neutrophils
may actually assume APC properties under such conditions, as
evidence of a gain of new function. Yet, with a complex and
multilayered clinical phenomenon such as sepsis it is challenging
to dissect the relevance of APC-like neutrophils for infection
resolution and clinical outcome in vivo.
With their unique ability to recognize microbial metabolites in
a non-MHC–restricted manner, unconventional T cells such as
Vg9/Vd2 T cells and MAIT cells greatly outnumber Ag-specific
conventional CD4+ and CD8+ T cells at the site of infection and
represent early and abundant sources of proinflammatory cyto-
kines (23, 27), among which GM-CSF, IFN-g, and TNF-a each
make key contributions. Although conventional T cells may pro-
duce a similar combination of cytokines and provide similar sig-
nals to neutrophils, preliminary findings in our laboratory indicate
that Vg9/Vd2 T cells and MAIT cells represent together up to
50% of all TNF-a–producing T cells among peritoneal cells
stimulated with bacterial extracts, suggesting that these two cell
types are indeed major producers of proinflammatory cytokines in
response to microbial stimulation (A. Liuzzi and M. Eberl, un-
published observations). Although we cannot rule out a further
contribution of contact-dependent mechanisms, this observation
builds upon earlier studies describing the generation of human
neutrophils expressing MHC class II through the action of re-
combinant cytokines in vitro (22, 51–56) and in vivo (57–59).
Previous investigations reported an upregulation of MHC class II
on activated neutrophils under the control of GM-CSF and IFN-g,
albeit the physiological source of those mediators during acute
infection was not defined. Most importantly, in this study, we
describe a direct role for TNF-a in the efficient induction of MHC
class I–restricted CD8+ T cell responses by neutrophils. Of note,
plasma from sepsis patients was previously shown to induce some
(upregulation of CD64), but not other features (upregulation of
CD11b, loss of CD62L) (60) that are characteristic for uncon-
ventional T cell–primed neutrophils, indicating that circulating
cytokines alone do not confer APC properties. In support of local
cell-mediated processes at the site of inflammation, our findings
evoke earlier descriptions of APC-like neutrophils characterized
by MHC class II expression in infectious and noninfectious in-
flammatory scenarios such as periodontitis (17) and tuberculous
pleuritis (20), in which locally activated Vg9/Vd2 T cells were
found (61–63). These associations lend further support to the
existence of a peripheral immune surveillance network comprised
of distinct types of unconventional T cells and their crosstalk with
FIGURE 6. Cross-presentation of exogenous Ags by unconventional T cell–primed neutrophils and sepsis neutrophils. (A) IFN-g production by Ag-
specific CD8+ T cells in response to neutrophils cultured for 48 h in the presence of HMB-PP–activated Vg9/Vd2 T cell– or anti-CD3/CD28–activated
MAIT cell–conditioned medium (top), or neutrophils cultured for 48 h with the recombinant cytokines indicated (bottom). Neutrophils were pulsed for 1 h
with 0.1 mM influenza M1(p58–66) peptide or for 18 h with recombinant M1 protein (means + SD, n = 3). Data were analyzed by two-way ANOVAwith
Bonferroni’s post hoc tests; comparisons were made with freshly isolated neutrophils. (B) Failure of M1 protein to be pulsed directly onto neutrophils, as
judged by IFN-g production of Ag-specific CD8+ T cells alone or in response to neutrophils cultured for 48 h in the absence or presence of HMB-PP–
activated Vg9/Vd2 T cell– or anti-CD3/CD28–activated MAIT cell–conditioned medium. Neutrophils were pulsed for 1 h with either 0.1 mM influenza M1
(p58–66) peptide or 1 mM recombinant M1 protein; CD8+ T cells were incubated directly with the peptide or M1 protein (means + SD, n = 2). (C) IFN-g
production by M1-specific CD8+ T cells in response to freshly isolated neutrophils loaded with 0.1 mM synthetic M1(p58–66) peptide or 1 mMM1 protein.
Data shown are representative of three HLA-A2+ sepsis patients and three HLA-A2+ healthy volunteers as controls. Sepsis patients recruited for these APC
assays had confirmed infections as identified by positive culture results: Escherichia coli (urine), Klebsiella pneumoniae (respiratory culture), and
Staphylococcus epidermidis (blood), respectively. (D) Summary of all stimulation assays conducted, shown as percentage of IFN-g–positive CD8+ T cells
in response to freshly isolated neutrophils loaded with peptide or the indicated concentrations of M1 protein (means 6 SD, n = 3). Data were analyzed by
two-way ANOVA with Bonferroni’s post hoc tests. Differences were considered significant as indicated: *p , 0.05, **p , 0.01, ***p , 0.001.
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local immune and nonimmune cells. In the absence of uncon-
ventional T cell–derived signals, such as during sterile inflam-
mation induced by LPS administration (64), neutrophils may not
become fully primed, in accordance with our failure to induce
APC-like neutrophils using LPS alone. Of note, a possible feed-
back regulation may require the activation of unconventional
T cells to reach a certain threshold to overcome the inhibitory
effect of bystander neutrophils (65–67).
Our present data demonstrate that both isoprenoid and riboflavin
precursors are released by human neutrophils upon phagocytosis of
live bacteria and depend on uptake by monocytes and loading onto
butyrophilin 3A and MR1, respectively. The surprising similarities
between Vg9/Vd2 T cells and MAIT cells illustrate their over-
lapping, yet distinct roles. Given the broad distribution of the
nonmevalonate and riboflavin pathways across pathogenic, op-
portunistic, and commensal species, the vast majority of invading
microbes is likely to be detected by either Vg9/Vd2 T cells or
MAIT cells, or both. Our analysis of sepsis patients identified
a systemic mobilization of Vg9/Vd2 T cells in response to HMB-
PP–producing species, in support of their differential responsive-
ness to distinct groups of bacteria (28, 46). Because the present
clinical study was conceived before information about the re-
sponsiveness of MAIT cells for riboflavin metabolites became
available in the literature, we did not conduct a differential anal-
ysis for MAIT cells during acute sepsis. Of note, except for two
cases of streptococcal infections, all bacterial and fungal patho-
gens identified in this patient cohort in fact possessed the ribo-
flavin pathway, that is, were theoretically capable of stimulating
MAIT cells. Intriguingly, Grimaldi et al. (68) recently reported
a specific depletion of peripheral MAIT cells in sepsis patients
with nonstreptococcal (i.e., riboflavin-producing) bacteria com-
pared with infections caused by riboflavin-deficient species,
which may indicate differences in the recruitment and retention
of different types of unconventional T cells at sites of infection,
depending on the nature of the causative pathogen and the un-
derlying pathology (69–72). The contribution of tissue-resident
and freshly recruited unconventional T cells to acute inflam-
matory responses has implications for clinical outcome and for
the development of novel diagnostics and therapeutic inter-
ventions (46).
Taken together, our present study provides evidence 1) that
Vg9/Vd2 T cells and MAIT cells respond similarly to microbial
pathogens that produce the corresponding ligands when phago-
cytosed by human neutrophils, 2) that, once activated, both types
of unconventional T cells trigger longer-term survival and dif-
ferentiation of neutrophils into APC-like cells, 3) that unconven-
tional T cell–primed neutrophils readily process exogenous Ags
and prime both CD4+ and CD8+ T cells, and 4) that circulating
neutrophils from patients with acute sepsis possess a similar APC-
like phenotype and are capable of cross-presenting soluble pro-
teins to Ag-specific CD8+ T cells ex vivo. These findings define
a possible physiological context for the generation of APC-like
neutrophils in response to a broad range of microbial pathogens
and imply a unique and decisive role for human unconventional
T cells in orchestrating local inflammatory events and in shaping
the transition of the innate to the adaptive phase of the antimi-
crobial immune response, with implications for diagnosis, therapy,
and vaccination.
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Early innate responses to pathogens: pattern
recognition by unconventional human T-cells
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ScienceDirectAlthough typically viewed as a feature of innate immune
responses, microbial pattern recognition is increasingly
acknowledged as a function of particular cells nominally
categorized within the adaptive immune system.
Groundbreaking research over the past three years has shown
how unconventional human T-cells carrying invariant or semi-
invariant TCRs that are not restricted by classical MHC
molecules sense microbial compounds via entirely novel
antigen presenting pathways. This review will focus on the
innate-like recognition of non-self metabolites by Vg9/Vd2 T-
cells, mucosal-associated invariant T (MAIT) cells and
germline-encoded mycolyl-reactive (GEM) T-cells, with an
emphasis on early immune responses in acute infection.
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Introduction
The human body is constantly exposed to a vast array of
microorganisms through contact with environmental spe-
cies and interactions with commensals, opportunists and
pathogens. This microbial bombardment exerts a perpet-
ual evolutionary pressure on the immune system to
identify and eliminate potentially dangerous agents.
Microbes express a plethora of pathogen-associated mo-
lecular patterns that engage with various components of
the human immune system, triggering rapid and distinct
responses as a first-line defense against specific groups
of organisms. The innate recognition of such patterns* These authors contributed equally.
www.sciencedirect.com ultimately induces unique clusters of immune and tissue-
related biomarkers that coalesce as pathogen-specific
‘immune fingerprints’ [1,2], with widespread implica-
tions for point-of-care diagnosis of acute infection.
In the adaptive immune system, somatic recombination
of V(D)J gene segments and junctional modifications
generate a diverse repertoire of clonotypically expressed
TCRs, enabling antigenic peptide-specific T-cell
responses restricted by MHC class I and class II mole-
cules. Although such genomic rearrangements occur in all
T-cells, ‘unconventional’ populations characterized by
semi-invariant, invariant or even germline-encoded
TCRs are universally present and serve to recognize
alternative antigens that are not restricted by classical
MHC molecules. Research over the past three years has
exposed how unconventional T-cells detect pathogens by
sensing microbial, non-peptidic compounds via entirely
novel antigen presenting pathways. High throughput
sequencing approaches have also hinted at the existence
of further unconventional T-cell subsets [3]. This review
will focus primarily on the innate-like recognition of non-
self metabolites by human Vg9/Vd2 T-cells, mucosal-
associated invariant T (MAIT) cells and germline-
encoded mycolyl-reactive (GEM) T-cells. The roles of
other unconventional T-cells and iNKT cells in tissue
homeostasis, stress surveillance and autoimmunity are
well described elsewhere [4–6].
Unconventional T-cells: Not based on or
conforming to what is generally done or
believed (Oxford Dictionary)
Given the energetic costs of somatic recombination and
thymic selection (largely unproven for unconventional T-
cells), innate-like recognition by certain ab and gd T-
cells must confer a crucial evolutionary advantage. In this
respect, Vg9/Vd2 T-cells, MAIT cells and other uncon-
ventional T-cells effectively bridge the innate and adap-
tive immune systems by orchestrating acute inflammatory
responses and driving the generation of antigen-present-
ing cells [7,8,9]. Akin to the discrimination between ‘self’
and ‘non-self’ via TLR4-mediated recognition of lipo-
polysaccharide (LPS), a cell wall constituent of Gram-
negative bacteria, and TLR5-mediated recognition of
flagellin, a component of bacterial flagella, the metabolic
pathways targeted by Vg9/Vd2 T-cells, MAIT cells andCurrent Opinion in Immunology 2015, 36:31–37
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Innate sensing of microbial pathogens by Toll-like receptors and unconventional T-cell receptors. Pattern recognition of clinically relevant microbial
pathogens via TLR4 and TLR5, and TCRs expressed by Vg9/Vd2 T-cells, MAIT cells and GEM T-cells. Blue symbols, recognition; red symbols, no
recognition.GEM T-cells incorporate key structures that allow the
body to sense a wide range of potentially harmful micro-
organisms and trigger an inflammatory response aimed at
effective pathogen control (Figure 1). These biochemi-
cal determinants are absent from human cells and in-
clude ligands derived from the non-mevalonate
pathway, which generates the building blocks of all
higher isoprenoids in most Gram-negative bacteria
and many Gram-positive species (as well as the protozoa
Plasmodium falciparum and Toxoplasma gondii) [10], com-
ponents of the riboflavin pathway, which yields vitamin
B2 in the vast majority of bacteria as well as yeasts and
fungi [11], and certain long-chain fatty acids (mycolic
acids) found exclusively in the cell wall of mycobacteria
and coryneform bacteria [12]. Similar principles govern
the recognition of microbial a-linked glycolipids by
iNKT cells [5,6]. Many unconventional T-cells also
respond to cytokines such as IL-1b, IL-12, IL-18 and
IL-23 in a TCR-independent manner, and may there-
fore act similarly to NK cells and other innate lymphoid
cells [13–15].Current Opinion in Immunology 2015, 36:31–37 To facilitate innate sensing of microbial pathogens, un-
conventional human T-cells are thought to undergo
extrathymic and presumably antigen-driven expansion
in the periphery, consistent with a predominant central
or effector memory phenotype and the capacity to mount
rapid responses. Unconventional T-cells also localize
frequently to specific tissues and may therefore play a
role in local immune surveillance. Intriguingly, human
Vg9/Vd2 T-cell and MAIT cell numbers increase in
peripheral blood after birth and subsequently decline
in older individuals; they are also more prevalent in
women [16,17]. These observations could reflect age-
related and gender-dependent exposure to environmen-
tal, commensal and/or pathogenic species. However, re-
cent studies show that both Vg9/Vd2 T-cells and MAIT
cells acquire their anti-microbial responsiveness during
fetal development, prior to contact with environmental
microbes and commensal microflora [18,19]. Of note, an
age-related decline associated with changes in peripheral
subset composition has also been reported for iNKT
cells [20].www.sciencedirect.com
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Recognition of microbial metabolites by unconventional T-cells. (a) ‘Presentation’ of HMB-PP to the Vg9/Vd2 TCR in a BTN3-dependent manner:
1, Uptake of soluble HMB-PP released by extracellular bacteria, phagocytes or infected cells, via endocytosis and/or active/passive transport
across the cell membrane (e.g. E. coli); 2, Transport of HMB-PP from endocytic vesicles across the membrane after phagocytosis or infection (e.g.
Mycobacterium tuberculosis); 3, Release of HMB-PP into the cytosol by intracellular pathogens (e.g. Salmonella spp.); 4, Putative intracellular
loading compartment for BTN3. High affinity ligand: HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; low affinity ligand: IPP,
isopentenyl pyrophosphate. Note that HMB-PP is a microbial metabolite, whereas IPP is present in all prokaryotic and eukaryotic cells. (b)
Presentation of vitamin B2 metabolites to the MAIT TCR by MR1: 1, Uptake of soluble vitamin B2 metabolites released by extracellular bacteria,
phagocytes or infected cells; 2, Shuttling of vitamin B2 metabolites to late endosomes; 3, Release of vitamin B2 metabolites into the cytosol; 4,
MR1 loading compartment. High affinity ligand: 5-OP-RU, 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil; low affinity ligand: RL-6,7-diMe, 6,7-
dimethyl-8-D-ribityllumazine. APC, antigen-presenting cell; PMN, polymorphonuclear cell; IgV, immunoglobulin-like V ectodomain; IgC,
immunoglobulin-like C ectodomain; LL, di-leucine motif; b2M, b2-microglobulin; li, MHC class II-associated invariant chain (CD74).Vg9/Vd2 T-cells: Antigen presentation without
presentation of an antigen?
Peripheral blood Vg9/Vd2 T-cells carrying a TRGV9/
TRGJP-encoded TCRg chain normally constitute 1–5%
of the circulating T-cell population in humans but can
increase in frequency to >50% during microbial infec-
tions. Despite their prevalence in blood, these cells
mobilize rapidly to mucosal surfaces, where they may
confer protection against tissue-localized infections [21].
Vg9/Vd2 T-cells display a striking responsiveness to
bacterial species capable of producing the isoprenoid
precursor (E)-4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMB-PP) in vitro and in vivo [9,22] (Figure 2).
In patients infected with a range of pathogens, HMB-PP-
producing organisms are associated with higher Vg9/Vd2
T-cell frequencies than HMB-PP-deficient species. This
appears to be true both for local responses at the site of
infection, as demonstrated in patients with acute bacterialwww.sciencedirect.com peritonitis [1,10], and for systemic responses during
acute sepsis [7]. These clinical observations are backed
up by studies in macaques, where an HMB-PP-deficient
vaccine strain of Listeria monocytogenes elicited significant-
ly reduced pulmonary and systemic Vg9/Vd2 T-cell
responses compared with the HMB-PP-producing paren-
tal strain [23]. Similarly, an HMB-PP-overproducing
vaccine strain of Salmonella enterica serovar Typhimurium
stimulated prolonged Vg9/Vd2 T-cell expansions in rhe-
sus monkeys, while the avirulent parental strain was less
efficient in this respect [24].
The unique responsiveness of Vg9/Vd2 T-cells to HMB-
PP remains enigmatic as it appears to embody the only
case where an antigen is not actually presented to the
TCR but instead binds intracellularly to an innate sensor
(butyrophilin 3; BTN3/CD277) (Figure 2). Although
Vg9/Vd2 T-cells are generally portrayed as a populationCurrent Opinion in Immunology 2015, 36:31–37
34 Host pathogensunique to primates and absent in rodents, immunogenetic
studies point to a co-evolution of the Vg9 and Vd2 genes
together with BTN3 in other placental mammals such as
alpacas [25]. However, functional proof for the presence of
HMB-PP-specific and BTN3-dependent Vg9/Vd2 T-cells
in these species is still lacking. Following the pioneering
discovery of BTN3 as a restriction element for human Vg9/
Vd2 T-cell responses [26,27] and the observation that
anti-BTN3 agonist antibodies and soluble phosphoanti-
gens induce identical signaling pathways [28], at least four
independent studies have provided evidence for direct
binding of HMB-PP to a positively charged pocket in the
cytosolic B30.2 (PRYSPRY) domain of BTN3A1
[29,30,31,32]. These findings contradict an alternative
model proposing that HMB-PP binds to the extracellular
IgV domain of BTN3A1 and is therefore a truly presented
antigen [27]. Despite this convergence of experimental
data, it remains entirely unclear how the Vg9/Vd2 TCR
actually recognizes the BTN3A1/HMB-PP complex. In-
side the cell, HMB-PP sensing might be accompanied by
interaction partners such as periplakin, which binds a di-
leucine motif located proximal to the cytoplasmic B30.2
domain of BTN3A1 [32]. These intracellular events may
subsequently propagate across the cell membrane and
induce conformational changes on the cell surface [33],
possibly in combination with co-factors or clustering
effects that enable recognition by Vg9/Vd2 TCRs. Never-
theless, it is challenging to reconcile how the detection of a
seemingly ubiquitous and non-polymorphic molecule such
as BTN3A1 is facilitated through a rearranged TCR.
MAIT cells: Unconventional pathogen-sensing
through conventional TCR diversity?
MAIT cells are innate-like T-cells that populate mucosal
tissues such as the intestine and lung, comprising in
addition up to 10% of the circulating CD8+ ab T-cell
compartment and as many as half of all T-cells present in
the liver [34]. They share phenotypic similarities with
iNKT cells, express IL-12Rb2 and IL-18Ra alongside
high levels of CD161 [14,35], and localize to sites of
infection via chemokine receptors such as CCR2,
CCR6 and CXCR6 [35,36]. Unlike conventional ab T-
cells, MAIT cells possess thymic effector functionality
despite a naı¨ve phenotype [34] and are selected by
hematopoietic cells [37]. They subsequently expand in
the periphery as antigen-experienced, effector memory
T-cells upon microbial exposure [36,37]. Of note, the
presence of an intact commensal flora and expression of
the non-polymorphic MHC-related protein 1 (MR1) by
B-cells are both essential for this peripheral expansion,
whereas macrophages and dendritic cells are dispensable
[37]. Recent data have also revealed an essential role for
STAT3 signaling downstream of IL-21R and IL-23R in
controlling human MAIT cell numbers [38].
Pathogen recognition by human MAIT cells is driven by
a semi-invariant MR1-restricted TCR that typicallyCurrent Opinion in Immunology 2015, 36:31–37 incorporates a TRAV1-2/TRAJ33 (Va7.2-Ja33) TCRa
chain paired predominantly with a TRBV20-1 (Vb2) or
TRBV6 (Vb13) TCRb chain. Infrequent usage of other
TRAJ and TRBV gene segments has also been described
[3,39]. Unlike MHC class I-restricted epitopes, MAIT
cell ligand presentation by MR1 is independent of
proteasomal degradation and the transporter associated
with antigen processing (TAP), but requires the MHC
class II chaperones invariant chain (li) and HLA-DM
[40]. After initial observations that both human and
murine MAIT cells respond to species such as enter-
obacteria, staphylococci and mycobacteria, but not to
streptococci [7,36], key mechanistic advances have
shown that MAIT TCRs recognize ligands derived from
microbial vitamin B2 metabolism [11,41,42] (Figure 2).
Recent analyses have also revealed that the MAIT cell
repertoire is more diverse than initially thought [43,44],
which may allow these cells to discriminate between
different microbial pathogens via TCR-dependent
‘sensing’ of distinct MR1-bound ligands [39,44]. These
findings suggest the existence of other, as yet undiscov-
ered, microbial antigens within the MAIT cell recogni-
tion spectrum, a possibility consistent with structural
interpretations of MR1 ligand promiscuity [41,45–47].
However, a recent study in mice has challenged this idea
of ligand discrimination  via the TCRb chain [48], which
may point to species-specific differences between hu-
man and murine MAIT cells.
Patients with severe sepsis display an early decrease in
circulating MAIT cells compared with healthy controls
and uninfected critically ill patients [49]. In particular,
non-streptococcal bacterial infection was identified as an
independent determinant of peripheral MAIT cell de-
pletion, suggesting recruitment to the site of infection in
response to pathogens with an intact riboflavin pathway
[36,50,51]. In HIV-1 infection, circulating Va7.2+
CD161+ T-cells are depleted and fail to recover with
antiretroviral therapy [52,53]. This may indicate a pro-
gressive translocation of MAIT cells to peripheral tissues,
down-regulation of CD161, functional exhaustion and/or
activation-induced apoptosis. In a number of autoim-
mune and metabolic disorders, MAIT cells typically
display similarly decreased levels in peripheral blood
[54–56], possibly as a result of low-grade inflammation
and alterations of the microbiota.
Other pathogen-specific unconventional
T-cells: GEM T-cells and beyond
The MHC class I-related molecule CD1b was found
almost 20 years ago to present bacterial glycolipids such
as glucose monomycolate (GMM), yet the identity and
specificity of CD1b-restricted T-cells has remained elu-
sive until recently [57]. Mycolic acids (MAs) are the
predominant cell wall lipids in Mycobacterium tuberculosis
and represent a major virulence factor for this pathogen.
Rare MA-specific T-cells are detectable in tuberculosiswww.sciencedirect.com
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BCG-vaccinated individuals [58]. These T-cells are
CD1b-restricted, exhibit both central and effector mem-
ory phenotypes, produce IFN-g and IL-2 upon stimula-
tion, and appear to localize preferentially at the site of
infection. The availability of CD1b tetramers allowed
direct visualization of MA-specific T-cells, which were
estimated to comprise approximately 0.01% of all circu-
lating T-cells [59]. These advances eventually led to the
description of CD1b-restricted T-cells as Va7.2+ CD4+
germline-encoded mycolyl-reactive (GEM) T-cells,
which carry an invariant TRAV1-2/TRAJ9 TCRa chain
[12]. MA-specific T-cells were also shown to decline
after successful treatment and therefore appear to corre-
late with pathogen burden [58], emphasizing the poten-
tial importance of these unconventional T-cells as novel
diagnostic and prognostic biomarkers of tuberculosis.
As mycolic acids are a hallmark of all Corynebacteriales, it
is tempting to speculate that MA-specific T-cells may also
sense infections caused by bacteria such as Corynebacteri-
um spp. and Nocardia spp. (Figure 1). Of note, a second
population of GMM-specific T-cells has been identified
recently. These cells exhibit lower avidities for CD1b
tetramers and, in contrast to GEM T-cells, express TCRs
with a marked preference for the TRAV17 and TRBV4-1
genes [60]. High throughput sequencing of TRAV1-2+
TCRa chains further suggests that we are only seeing the
tip of the iceberg with regard to our knowledge of
unconventional T-cell populations [3]. It therefore seems
likely that many exciting discoveries will ensue in this
hybrid field.
Conclusions and future directions
The last three years have witnessed major advances in our
understanding of unconventional T-cell subsets, in part
due to the skillful application of cutting-edge experimen-
tal techniques to well-defined patient cohorts. Future
research can now build on this foundation to define the
true extent of these T-cell populations and define the
mechanisms that underlie microbial pattern recognition
within the adaptive immune system. Many questions
remain in this regard. Precisely how do unconventional
TCRs interact with non-polymorphic presenting mole-
cules? Are specific gene segments within the TCR locus
conserved for this purpose? Does the process of somatic
recombination serve to diversify bound ligand recogni-
tion? Do unconventional T-cells undergo positive selec-
tion in the thymus and does this process involve the
engagement of endogenous ligands? What are the molec-
ular processes involved in antigen uptake and intracellu-
lar trafficking that allow the presentation of microbial
metabolites?
Key pieces of the puzzle are also missing at the functional
level. How do unconventional T-cells migrate to and from
sites of infection? Do they persist as tissue-residentwww.sciencedirect.com memory-like cells after pathogen clearance? What is
the role of the commensal microbiota? Why do most
unconventional T-cells possess a memory phenotype
from early life? What mechanisms underlie the pro-
nounced age and gender bias? Are there implications
for homeostasis and susceptibility to infections, autoim-
munity and malignancy? How do accessory molecules
such as CD4, CD8, CD161 and NKG2D contribute in
this setting?
It is becoming increasingly clear that unconventional T-
cells play a pivotal role in the orchestration of early
inflammatory responses. In parallel, emerging mechanis-
tic insights have started to unlock the secrets of innate-
like recognition encoded by specific portions of the TCR
repertoire. The highly constrained genetic and microbial
elements inherent within each of these various systems
potentially offer unique molecular targets for the devel-
opment of novel and universally applicable diagnostics,
vaccines and immunotherapeutics. The overarching
question is therefore, as always, a humanitarian one.
How can we best harness the unique attributes of uncon-
ventional T-cells to combat the infectious and malignant
plagues of our times?
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ABSTRACT 
The anti-microbial responsiveness and function of unconventional human T-cells are poorly 
understood, with only limited access to relevant specimens from sites of infection.  Peritonitis 
is a common and serious complication in individuals with end-stage kidney disease receiving 
peritoneal dialysis (PD).  By analyzing local and systemic immune responses in PD patients 5 
presenting with acute bacterial peritonitis and monitoring individuals before and during defined 
infectious episodes, our data show that Vγ9/Vδ2+ γδ T-cells and mucosal-associated invariant 
T (MAIT) cells accumulate at the site of infection with organisms producing (E)-4-hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMB-PP) and vitamin B2, respectively.  Such 
unconventional human T-cells are major producers of IFN-γ and TNF-α in response to these 10 
ligands that are shared by many microbial pathogens, and affect the cells lining the peritoneal 
cavity by triggering local inflammation and inducing tissue remodeling with consequences for 
peritoneal membrane integrity.  Our data uncover a crucial role for Vγ9/Vδ2 T-cells and MAIT 
cells in bacterial infection, and suggest that they represent a useful predictive marker for 
important clinical outcomes, which may inform future stratification and patient management.  15 
These findings are likely to be applicable to other acute infections where local activation of 
unconventional T-cells contributes to the anti-microbial inflammatory response. 
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INTRODUCTION 
The classical view of the immune response to infection is based on the assumption that ‘innate’ 
immune cells sense pathogens via pattern recognition receptors such as the Toll-like receptors 
(TLRs), while antigen-specific ‘adaptive’ T-cell responses are restricted by molecules of the 
major histocompatibility complex (MHC).  This simplistic model is being eroded by the 5 
growing realization that substantial numbers of T-cells in the body are non-MHC restricted and 
integrate innate and adaptive features [1,2].  Such innate-like T-cells include γδ T-cells, 
mucosal-associated invariant T (MAIT) cells, natural killer T (NKT) cells, germline-encoded 
mycolyl-reactive (GEM) T-cells and other CD1-restricted T-cells [3-8] .  Together, these 
‘unconventional’ T-cell populations comprise a sizeable proportion of all T-cells in blood, 10 
epithelia, organs such as the liver, and inflamed tissues.  Sensing non-peptide antigens by 
unconventional T-cells endows the body with the capacity to respond to a plethora of foreign 
and self molecules produced by invading pathogens or released by stressed, infected or 
metabolically active tissues.  In humans, microbial organisms sensed by one or more of these 
T-cell subsets include the causative agents of tuberculosis, malaria and most hospital-acquired 15 
bacterial infections [9]. 
There is an increasing appreciation of the role played by unconventional T-cells in 
orchestrating early cellular events in response to invading pathogens, which is likely to 
contribute to microbial clearance and the development of immunological memory, but which 
may also result in inflammation-associated tissue damage [1,9-11].  Progress in the 20 
understanding of unconventional T-cell biology has been hampered by their responsiveness to 
relatively poorly defined structures, and the paucity of appropriate experimental research tools.  
These cells also display striking species-specific differences with respect to their TCR 
repertoires, activities and anatomical locations, with the restricting elements butyrophilin-3 
(BTN3), CD1a, CD1b and CD1c as well as the corresponding T-cell subpopulations being 25 
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absent in mice [1,8,9,12].  As a consequence, no small animal model replicates the complex 
interactions between unconventional T-cells and other immune and non-immune cells in the 
human body. 
The characterization of unconventional T-cell responses in vivo and their relevance for 
homeostasis, immune surveillance and inflammation remains challenging [3-9].  In particular, 5 
the microbial and environmental signals that lead to the migration, differentiation, expansion 
and maintenance of unconventional T-cells under physiological conditions are poorly defined.  
Studies into human responses during acute infections are notoriously difficult to undertake, 
with only limited access to relevant specimens, in particular from the site of infection, and to 
matched samples collected before disease onset.  We here addressed this knowledge gap by 10 
studying a well-defined cohort of individuals receiving peritoneal dialysis (PD) and presenting 
with acute peritonitis.  PD is a live-saving treatment for people with end-stage kidney disease 
that permits immunological investigations with direct clinical relevance, where a permanently 
inserted catheter affords continuous and non-invasive access to localized responses to a range 
of bacterial species [13-15].  We recently reported elevated numbers of Vγ9/Vδ2 T-cells in a 15 
cross-sectional cohort of PD patients with acute peritonitis, particularly in those with infections 
caused by Gram-negative bacteria and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate 
(HMB-PP) producing bacteria [14-15].  However, it is unclear whether those elevated numbers 
are due to preferential recruitment of Vγ9/Vδ2 T-cells to the peritoneal cavity in certain 
infections, and/or a result of ligand-specific local activation and expansion in response to the 20 
respective pathogens.   
Our present data show that both Vγ9/Vδ2 T-cells and MAIT cells specifically accumulate at 
the site of infection in response to organisms producing HMB-PP and vitamin B2, respectively, 
and have the capacity to activate local tissues with consequences for acute inflammation, 
peritoneal membrane integrity and clinical outcomes.  In a wider context, the present study 25 
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demonstrates the power of using PD as an experimental and clinical model for monitoring 
individuals before, during and after defined microbial infections. 
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MATERIALS AND METHODS 
Study approval.  Recruitment of PD patients and healthy volunteers for this study was 
approved by the South East Wales Local Ethics Committee under reference numbers 
04WSE04/27 and 08/WSE04/17, respectively, and conducted according to the principles 
expressed in the Declaration of Helsinki.  All individuals provided written informed consent.  5 
The PD study was registered on the UK Clinical Research Network Study Portfolio under 
reference numbers #11838 "Patient immune responses to infection in Peritoneal Dialysis" 
(PERIT-PD) and #11839 "Leukocyte phenotype and function in Peritoneal Dialysis" (LEUK-
PD).  Fresh omentum samples from consented patients were obtained from the Wales Kidney 
Research Tissue Bank.   10 
Patient samples.  The local study cohort comprised 101 adults PD patients admitted to the 
University Hospital of Wales, Cardiff, on day 1 of acute peritonitis between September 2008 
and April 2016.  41 stable individuals receiving PD for at least 3 months and with no previous 
infection served as non-infected controls.  Subjects known to be positive for HIV or hepatitis C 
virus were excluded.  Clinical diagnosis of acute peritonitis was based on the presence of 15 
abdominal pain and cloudy peritoneal effluent with >100 white blood cells/mm3.  According to 
the microbiological analysis of the effluent by the routine Microbiology Laboratory, Public 
Health Wales, episodes of peritonitis were defined as culture-negative (with unclear etiology) 
or as confirmed bacterial infections caused by specific subgroups of Gram-positive and Gram-
negative organisms.  The distribution of the non-mevalonate (HMB-PP) and vitamin B2 20 
pathways across microbial species was determined based on the absence or presence of the 
enzymes HMB-PP synthase (EC 1.17.7.1) and 6,7-dimethyl-8-D-ribityllumazine (DMRL) 
synthase (EC 2.5.1.78), respectively, in the corresponding genomes, according to the Kyoto 
Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg).  Cases of fungal 
infection and mixed or unclear culture results were excluded from this analysis.   25 
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Outcome analysis.  Microbiological and clinical outcome data were obtained from 5,071 adult 
patients of the Australia and New Zealand Dialysis Transplant (ANZDATA) Registry who 
developed first-time peritonitis between April 2003 and December 2012, excluding cases of 
fungal infection, polymicrobial infection or unrecorded culture results.  Endpoints of outcome 
analyses were 30 day mortality and measurements of overall technique failure including 5 
catheter removal, interim transfer to hemodialysis and permanent transfer to hemodialysis over 
90 days. 
Media, reagent and antibodies.  Peritoneal leukocytes were cultured in RPMI-1640 
supplemented with 2 mM L-glutamine, 1% sodium pyruvate, 50 µg/ml penicillin/streptomycin 
and 10% fetal calf serum (Life Technologies).  Mesothelial cells were cultured in Earle’s 10 
buffered Medium 199 (Life Technologies) containing 10% fetal calf serum, peritoneal 
fibroblasts were cultured in a 1:1 (v/v) mixture of DMEM and Ham’s F-12 nutrients (Life 
Technologies) with 20% fetal calf serum; both media were supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (Life Technologies) as well as 5 
µg/ml transferrin, 5 µg/ml insulin and 0.4 µg/ml hydrocortisone (all from Sigma-Aldrich).  15 
Synthetic (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) was provided by Dr 
Hassan Jomaa, University of Giessen, Germany; synthetic 6,7-dimethyl-8-D-ribityllumazine 
(DMRL) by Dr Boris Illarionov, Hamburg School of Food Science, Germany.  Biotinylated 
human MR1:rRL-6-CH2OH (active ligand) and MR1:6-FP (negative control) monomers were 
provided by Dr Lars Kjer-Nielsen, University of Melbourne, Australia, and reconstituted as 20 
described before [16].  Recombinant IFN-γ, TNF-α and IL-1β were purchased from Miltenyi.  
Human T-Activator CD3/CD28 Dynabeads were purchased from Life Technologies.  Blocking 
reagents used included anti-BTN3 (103.2; Dr Daniel Olive, Université de la Méditerranée, 
Marseille, France); anti-MR1 (26.5; Dr Ted Hansen, Washington University School of 
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Medicine, St. Louis, Missouri, USA); anti-IFN-γ (B27) and anti-IL-1β (H1b-27) (Biolegend); 
and sTNFR p75-IgG1 fusion protein (etanercept/Enbrel; Amgen). 
Bacteria.  Clinical isolates of Escherichia coli (Gram− HMB-PP+ vit.B2+), Klebsiella 
pneumoniae (Gram− HMB-PP+ vit.B2+), Pseudomonas aeruginosa (Gram− HMB-PP+ vit.B2+), 
Corynebacterium striatum (Gram+ HMB-PP+ vit.B2+), Listeria monocytogenes (Gram+ HMB-5 
PP+ vit.B2−), Staphylococcus aureus (Gram+ HMB-PP− vit.B2+), Streptococcus pneumoniae 
(Gram+ HMB-PP− vit.B2−) and Enterococcus faecalis (Gram+ HMB-PP− vit.B2−) were grown 
in LB broth, harvested at an OD600 of 0.5-0.8, and sonicated in 1/10 (v/v) PBS, pH 8.0.  
Insoluble debris was removed by centrifugation, the supernatants were passed through 0.1 μm 
sterile filter units (Millipore), and the protein concentrations were determined using the BCA 10 
protein assay kit (Pierce).  Low molecular weight fractions were obtained using cellulose filters 
with a molecular mass cut-off of 3 kDa (Millipore).  Bacterial extracts were used in cell culture 
at dilutions corresponding to protein concentrations of the original samples (before 3 kDa 
filtration) of 60-100 µg/ml.   
T cells.  PBMC were isolated from peripheral blood of healthy volunteers using Lymphoprep 15 
(Axis-Shield).  Vγ9+ T-cells (>98%) were isolated from PBMC using monoclonal antibodies 
(mAbs) against Vγ9-PECy5 (Beckman Coulter) and anti-PE magnetic microbeads (Miltenyi); 
Vα7.2+ T-cells (>98%) were isolated using anti-Vα7.2-APC (Biolegend) and anti-APC 
microbeads (Miltenyi).  To generate unconventional T-cell conditioned medium, purified blood 
Vγ9/Vδ2 T-cells and MAIT cells were incubated for 24 hours in the presence of 10 nM HMB-20 
PP and anti-CD3/CD28 dynabeads at 0.5 beads/cell, respectively.  Human peritoneal 
leukocytes were harvested from overnight dwell effluents of stable PD patients [13], and 
cultured in the absence or presence of 1-100 nM HMB-PP, 100 µM DMRL or bacterial 
extracts at dilutions corresponding to protein concentrations of 60-100 µg/ml.  For blocking 
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experiments, anti-BTN3 and anti-MR1 were used at 10 µg/ml and added 30 min before 
stimulating the cells.   
Mesothelial cells and peritoneal fibroblasts.  Human peritoneal mesothelial cells were 
obtained from fresh omental samples after two cycles of tissue digestion in the presence of 
trypsin (15 min each); peritoneal fibroblasts were obtained after a third digestion cycle lasting 5 
1 hour [17-19].  All data presented are from experiments performed with confluent mesothelial 
cells and fibroblasts between the first and third passage.  Mesothelial cells were growth 
arrested for 48 hours in serum-free medium prior to treatment, fibroblasts in medium 
containing 0.2% FCS.  After starvation, cells were exposed for 24 hours to T-cell conditioned 
medium at the indicated dilutions; recombinant TNF-α and IFN-γ were used as controls.  Cell-10 
free peritoneal effluent from stable and infected patients (n=3-4) was added to cell cultures at a 
dilution of 1:4.  In blocking experiments, T-cell conditioned medium or peritoneal effluent 
were pre-treated for 30 min with anti-IFN-γ, anti-IL-1β and sTNFR, either alone or in 
combination at 10 µg/ml.  Supernatants were harvested and assessed by ELISA; cells were 
analyzed by qPCR.  15 
Flow cytometry.  Cells were acquired on an eight-color FACSCanto II (BD Biosciences) and 
analyzed with FlowJo 10.1 (TreeStar), using monoclonal antibodies against CD3 (SK7), CD69 
(FN50), CCR4 (1G1), CCR5 (2D7) and CCR6 (11A9) from BD Biosciences; anti-TCR-Vγ9 
(Immu360) from Beckman Coulter; anti-CD161 (HP-3G10), CCR2 (K036C2) and anti-TCR-
Vα7.2 (3C10) from Biolegend; together with appropriate isotype controls.  Anti-mouse 20 
antibodies reactive beads were used to set compensation (Life Technologies).  Intracellular 
cytokines were detected using anti-IFN-γ (B27; Biolegend) and anti-TNF-α (188; Beckman 
Coulter).  For detection of intracellular cytokines, 10 µg/ml brefeldin A (Sigma) was added to 
cultures 5 hours prior to harvesting.  Leukocyte populations were gated based on their 
appearance in side scatter and forward scatter area/height and exclusion of live/dead staining 25 
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(fixable Aqua; Invitrogen).  Unless stated otherwise, peritoneal γδ T-cells were defined as Vγ9+ 
CD3+ lymphocytes.  Peritoneal MAIT cells were defined as Vα7.2+ CD161+ CD3+ 
lymphocytes; control stainings using MR1 tetramers as reference confirmed the validity of this 
approach (data not shown). 
ELISA.  Cell-free peritoneal effluents were analyzed on a SECTOR Imager 6000 (Meso Scale 5 
Discovery) for IFN-γ, TNF-α, IL-1β, CCL3, CCL4 and CXCL8.  Conventional ELISA kits and 
a Dynex MRX II reader were used for CCL2 (eBioscience) and CCL20 (R&D Systems).  Cell 
culture supernatants were analyzed using conventional ELISA kits for IFN-γ (Biolegend), 
TNF-α and CCL2 (eBioscience) as well as for CXCL8, CXCL10 and IL-6 (R&D Systems).   
Real-time PCR.  Total RNA was isolated from mesothelial cells cultured under the indicated 10 
conditions using Trizol (Invitrogen).  cDNA was generated from 0.5 µg of RNA using the high 
capacity cDNA reverse transcription kit (Thermo Fisher), 100 mM dNTPs, 40 U/µl RNase 
inhibitor (New England Biolabs), 50 U/µl MultiScribe reverse transcriptase and 1 × random 
primers, according to the manufacturer’s recommendations.  Quantitative PCRs were run on a 
ViiA7 real-time PCR system (Thermo Fisher), using the power SYBR green PCR master mix 15 
(Thermo Fisher) and 300 nM forward and reverse primers: 
TCCCAATACATCTCCCTTCACA and ACCCACCTCTAAGGCCATCTTT for E-cadherin; 
TAAATCCACGCCGGTTCCTGAAGT and AGGTGTCTCAAAGTTACCACCGCT for 
occludin; CCGAGGTTTTAACTGCGAGA and TCACCCACTCGGTAAGTGTTC for 
fibronectin; CGAGCCCACCGGGAACGAAA and GGACCGAAGGCGCTTGTGGAG for 20 
IL-6; CCTCTGACTTCAACAGCGACAC and TGTCATACCAGGAAATGAGCTTGA for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH); TTTACCTTCCAGCAGCCCTA and 
GGACAGAGTCCCAGATGAGC for Snail; AACTGGGACGACATGGAAA and 
AGGGTGGGATGCTCTTCAG for α-smooth muscle actin (α-SMA); 
GGAGAGGTGTTCCGTGTTGT and GGCTAGCTGCTCAGCTCTGT for zona occludens-1 25 
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(ZO-1); CGGGTTGCTTGCAATGTGC and CCGGCGACAACATCGTGAC for claudin-1. 10 
ng of total RNA were used for cellular microRNAs using the Taqman Universal Master Mix II 
and specific primers for miR-21 and miR-191 (Applied Biosystems).  mRNA and microRNA 
expression levels were normalized to the endogenous controls GAPDH and miR-191, 
respectively. 5 
Statistics.  Statistical analyses were performed using GraphPad Prism 6.0 software.  Data 
distributions were analyzed using D’Agostino-Pearson omnibus normality tests.  Data were 
analyzed using two-tailed Student’s t-tests for normally distributed data and two-tailed Mann-
Whitney tests for non-parametric data.  Differences between groups were analyzed using one 
way ANOVA with Holm-Sidak’s post tests for multiple comparisons of parametric data, or 10 
Kruskal-Wallis tests combined with Dunn’s post tests for non-parametric data.  Matched data 
were analyzed using paired t-tests or Wilcoxon matched pairs tests for two groups, or Friedman 
tests combined with Dunn’s multiple comparisons tests for more than two groups.  Differences 
were considered statistically significant as indicated in the figures and tables: *, p<0.05; **, 
p<0.01; ***, p<0.001.   15 
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RESULTS 
Blood unconventional T-cells migrate early into the inflamed peritoneal cavity, at the 
time of peak neutrophil influx.  Acute disease is characterized by a considerable influx of 
leukocytes to the site of infection, together with locally elevated levels of inflammatory 
mediators.  Here, the effluent of PD patients presenting with acute peritonitis, before 5 
commencing antibiotic treatment, contained increased levels of total cells and of chemokines 
like the neutrophil-attracting molecule CXCL8 (IL-8), compared to effluent from stable non-
infected PD patients (Figure 1A).  Absolute numbers of both Vγ9/Vδ2 T-cells and MAIT cells 
were increased during acute peritonitis compared to stable patients (Figure 1B), indicating 
rapid co-recruitment of unconventional T-cells from blood to the inflamed peritoneal cavity, 10 
alongside neutrophils.  These observations were in agreement with the migratory profiles of 
these cells.  Circulating Vγ9/Vδ2 T-cells and MAIT cells in stable PD patients preferentially 
expressed the chemokine receptors CCR2, CCR5 and CCR6, compared to their non-Vγ9 and 
non-MAIT counterparts (Figs. 1C+D).  We detected markedly increased levels of the 
corresponding chemokines CCL2 (CCR2 ligand), CCL3 and CCL4 (CCR5 ligands) and 15 
CCL20 (CCR6 ligand) in early peritonitis (Figure 1E), demonstrating a substantial production 
of inflammatory chemokines with the potential to attract unconventional T-cells to the site of 
infection, thereby complementing the local pool of tissue-resident Vγ9/Vδ2 T-cells and MAIT 
cells.  In accordance, local frequencies of Vγ9/Vδ2 T-cells and MAIT cells during peritonitis 
were generally higher than in blood (Figure 2A).  No systemic increase in blood 20 
unconventional T-cell levels was seen in patients with peritonitis, in support of the locally 
confined nature of the infection.   
Unconventional T-cells are locally enriched during acute infections caused by bacterial 
pathogens producing the corresponding ligands.  To avoid confounding resulting from the 
considerable biological variations between people and the underlying pathologies, we collected 25 
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matched samples from the same individuals to examine systemic responses in blood and local 
responses in the peritoneal cavity, before and during episodes of peritonitis.  Such 
investigations in acutely infected people have not been attempted before, and are a unique 
advantage of studying individuals receiving PD.  These matched analyses in fact identified 
further ligand-specific effects on local frequencies, as Vγ9/Vδ2 T-cells and MAIT cells were 5 
particularly elevated in peritonitis caused by bacteria producing HMB-PP and vitamin B2, 
respectively, even in individuals with multiple infection episodes (Figure 2B).   
Across the cohort, proportions of Vγ9/Vδ2 T-cells among all CD3+ T-cells in blood and 
peritoneal cavity were comparable in the absence of infection, indicating that under 
homeostatic conditions Vγ9/Vδ2 T-cells are not enriched locally (Figure 3A).  In contrast, on 10 
the day of presentation with acute peritonitis, local levels of Vγ9/Vδ2 T-cells were elevated 
compared to blood, suggesting preferential recruitment and/or accumulation at the site of 
infection (Figure 3B).  This preferential increase in local Vγ9/Vδ2 T-cell levels was apparent 
in patients infected with HMB-PP+ bacteria but not in patients with HMB-PP− infections 
(Figure 3B), despite highly elevated peritoneal chemokine levels in both HMB-PP+ and HMB-15 
PP− infections (data not shown).  Finally, we performed a longitudinal study and observed a 
significant increase in local Vγ9/Vδ2 T-cell levels in patients who developed acute peritonitis 
caused by HMB-PP+ organisms, over pre-infection baseline levels when the same individuals 
were stable (Figure 3C).  As there was no such difference between pre-infection and post-
infection levels in individuals presenting with HMB-PP− infections, these findings show that 20 
Vγ9/Vδ2 T-cells accumulate locally at the site of infection in response to HMB-PP+ but not 
HMB-PP− organisms. 
Parallel studies on the distribution of MAIT cells revealed analogous patterns.  While in stable 
PD patients local MAIT cell frequencies in the peritoneal cavity were slightly higher than those 
in blood (Figure 3D), such differences between anatomical sites were much more pronounced 25 
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in acutely infected individuals (average 3.99% of all T-cells in the peritoneal cavity versus 
0.83% in blood), particularly during infections caused by vitamin B2 producing (vit.B2+) 
bacteria (Figure 3E).  As observed for peritoneal Vγ9/Vδ2 T-cell responses to HMB-PP+ 
bacteria, a comparison with matched pre-infection values revealed a significant local increase 
in MAIT cell levels in individuals infected with vit.B2+ organisms (Figure 3F), confirming the 5 
responsiveness of MAIT cells to vitamin B2 derivatives in vivo.  These findings on Vγ9/Vδ2 
T-cells and MAIT cells support a ligand-induced local expansion of unconventional T-cells at 
the site of infection. 
Peritoneal unconventional T-cells respond to bacterial pathogens producing the 
corresponding ligands.  To address the pathogen specificity of local unconventional T-cell 10 
responses, we cultured peritoneal leukocytes from stable PD patients in the presence of 
different microbial stimuli.  In agreement with our earlier data on blood cells [10], peritoneal 
Vγ9/Vδ2 T-cells were highly specific for HMB-PP whereas MAIT cells recognized the vitamin 
B2 precursor, 6,7-dimethyl-8-D-ribityllumazine (DMRL), as judged by upregulation of CD69 
and production of TNF-α by responding cells (Figure 4A).  When testing extracts from defined 15 
clinical isolates covering the majority of pathogens associated with PD-related peritonitis, 
peritoneal Vγ9/Vδ2 T-cells responded readily to HMB-PP producing Gram-negative (E. coli, 
Klebsiella pneumoniae, Pseudomonas aeruginosa) and Gram-positive bacteria 
(Corynebacterium striatum, Listeria monocytogenes), but not to HMB-PP deficient 
Enterococcus faecalis and Streptococcus pneumoniae (Figure 4B).  Blocking experiments 20 
using neutralizing antibodies confirmed that these HMB-PP dependent responses were 
mediated via BTN3 (Figure 4C).  Strikingly, peritoneal Vγ9/Vδ2 T-cells also responded to 
Staphylococcus aureus despite this organism’s lack of HMB-PP, possibly via superantigens 
[20].  Peritoneal MAIT cells were activated by the vit.B2+ bacteria E. coli, K. pneumoniae, C. 
striatum and S. aureus but not by the vit.B2− species L. monocytogenes, E. faecalis and S. 25 
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pneumoniae; responses to the vit.B2+ organism P. aeruginosa did not reach statistical 
significance (Figure 4B). 
Although Vγ9/Vδ2 T-cells and MAIT cells constitute only minor proportions of the peritoneal 
T-cell pool, these cells represented major producers of pro-inflammatory cytokines in response 
to bacterial extracts (Figure 5A).  Using E. coli as example of an organism producing both 5 
HMB-PP and vitamin B2, responding peritoneal Vγ9/Vδ2 T-cells and MAIT cells together 
made up a large fraction of TNF-α+ T-cells (median 31.7%) and IFN-γ+ T-cells (median 
39.2%) despite considerable variability across PD patients (Figure 5B).  In contrast, both cell 
types constituted far lower proportions amongst TNF-α− and IFN-γ− T-cells in E. coli-
stimulated peritoneal leukocytes.  Similar results were obtained using HMB-PP+ vit.B2+ C. 10 
striatum extracts (data not shown).  Analyses of supernatants from peritoneal leukocytes 
exposed to different bacteria demonstrated that only organisms producing HMB-PP and/or 
vitamin B2 (S. aureus, C. striatum) but not HMB-PP− vit.B2− E. faecalis induced secretion of 
IFN-γ and the IFN-γ inducible chemokine CXCL10 (Figure 5C).  As control, levels of CXCL8 
were comparable in response to all three bacterial species, demonstrating an equal potential to 15 
stimulate peritoneal leukocytes other than Vγ9/Vδ2 T-cells and MAIT cells (data not shown).  
Secretion of TNF-α was not assessed in these experiments as any unconventional T-cell 
derived TNF-α would have been masked by peritoneal macrophages and neutrophils sensing 
diverse pathogen-associated molecular patterns.  The contribution of Vγ9/Vδ2 T-cells and 
MAIT cells to the overall secretion of IFN-γ by peritoneal leukocytes in response to HMB-PP+ 20 
vit.B2+ organisms was confirmed by anti-BTN3 and anti-MR1 blocking antibodies (Figure 
5D).  Taken together, these findings show that peritoneal unconventional T-cells are major 
producers of IFN-γ and TNF-α in response to a wide range of microbial pathogens, and that 
abrogation of ligand recognition through BTN3 and MR1 abrogates this cytokine production. 
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Crosstalk with local tissue amplifies the pro-inflammatory response to bacterial 
pathogens.  Local activation of unconventional T-cells in acute infection is likely to occur in 
close proximity to the peritoneal membrane, thus exposing the mesothelial cell layer that lines 
the peritoneal cavity to T-cell derived mediators.  Using supernatants from activated 
unconventional T-cells, our experiments demonstrate that Vγ9/Vδ2 T-cells and MAIT cells 5 
induced secretion of CCL2, CXCL8, CXCL10 and IL-6 by omentum-derived primary 
mesothelial cells (Figure 6A) and peritoneal fibroblasts (Figure 6B).  This activation of 
peritoneal tissue cells was dose-dependent (data not shown).  Neutralization of TNF-α and/or 
IFN-γ in the conditioned media prior to addition to peritoneal tissue cells attenuated these 
responses considerably, with the CXCL8 and IL-6 secretion being particularly sensitive to 10 
inhibition of TNF-α while the CXCL10 secretion was mainly driven by IFN-γ (Figure 6A,B).  
These findings were in accordance with control experiments showing that recombinant TNF-α 
was a potent inducer of CCL2, CXCL8 and IL-6 expression by mesothelial cells and 
fibroblasts (data not shown).  Recombinant IFN-γ on its own was mainly effective at inducing 
CCL2 and, to a lesser extent, IL-6 expression by mesothelial cells and fibroblasts while having 15 
no effect on CXCL8.  These findings identify unconventional T-cell derived TNF-α and IFN-γ 
as major stimulators of peritoneal tissue cells, which is likely to enhance local inflammation 
and contribute to further recruitment of monocytes, neutrophils and lymphocytes to the site of 
infection. 
Activation of peritoneal tissue cells by effluent from PD patients with acute peritonitis.  20 
We next sought to address the physiological relevance of the findings above in more detail.  
Our previous work already demonstrated that peritoneal effluent of patients presenting with 
acute peritonitis can contain considerable levels of TNF-α and IFN-γ [13-15].  We therefore 
tested whether cytokines released into the dialysis fluid during acute infection had similar 
bioactivity to unconventional T-cell conditioned media and the recombinant proteins 25 
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themselves.  Here, the effluent from three patients with peritonitis induced CCL2 and CXCL8 
secretion by mesothelial cells while effluent from stable patients showed only background 
activity (Figure 7A).  This chemokine production was in part blocked by combined pre-
treatment of the infected effluent with sTNFR and anti-IFN-γ (Figure 7B).  These experiments 
demonstrate that TNF-α and IFN-γ are produced locally in response to bacterial pathogens at 5 
concentrations that are sufficiently high to affect the cells lining the peritoneal cavity, and that 
targeting cytokine production by unconventional T cells may diminish local inflammation. 
Clinical outcome from peritonitis depends on the capacity of the causative pathogen to 
produce unconventional T-cell ligands.  Acute inflammatory events make a major 
contribution to tissue fibrosis.  In particular, peritonitis has a direct effect on peritoneal 10 
membrane morphology and function [21,22] and is hence a major reason for technique failure 
in PD patients.  Yet, little is known about the role of unconventional T-cells in these processes.  
Given the contribution of Vγ9/Vδ2 T-cells and MAIT cells to the local immune response to 
HMB-PP+ and vit.B2+ bacteria, respectively, we investigated the short and mid-term impact of 
infections by such organisms on the clinical outcome in 5,071 PD patients presenting with 15 
first-time peritonitis recorded in the Australia and New Zealand Dialysis and Transplant 
(ANZDATA) Registry (Table 1).  In accordance with our earlier findings in a much smaller 
subgroup of the same cohort [14], infections by HMB-PP+ bacteria were associated with poorer 
outcomes as determined by higher rates of catheter removal, permanent transfer to 
hemodialysis and overall technique failure, compared to HMB-PP− infections (Figure 8, Table 20 
2).  This was true for episodes of peritonitis caused by both Gram+ and Gram− species, thereby 
identifying the utilization of the non-mevalonate pathway of isoprenoid biosynthesis by the 
causative organism as useful predictive marker, and implying that Vγ9/Vδ2 T-cell driven 
responses may contribute to overall clinical outcome.  Within the HMB-PP+ group, Gram− 
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organisms caused even more severe complications than Gram+ species, including significant 
mortality within the first month after the onset of acute peritonitis. 
Since all HMB-PP+ bacteria in the ANZDATA cohort were also positive for vitamin B2 (and 
did not include L. monocytogenes as the only relevant HMB-PP+ vit.B2− pathogen in PD 
patients), outcome predictions based on the presence of the vitamin B2 pathway followed 5 
closely those seen for HMB-PP+ organisms (Table 2).  However, differential analysis of HMB-
PP− infections allowed us to determine the clinical impact of vit.B2+ species in that patient 
subgroup.  Here, vit.B2+ infections showed a trend toward higher rates of catheter removal, 
compared to vit.B2− infections, which was also reflected in total technique failure rates (Figure 
8).  However, no such differences between vit.B2+ and vit.B2− infections were seen with regard 10 
to transfer to hemodialysis or mortality.  This relatively benign course of HMB-PP− vit.B2+ 
peritonitis may have been due to the high prevalence of infections caused by the comparatively 
avirulent skin commensal Staphylococcus epidermidis and related coagulase-negative species 
(67.6% of all infections in this group).  As expected [23,24], S. aureus infections were 
associated with a considerably greater risk of technique failure and catheter removal than 15 
coagulase-negative staphylococcal infections (data not shown).  These findings indicate that 
while the presence of the vitamin B2 pathway alone may not be sufficiently predictive of 
clinical outcome in that patient group, MAIT cells are nevertheless likely to make a 
contribution to the overall inflammatory response during acute peritonitis caused by vit.B2+ 
organisms. 20 
Unconventional T-cell driven epithelial-mesenchymal transition of peritoneal mesothelial 
cells.  Finally, we investigated the functional impact of activated unconventional T-cells on the 
surrounding tissue.  Inflammatory mediators including TNF-α have previously been associated 
with the induction of an epithelial-mesenchymal transition (EMT)-like process in mesothelial 
cells [25], and IFN-γ has been identified as major driver of tissue fibrosis in the peritoneal 25 
Liuzzi et al.: page 19 
cavity [22].  Here, primary omentum-derived mesothelial cells exposed to supernatants from 
activated Vγ9/Vδ2 T-cells (data not shown) and MAIT cells  (Figure 9A) underwent striking 
changes from an epithelial-like appearance to a spindled fibroblastic shape within 24 hours.  
Such pronounced morphological changes were greatly diminished when neutralizing TNF-α 
and/or IFN-γ in the unconventional T-cell conditioned media prior to addition to mesothelial 5 
cells (Figure 9A).  As controls, similar effects were observed when mesothelial cells were 
cultured in the presence of TNF-α or IFN-γ, particularly when both cytokines were combined 
(Figure 9B).  In agreement with these morphological changes, the expression of epithelial cell-
associated markers such as E-cadherin and occludin by mesothelial cells was downregulated 
upon exposure to MAIT cell conditioned media, whereas the mesenchymal marker fibronectin 10 
was upregulated, as determined by RT-qPCR (Figure 9C).  A similar upregulation of 
fibronectin expression was seen with Vγ9/Vδ2 T-cell conditioned medium, while effects on E-
cadherin and occludin were less pronounced, most likely due to the generally lower levels of 
TNF-α and IFN-γ in the preparations used for those experiments, compared with MAIT cell 
conditioned medium (data not shown).  As viability control, expression of IL-6 was greatly 15 
enhanced by unconventional T-cells at the mRNA level (data not shown), in agreement with 
the protein data.  In addition to fibronectin, MAIT cell stimulated mesothelial cells also 
expressed elevated levels of the microRNA miR-21, which has been linked to TGF-β induced 
EMT in mesothelial cells, and to membrane fibrosis in patients receiving PD (Melisa López 
Antón and Donald J. Fraser, unpublished observations).  This miR-21 induction by MAIT cells 20 
was decreased upon neutralization of TNF-α and IFN-γ (Figure 9D).  Further epithelial (zona 
occludens-1, claudin) and mesenchymal markers (Snail, collagen-1, α-smooth muscle actin) 
were not significantly affected by unconventional T-cell secreted factors (Figure 9C and data 
not shown), indicating incomplete initiation of the EMT process under these conditions.  
Notably, while mesothelial cells treated with a combination of TNF-α and IFN-γ 25 
downregulated the expression of all epithelial markers tested (data not shown), only Vγ9/Vδ2 
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T-cells and MAIT cells triggered a parallel upregulation of the mesenchymal marker 
fibronectin.  These data imply that unconventional T-cells may produce as yet unidentified 
mediators, in addition to TNF-α and IFN-γ, that may affect mesothelial cells and reprogram 
their morphology and phenotype.  Taken together, these findings indicate that microbe-
responsive unconventional T-cells have the capacity to trigger local tissue remodeling with 5 
potential consequences for peritoneal membrane integrity and long-term clinical outcome. 
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DISCUSSION 
By combining cross-sectional and longitudinal sampling in PD patients together with a 
functional characterization of peritoneal immune and tissue cells ex vivo and an 
epidemiological analysis of organism-dependent outcomes, we show that Vγ9/Vδ2 T-cells and 
MAIT cells specifically accumulate locally during infections with bacteria producing HMB-PP 5 
and vitamin B2 derivatives, respectively, and that utilization of the HMB-PP and vitamin B2 
pathways by the causative organism represents an effective predictive marker for technique 
failure.  Our data thus provide the first conclusive evidence in humans for a ligand-specific role 
of Vγ9/Vδ2 T-cells and MAIT cells at the site of infection.  Due to the limited access to 
relevant patient samples such a physiological role has so far only been hinted at in complex 10 
experimental animal models [26-28].  Our data also show that such unconventional human T-
cells are major producers of IFN-γ and TNF-α in response to microbial pathogens, thereby 
affecting the cells lining the peritoneal cavity and amplifying local inflammation.  These 
findings are likely to be applicable to other acute infections where local activation of 
unconventional T-cells contributes to the anti-microbial inflammatory response. 15 
The present study demonstrates that PD patients offer exceptional opportunities for 
immunological studies into acute disease.  First, peritoneal effluent can be sampled repeatedly 
and non-invasively, thus providing continuous access to the site of infection on the first day of 
microbial infection, before antibiotic therapy commences, to study the development and 
resolution of acute responses.  Second, stable PD patients without overt inflammation serve as 20 
age and gender-matched non-infected controls in cross-sectional studies.  Third, peritonitis 
remains a relatively frequent complication of PD therapy, with typical incidences in the UK of 
one episode per 15-30 patient months [29].  Thorough immunological profiling of a stable PD 
cohort therefore allows to establish pre-infection baseline parameters in individuals prone to 
develop peritonitis later on.  Fourth, PD-related peritonitis can be caused by Gram-positive and 25 
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Gram-negative bacteria as well as fungi, thereby allowing to study the local immune response 
to a wide spectrum of pathogens under closely related conditions.  Since acute infection and 
associated inflammation remain a major cause of treatment failure and even death in PD 
patients [30], our findings not only improve our insight into the complex local cell interactions 
in early infection, but also provide relevant clues to the mechanisms that underpin the clinical 5 
severity of infectious episodes, and are readily translatable to improve patient management and 
outcomes. 
Many unconventional T-cell populations are rare in humans, with NKT cells typically 
representing 0.01–0.5% of T-cells in blood and frequencies of GEM T-cells being even lower 
[31,32].  Given the rare nature of these populations and the low prevalence of organisms that 10 
produce the corresponding ligands in PD patients, we focused on Vγ9/Vδ2 T-cells and MAIT 
cells, the two most abundant unconventional T-cell populations in the peritoneal cavity.  Our 
data provide in vitro and in vivo evidence for the specificity of peritoneal Vγ9/Vδ2 T-cells and 
MAIT cells for the corresponding ligands, HMB-PP [33] and vitamin B2 derivatives [16,34].  
In particular, our research suggests that Vγ9/Vδ2 T-cells and MAIT cells discriminate locally 15 
between different organisms and accumulate rapidly at the site of infection, where they engage 
local monocytes and neutrophils as well as tissue cells, and orchestrate early inflammatory 
events [10,13,14].  While others have suggested that circulating MAIT cells decrease in certain 
clinical scenarios sufficiently to reach statistical significance [35], our data indicate for the first 
time that local recruitment of MAIT cells takes place in acute infection.  Unconventional T-cell 20 
driven responses are likely to contribute to the transition from local innate immunity to 
antigen-specific adaptive immunity [11], and have potential to be exploited for improved 
patient management through novel diagnostics, therapeutics and vaccines.  As such, we show 
here that local Vγ9/Vδ2 T-cells and MAIT cells represent dominant sources of IFN-γ and TNF-
α in response to diverse bacteria.  As these cytokines control leukocyte recruitment to the site 25 
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of infection but also possess pro-fibrotic functions, unconventional T-cells represent key 
regulators of acute immune responses as well as collateral tissue damage, ultimately affecting 
outcomes. 
The present study identified unconventional T-cell derived TNF-α and IFN-γ as potent 
stimulators of primary mesothelial cells and peritoneal fibroblasts, the two major types of 5 
tissue cells constituting the peritoneal membrane.  Through induction of IL-6 as well as 
chemokines such as CCL2, CXCL8 and CXCL10, Vγ9/Vδ2 T-cells and MAIT cells are likely 
to enhance local inflammation and contribute to further recruitment of monocytes, neutrophils 
and lymphocytes to the site of infection.  This interaction with local tissue cells complements 
our earlier findings on a potent crosstalk of Vγ9/Vδ2 T-cells and MAIT cells with monocytes 10 
and neutrophils triggering chemokine production and leading to monocyte and neutrophil 
survival and acquisition of APC features [10,11,13,14].  Together, these findings indicate that 
Vγ9/Vδ2 T-cells and MAIT cells play a crucial role in driving local inflammatory events by 
engaging both immune and non-immune cells at the site of infection by organisms producing 
the corresponding ligands.  The timely detection of Vγ9/Vδ2 T-cell and MAIT cell responses 15 
in PD patients presenting with acute peritonitis may therefore allow an ‘immune fingerprint’-
based point-of-care definition of the causative pathogen, which would improve early patient 
management by targeting treatments more efficiently than current empirical approaches, 
reducing unnecessary exposure to broad-spectrum antibiotics, and identifying individuals at 
increased risk of subsequent complications who may require prolonged hospitalization [15,36]. 20 
The orchestration of early anti-microbial responses by unconventional T-cells is likely to 
contribute to pathogen clearance and wound healing, and thus be beneficial to the host in many 
different infectious scenarios.  However, the situation is different in individuals receiving PD 
who are highly susceptible to inflammation-related tissue damage with immediate 
consequences for their treatment [37-39].  In particular, IL-6 has been linked to tissue fibrosis 25 
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via induction of Th1 cell responses as a consequence of peritoneal inflammation [22].  
Unconventional T-cells are therefore likely to contribute to scarring in the peritoneal cavity, 
both directly via the local release of IFN-γ and indirectly via induction of IL-6 production by 
mesothelial cells and fibroblasts.  Our present study identified striking morphological and 
phenotypical changes of mesothelial cells in response to Vγ9/Vδ2 T-cells and MAIT cell 5 
secreted cytokines, changes that are linked to infection-driven peritoneal fibrosis and technique 
failure.  Such local tissue remodeling by downregulating epithelial features and inducing 
expression of mesenchymal markers will ultimately affect the integrity of the peritoneal 
membrane and affect long-term clinical outcomes.  Together, these complex interactions may, 
at least in part, explain why organisms that are capable of activating local unconventional T 10 
cells are frequently associated with higher rates of technique failure in PD patients.  Besides 
predicting important clinical outcomes, unconventional T-cell driven responses to ligands 
shared by many microbial pathogens therefore also represent potential targets to suppress 
overshooting inflammation and limit damage on the peritoneal membrane, with the possibility 
to deliver treatments locally via the peritoneal catheter.  Novel interventions will benefit 15 
greatly from the recent elucidation of the BTN3 and MR1 presentation pathway, and the 
availability of reagents blocking the TCR-mediated recognition of microbial ligands [40,41], 
antibiotics shutting off the non-mevalonate and riboflavin biosynthesis [42-45], and biologics 
interfering with key effector cytokines. 
  20 
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Table 1.  Characteristics of all PD patients analyzed in the present study. 
 Cardiff ANZDATA
Number of stable patients 45 n/a 
Age (mean ± SD) 69.1 ± 13.5 n/a 
Women (%) 18.6 n/a 
Days on PD (mean ± SD) 624 ± 546 n/a 
Number of patients presenting with acute peritonitis 101 5,071 
Age (mean ± SD) 66.0 ± 13.3 60.1 ± 16.9 
Women (%) 32.6 43.9 
Days on PD (mean ± SD) 936 ± 856 1010 ± 791 
No culture samples obtained (%) 0.0 0.4 
Culture negative episodes (%) 22.8 16.6 
Fungi (%) 1.0 2.3 
Polymicrobial infections (%) 4.0 6.8 
HMB-PP+ vit.B2+ species among single bacteria (%) 34.2 35.3 
HMB-PP− vit.B2+ species among single bacteria (%) 42.5 50.2 
HMB-PP− vit.B2− species among single bacteria (%) 23.3 14.5 
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Table 2.  Odds ratios for risk of technique failure in patients presenting with first-time peritonitis, depending on the causative 
pathogen.  OR, odds ratio of the indicated type of technique failure; CI, confidence interval; HD, hemodialysis. 
ANZDATA  
n=5,071 
90th day
overall technique failure
30th day 
mortality
90th day  
catheter removal 
30th day 
transfer to interim HD
90th day transfer
to permanent HD
OR 
(95% CI) p 
OR
(95% CI) p 
OR
(95% CI) p 
OR
(95% CI) p 
OR
(95% CI) p 
Reference: 
culture-negative 1.0  1.0  1.0  1.0  1.0  
Gram+ HMB-PP+ 
vitamin B2+ 
2.4 
(1.389-4.129) 0.002 
0.262
(0.043-2.360) 0.262 
3.2
(1.812-5.637) *** 
7.3
(1.606-33.143) 0.010 
2.3
(1.253-4.398) 0.008 
Gram+ HMB-PP− 
vitamin B2+ 
1.1 
(0.866-1.468) 0.374 
0.737
(0.455-1.192) 0.213 
1.2
(0.895-1.637) 0.215 
3.2
(1.125-9.353) 0.029 
1.0
(0.763-1.437) 0.775 
Gram+ HMB-PP− 
vitamin B2- 
0.9 
(0.662-1.381) 0.812 
0.794
(0.409-1.543) 0.497 
1.0
(0.658-1.523) 0.998 
2.7
(0.758-9.615) 0.126 
1.0
(0.655-1.551) 0.971 
Gram− HMB-PP+ 
vitamin B2+ 
4.3 
(3.318-5.500) *** 
2.6
(1.713-4.037) *** 
4.4
(3.358-5.946) *** 
9.0
(3.242-25.319) *** 
3.4
(2.506-4.550) *** 
Reference: 
culture-negative 1.0  1.0  1.0  1.0  1.0  
HMB-PP+ 4.1 (3.194-5.271) *** 
2.43
(1.589-3.737) *** 
4.3
(3.285-5.792 ) *** 
8.9
(3.201-24.863) *** 
3.3
(2.449-4.425) *** 
HMB-PP− 1.0 (0.843-1.405) 0.515 
0.75
(0.474-1.184) 0.217 
1.2
(0.868-1.558) 0.312 
3.1
(1.099-8.873) 0.033 
1.0
(0.766-1.408) 0.808 
Reference: 
culture-negative 1.0  1.0  1.0  1.0  1.0  
Vitamin B2+ 2.1 (1.703-2.734) *** 
1.4
(0.939-2.129) 0.097 
2.3
(1.789-3.074) *** 
5.5
(2.021-15.235) 0.001 
2.0
(1.403-3.049) *** 
Vitamin B2− 0.9 (0.662-1.381) 0.812 
0.8
(0.409-1.543) 0.497 
1.0
(0.658-1.523) 0.998 
2.7
(0.758-9.615) 0.126 
0.9
(0.493-1.689) 0.771 
Reference: 
HMB-PP− 1.0  1.0  1.0  1.0  1.0  
Gram+ HMB-PP+ 2.2 (1.312-3.689) 0.003 
0.424
(0.058-3.098) 0.398 
2.7
(1.618-4.670) *** 
0.9
(0.700-7.796) 0.167 
2.3
(1.248-4.095 ) 0.007 
Gram− HMB-PP+ 3.9 (3.263-4.721) *** 
3.5
(2.488-4.947) *** 
3.8
(3.141-4.700) *** 
2.9
(1.821-4.623) *** 
3.3
(2.614-4.046) *** 
Reference: 
Vitamin B2− 1.0  1.0  1.0  1.0  1.0  
Gram+ vitamin B2+ 1.2 (0.892-1.721) 0.201 
0.9
(0.480-1.688) 0.742 
1.3
(0.896-1.883) 0.167 
1.3
(0.526-3.105) 0.588 
1.1
(0.748-1.617) 0.629 
Gram− vitamin B2+ 4.5 (3.235-6.168) *** 
3.3
(1.832-5.985) *** 
4.4
(3.108-6.415) *** 
3.4
(1.420-7.933) 0.006 
3.3
(2.302-4.874) *** 
Reference: 
Gram− HMB-PP+ vitamin B2+ 1.0  1.0  1.0  1.0  1.0  
Gram+ HMB-PP+ 
vitamin B2+ 
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Figure 1.  Pro-inflammatory migratory profile of unconventional T-cells.  (A) Total cell 
counts and concentration of the neutrophil-attracting chemokine CXCL8 in the peritoneal 
effluent of stable PD patients and patients presenting with acute peritonitis.  (B) Total numbers 5 
of Vγ9+ CD3+ T-cells and Vα7.2+ CD3+ T-cells within the peritoneal cell population in stable 
PD patients and during acute peritonitis.  (C) Representative example for the co-expression of 
CCR2, CCR5 and CCR6 with CD161 on blood Vα7.2+ CD3+ T-cells in a stable PD patient.  
(D) Percentage of CCR2+, CCR5+ and CCR6+ cells amongst Vγ9− and Vγ9+ CD3+ T-cells 
(upper panels) or amongst Vα7.2+ CD161− and Vα7.2+ CD161+ CD3+ T-cells in the blood of 10 
stable PD patients (lower panels).  (E) Concentration of the indicated chemokines in the 
effluent of patients presenting with acute peritonitis; upper limits of detection for CCL3 and 
CCL4 were 4.12 ng/ml and for 4.32 ng/ml, respectively.  Data were analyzed using Mann 
Whitney tests (in the case of CCL2 after normalization).  Each data point represents an 
individual patient, error bars depict the median ± interquartile range. 15 
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Figure 2.  Systemic and local levels of unconventional T-cells in stable PD patients and 
during acute peritonitis.  (A) Blood (PBMC) and peritoneal dialysis effluent (PDE) were 
analyzed by flow cytometry for the proportion of Vγ9/Vδ2 T-cells (identified as Vγ9+; left) and 
MAIT cells (Vα7.2+ CD161+; right), expressed as percentage of all CD3+ T-cells.  Samples 
were collected from stable PD patients and patients presenting with acute peritonitis (day 1), 10 
before commencing antibiotic treatment.  Data were analyzed using Kruskal-Wallis tests 
combined with Dunn’s multiple comparisons tests.  Each data point represents an individual 
patient; asterisks indicate significant differences between groups.  (B) Local levels of 
unconventional T-cells in the effluent of two PD patients whilst the individuals were stable and 
when they presented with distinct peritonitis episodes caused by bacteria capable or not of 15 
producing HMB-PP or vitamin B2 (day 1). 
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Figure 3.  Matched levels of unconventional T-cells in blood and effluent of PD patients 
before and during acute peritonitis.  Blood and peritoneal effluent samples from the same 
individuals were analyzed by flow cytometry for the proportion of Vγ9/Vδ2 T-cells (identified 5 
as Vγ9+; A-C) and MAIT cells (Vα7.2+ CD161+; D-F), expressed as percentage of all CD3+ T-
cells.  Samples were collected whilst patients were stable and when they presented with acute 
peritonitis (day 1), before commencing antibiotic treatment.  (A,D) Unconventional T-cell 
levels in blood and effluent of stable individuals.  (B,E) Unconventional T-cell levels in blood 
and effluent of all patients with acute peritonitis (left), and in subgroups of patients with 10 
confirmed infections by bacteria capable or not of producing HMB-PP or vitamin B2 (middle, 
right).  (C,F) Local unconventional T-cell levels in the effluent of PD patients before and 
during acute peritonitis (left), and in subgroups of patients with infections by bacteria 
producing HMB-PP and/or vitamin B2 (middle, right).  Data were analyzed using Wilcoxon 
matched-pairs signed rank tests.  Each data point represents an individual patient. 15 
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Figure 4.  Peritoneal unconventional T-cell responses to microbial metabolites.  (A) 
Activation of peritoneal Vγ9+ γδ T-cells and Vα7.2+ CD161+ MAIT cells from stable PD 
patients upon overnight stimulation with HMB-PP (n=4 individual patients) or DMRL (n=3), 5 
as analyzed by flow cytometry and expressed as proportion of γδ or MAIT cells co-expressing 
CD69 and TNF-α (means ± SEM).  (B) Activation of peritoneal Vγ9+ γδ T-cells and Vα7.2+ 
CD161+ MAIT cells upon overnight stimulation in the presence of extracts from different 
clinical isolates that produce (in blue) or do not produce (in red) the corresponding ligands 
(median ± interquartile range): E. coli (HMB-PP+ vit.B2+), Klebsiella pneumoniae (HMB-PP+ 10 
vit.B2+), Pseudomonas aeruginosa (HMB-PP+ vit.B2+), Corynebacterium striatum (HMB-PP+ 
vit.B2+), Listeria monocytogenes (HMB-PP+ vit.B2−), Staphylococcus aureus (HMB-PP− 
vit.B2+), Enterococcus faecalis (HMB-PP− vit.B2−), and Streptococcus pneumoniae (HMB-PP− 
vit.B2−).  Each data point represents an individual patient.  (C) Activation of total peritoneal 
leukocytes by extracts of the indicated bacteria, in the absence or presence of anti-BTN3 15 
blocking antibodies, shown as co-expression of CD69 and TNF-α (left) or IFN-γ (right) by 
Vγ9+ T-cells after overnight stimulation.  Data were analyzed using Wilcoxon matched-pairs 
signed rank tests.  Each data point represents an individual patient; asterisks depict significant 
differences of anti-BTN3 treated samples compared to untreated controls.   
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Figure 5.  Ex vivo responsiveness of peritoneal leukocytes to pathogenic bacteria.  5 
Peritoneal cells were obtained from the effluent of stable patients and exposed overnight to 
extracts prepared from the indicated bacterial species.  (A) Representative example of an 
intracellular staining of TNF-α in peritoneal leukocytes cultured in the absence (medium; top 
panel) or presence of E. coli extract (middle panel), as analyzed by flow cytometry within the 
CD3+ gate.  Bottom panel, distribution of Vα7.2+ and Vγ9+ cells within all CD3+ TNF-α+ 10 
peritoneal cells after stimulation with E. coli extract.  (B) Proportion of Vα7.2+ (black) and 
Vγ9+ cells (shaded) T-cells amongst peritoneal T-cells producing or not TNF-α and IFN-γ in 
response to E. coli, as analyzed by flow cytometry in nine stable individuals.  (C) Overnight 
secretion of IFN-γ, CXCL10 and CXCL8 by peritoneal cells in response to bacteria that 
produce (S. aureus, C. striatum; in blue) or do not produce (E. faecalis; in red) ligands for 15 
Vγ9/Vδ2 T-cells and/or MAIT cells, as analyzed by ELISA (median ± interquartile range).  
Data were analyzed using Kruskal-Wallis tests combined with Dunn’s multiple comparisons 
tests.  Each data point represents an individual patient; asterisks indicate significant differences 
compared to medium controls.  ND, not done.  (D) Specific inhibition of IFN-γ secretion by 
peritoneal leukocytes in response to bacterial extracts, in the absence or presence of anti-BTN3 20 
and anti-MR1 blocking antibodies, alone or in combination.  Data shown are means ± SEM 
from independent experiments with 3 omental donors.   
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Figure 6.  Activation of peritoneal tissue cells by γδ T-cell and MAIT cell derived 
cytokines.  Growth-arrested peritoneal mesothelial cells (A) or peritoneal fibroblasts (B) from 5 
human omentum were exposed to supernatants derived from activated Vγ9/Vδ2 T-cells and 
MAIT cells at a dilution of 1:4, in the absence or presence of 10 μg/ml sTNFR and 10 μg/ml 
anti-IFN-γ, alone or together.  Data shown are levels of CCL2, CXCL8, CXCL10 and IL-6 
secreted into the culture medium over 24 hours by ELISA (means ± SEM from independent 
experiments with 4-7 omental donors).  Data were analyzed using Friedman tests combined 10 
with Dunn’s multiple comparisons tests.  Asterisks indicate significant differences compared to 
medium controls.   
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 10 
Figure 7.  Activation of peritoneal tissue cells by effluent from PD patients with acute 
peritonitis.  (A) Growth-arrested peritoneal mesothelial cells from human omentum (n=2-4) 
were exposed to peritoneal effluent obtained from three stable PD patients in the absence of 
any inflammation (#1-3) and from three patients presenting with acute peritonitis (#4: 
Enterobacter sp., #5: E. coli and #6: Acinetobacter sp.).  Data shown are levels of CCL2 and 15 
CXCL8 secreted into the culture medium over 24 hours by ELISA (median ± interquartile 
range).  Data were analyzed using Kruskal-Wallis tests combined with Dunn’s multiple 
comparisons tests.  Asterisks indicate significant differences compared to medium controls 
(Ctrl).  (B) Mesothelial cells were exposed to peritoneal effluent from patients presenting with 
peritonitis, in the absence or presence of 10 μg/ml sTNFR and 10 μg/ml anti-IFN-γ.  Data 20 
shown are expressed as percent inhibition of CCL2 and CXCL8 secretion over 24 hours, 
compared to untreated controls (median ± interquartile range).  Data were analyzed using 
Wilcoxon matched-pairs signed rank tests.  Each data point represents an independent 
experiment. 
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Figure 8.  Association of first-time peritonitis caused by HMB-PP+ and vit.B2+ bacteria 
with poor clinical outcome.  Cumulative rates of technique failure (top left), mortality (top 
right), catheter removal (bottom left) and transfer to permanent hemodialysis (HD; bottom 5 
right) of patients from the ANZDATA registry with first-time peritonitis, grouped into 
infections with Gram+ HMB-PP– vit.B2– (green), Gram+ HMB-PP– vit.B2+ (grey), Gram+ 
HMB-PP+ vit.B2+ (blue) or Gram– HMB-PP+ vit.B2+ bacteria (red); episodes caused by Gram– 
HMB-PP– (e.g. Legionella spp.) or Gram+ HMB-PP+ vit.B2– species (e.g. Listeria 
monocytogenes) were not recorded and/or were too rare for this comparison.  Numbers indicate 10 
the number of cases of acute peritonitis caused by the listed organisms.  Comparisons were 
made using log-rank tests. 
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Figure 9.  Unconventional T-cell induced reprogramming of peritoneal mesothelial cells.  
Growth-arrested peritoneal mesothelial cells from human omentum were cultured in medium 
alone or exposed to supernatants derived from activated MAIT cells, in the absence or presence 5 
of 10 μg/ml sTNFR and 10 μg/ml anti-IFN-γ (A), or stimulated with 5 ng/ml of TNF-α and 
IFN-γ, alone or in combination (B).  Images were captured after 24 hours in culture with a light 
microscope at a 20× magnification, and are representative of 3-4 individual donors.  (B) 
Expression of epithelial (E-cadherin, occludin, zona occludens-1 [ZO-1], claudin-1) and 
mesenchymal markers (fibronectin, Snail) by mesothelial cells after 24 hour exposure to MAIT 10 
cell supernatants, as determined by quantitative PCR as relative expression compared to 1,000 
copies of GAPDH as housekeeping gene.  (C) Expression of miR-21 by mesothelial cells after 
24 hour exposure to MAIT cell supernatants in the absence or presence of 10 μg/ml sTNFR 
and 10 μg/ml anti-IFN-γ, as determined by quantitative PCR as relative expression compared 
to miR-191 as reference microRNA.  Data were analyzed using Wilcoxon matched-pairs 15 
signed rank tests or paired t-tests.  Each data point represents an individual patient.  
